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iga nephropathy
Immunoglobulin A nephropathy (IgAN) is the most common noninfectious glomerular 
disease worldwide. Based on biopsy registries IgAN constitutes 30-40% of all 
glomerulopathies in Europe1. In the Netherlands, IgAN is diagnosed in 12% of patients 
undergoing a kidney biopsy2. The reported incidence of biopsy proven IgAN is 19 patients 
per 1*106 adults3. Since many patients with IgAN present with isolated, asymptomatic 
hematuria, geographical differences in reported incidence and prevalence rates are largely 
explained by differences in biopsy policies, and to a lesser extent by genetic variations. In 
North America 8% of patients with a glomerular disease are diagnosed with IgAN since 
it is less common in African Americans than in Caucasians. In Europa prevalence rates are 
13-20%, and in Asia prevalence is reported to be as high as 30-50%4,5. The impact of IgAN 
is best illustrated by its contribution to ESRD rates. IgAN is the cause of ESRD in 3-6% of 
patients treated with renal replacement therapy. Since a large number of patients with 
IgAN are young and without significant co-morbidity, they make good candidates for a 
kidney transplant, for example in 2005 22% of patients receiving a kidney transplant in 
Australia or New Zealand suffered from IgAN6. In North America ESRD was due to IgAN 
in only 1-4% of kidney transplant patients. In the Netherlands, IgAN accounted for 3% of 
patients on dialysis, and for 7% of kidney transplant patients (data obtained from Renine 
database). 
Clinical presentation and outcome
Clinical presentation of IgAN varies widely. Most patients present with isolated hematuria, 
but some present with rapidly progressive glomerulonephritis. The high prevalence 
of IgAN combined with its early age of onset, makes this glomerulopathy a significant 
renal disease. Studies conducted before implementation of routine use of ACE inhibitors 
report that 25-50% of patients with recurrent macroscopic hematuria or persistent 
microscopic hematuria progress to end-stage renal disease (ESRD) in 10-30 years7. The risk 
of development of ESRD in patients with IgAN is highly variable and associated with the 
clinical presentation (table 1). Patients presenting with microscopic hematuria without 
proteinuria have an excellent prognosis with <5% developing ESRD, whereas on the other 
end of the spectrum, 40-75% of patients with crescentic IgAN progress to ESRD8,9.
Diagnosis and pathogenesis
A kidney biopsy and immunofluorescence studies are needed to diagnose IgAN. 
Histologically, IgAN is defined by dominant staining of IgA in the glomeruli and should 
include staining of the mesangium. The pathogenesis of IgAN has been considerably 
clarified by recent studies. Four processes are needed to come together to induce renal 
injury resulting in IgAN (figure 1). First, the normal glycosylation pattern of IgA1 is altered 
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 Blockade of cytokines/ 
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Figure 1. Model for pathogenesis of IgA nephropathy and current therapeutic options.
Adapted from Floege J. Am J Kidney Dis. 2011 Dec;58(6):992-1004
Table 1. Clinical presentation of IgAN and risk of ESRD.
Clinical presentation Reported prevalence Reported risk of ESRD **
Isolated microscopic hematuria 5% 1-2%
Macroscopic hematuria 20-30% 25%
Hematuria and proteinuria 25-50% 0-60%
Proteinuria <1g/d 30-70% 0-10%
Proteinuria 1-3 g/d 20-47% 30-40%
Proteinuria >3g/d 7-17% 60%
Chronic renal insufficiency 20-35% 30-50%
Nephrotic syndrome * 2-4% 0-15%
Rapidly progressive or crescentic 
glomerulonephritis
2% 40-75%
*   this small group likely represents patients with selective proteinuria and normally appearing glomeruli, apart from 
IgA deposits in the mesangium, and with foot process effacement. These patients should be regarded as primarily 
having minimal change disease. 
** risk of ESRD after 10-20 years.
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and characterised by a deficiency of galactose in the hinge region of the IgA1 heavy 
chains. Second, IgG (or IgA) autoantibodies directed against galactose deficient IgA1 must 
be synthesized. Binding of galactose deficient IgA1 with IgG autoantibodies results in the 
formation of immune complexes, which accumulate in the mesangium. Finally, mesangial 
cells proliferate and produce matrix resulting in fibrosis.
Prediction of outcome
The individual outcome of patients with IgAN remains difficult to predict. Previous 
longitudinal studies have associated proteinuria, hypertension, and impaired kidney 
function at the time of diagnosis with progression of IgAN. The degree of proteinuria is 
one of the strongest predictors of outcome. Whereas in other types of glomerulonephritis 
subnephrotic proteinuria at presentation is not associated with progression of disease, 
such lower levels of proteinuria are of prognostic significance in IgAN. Proteinuria at 
presentation <1g/d is associated with a risk of ESRD at 10 years ~10%, whereas this is up 
to 30-40% in patients with proteinuria 1-3g/d, and even 60% in those with proteinuria 
>3g/d (table 1) 10. Although proteinuria at presentation is an important factor, proteinuria 
over time even more closely correlates with disease outcome11-13. If proteinuria over time 
is maintained <1g/d, the 10 year risk of ESRD is <5%12. Therefore, a reasonable therapeutic 
goal is achieving a consistent level of proteinuria <1g/d. Hypertension at presentation is 
also associated with an increased risk of loss of renal function in patients with IgAN as 
observed in multiple studies across cohorts of different ethnicities10,14,15. Lowering blood 
pressure is beneficial and blood pressure averaged over time is a better predictor of 
prognosis than blood pressure at presentation.
 Most studies investigating prognostic risk factors for progression of renal disease in 
IgAN have found that reduced estimated glomerular filtration (eGFR) at presentation is a 
consistent indicator of risk1,10,14,16-18. This is to be expected since these patients represent a 
subgroup that has already proven to have progressive renal disease as indicated by the 
loss of renal function. 
Therapy
Despite recent advances in clarifying the pathogenesis of IgAN, there is currently no 
treatment at our disposal to specifically halt the production of abberant IgA or prevent 
the mesangial deposition of the IgA containing immune complexes. An optimized 
supportive regimen constitutes the cornerstone of therapeutic approach in patients with 
IgAN (figure 2). Main goals are control of blood pressure and reduction of proteinuria 
preferably by renin-angiotensin blockade. As mentioned above, prognosis is excellent if 
proteinuria is significantly and persistently reduced. However, in a significant number of 
patients lowering of proteinuria to the target of <1.0g/d will prove impossible despite 
optimal supportive therapy. These patients are therefore at increased risk of progressive 
chronic kidney disease. Several randomized controlled trials suggest that a 6-month course 
of steroid therapy can reduce proteinuria and the risk of ESRD13,19,20. This treatment is most 
suited for patients with well-preserved eGFR. Treatment guidelines are less well defined 
for patients who had failed steroid therapy or patients with moderate kidney failure. 
Treatment of IgAN with corticosteroids in combination with other immunosuppressive 
agents remains controversial due to the limited number of trials, conducted in an era 
before the standard use of optimized supportive care. A small study in patients with 
progressive IgAN showed that treatment with prednisolone and cyclophosphamide 
followed by azathioprine resulted in a reduction in proteinuria and improvement in renal 
survival21. Since side effects occur more frequently with double immunosuppression, the 
risks of treatment need to be weighed against the risk of ESRD. Identifying those patients 
who are most likely to progress to ESRD is therefore essential. 
Figure 2. Suggested therapeutic approaches in patient with IgA nephropathy based on KDIGO Clinical Practice 
Guideline for Glomerulonephritis 2012
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Immunosuppressive therapy 
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for crescentic glomerulonephritis
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Rapid decline of renal function
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Role of biomarkers
As described above, clinicians treating patients with IgA nephropathy face a difficult 
task. On one hand, the majority of patients with hematuria and proteinuria <1g/d have a 
good prognosis, yet some develop a progressive decline of kidney function. On the other 
hand, patients with proteinuria >1g/d clearly have an increased risk of developing ESRD, 
but kidney function will remain stable over decades in a substantial number of patients. 
Thus, specific and sensitive biomarkers that allow prediction of outcome and treatment 
response are desperately needed.
 In patients with membranous nephropathy, measurement of low molecular weight 
proteins, which are markers of tubular damage, predict progression of renal failure, thus 
allowing identification of patients who are likely to benefit from immunosuppressive 
treatment22. Kidney injury molecule-1 (KIM-1) is a sensitive marker of early tubular injury. 
KIM-1 expression is absent in a healthy kidney, but induced in both acute and chronic 
kidney damage23. In human kidney disease, elevated urinary KIM-1 levels are strongly 
related to tubular KIM-1 expression24,25, thus urinary KIM-1 levels seem to be a sensitive 
marker of tubulointerstitial damage. 
 In 2005, neutrophil gelatinase-associated lipocalin (NGAL) was first described as a 
biomarker for acute kidney injury after cardiac surgery26. This 25-kD protein is released in 
blood and urine from injured tubular cells due to various stimuli and as such it is an early 
and sensitive marker of renal damage. Urinary NGAL also predicts progression of renal 
disease in human proteinuric kidney disease27. 
hepcidin
Hepcidin, a key hormone of iron homeostasis, has gained interest as a potential biomarker 
of iron status in chronic kidney disease (CKD) and dialysis patients over the last decade. 
Hepcidin was originally described as a peptide with antibacterial and antifungal 
properties28, yet focus shifted as hepcidin was discovered to regulate iron metabolism29. 
The potential role of urinary hepcidin as a biomarker for kidney disease or kidney injury 
was supported by studies that showed that urinary levels of hepcidin predicted renal 
lupus nephritis flares30 and acute kidney injury after coronary surgery31.
Synthesis, structure, and kinetics 
Hepcidin is mainly produced by hepatocytes as a 25 amino-acid peptide (MW of 2.8 kDa) 
and is secreted in the circulation. Subsequent amino-terminal processing of the 25 isoform 
creates two smaller hepcidin fragments of 22 and 20 amino-acids. These smaller isoforms 
have no known biological function. Under normal circumstances, substantial amounts 
can be detected in urine, but not in blood32,33 suggesting that these isoforms are merely 
formed by urinary degradation of hepcidin-25. Recent studies demonstrate hepcidin 
expression by other cells, such as kidney tubules, heart, fat cells, and monocytes34-37. 
Although hepcidin synthesis by these cells may exert local effects, it does not influence 
systemic circulating concentrations. 
 Evidence that circulating hepcidin is bound to α2-macroglobulin with high affinity is 
derived from a single study, suggesting that approximately 90% of hepcidin was protein 
bound38. Clearance of hepcidin is assumed to take place via the kidneys. Unbound 
hepcidin is likely to be freely filtered by the glomerulus due to its low molecular weight. 
In humans fractional excretion of hepcidin is as low as 0-5%, possibly due to tubular 
reabsorption or impairment of free filtration (e.g. by protein binding)39.
Function and regulation
Hepcidin-25 has been shown to participate in iron regulation by binding to the sole 
cellular iron exporter ferroportin, which is present in the membranes of macrophages, 
hepatocytes and enterocytes. Hepcidin-25 induces the internalization and degradation 
of ferroportin, resulting in a decreased dietary iron uptake by the gut and sequestration 
of iron by reticulo-endothelial macrophages. As a consequence, an increase in hepcidin 
production leads to a decrease in plasma iron concentrations (figure 3). In addition, 
hepcidin peptides are able to bind divalent metals40,41, suggesting a non-hormonal role 
for hepcidin in iron metabolism.
Figure 3. Hepcidin and ferroportin interaction. 
 Hepcidin expression is regulated by body iron status, erythropoietic demand, oxygen 
Hepcidin acts by binding to ferroportin, expressed by duodenal enterocytes, macrophages and hepatocytes. 
Binding of hepcidin results in internalization and subsequent degradation of ferroportin. Binding of hepcidin 
to ferroportin expressed on enterocytes leads to a decreased iron absorption from the gut. Binding of hepcidin 
to hepatocytes and macrophages inhibits iron release from these cells. Iron deficiency and erythropoiesis 
suppress the production of hepcidin.
Adapted from Kemna EH et al. Haematologica. 2008 Jan;93(1):90-7.
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tension and inflammatory cytokines. An increased demand for iron - as is the case in 
conditions such as iron deficiency, hypoxia, anemia, and erythropoiesis - inhibits hepcidin 
synthesis, with subsequent release of stored iron and an increase in dietary iron uptake, 
finally resulting in increased plasma iron concentrations. In contrast, iron administration 
and inflammation both enhance hepcidin production, thereby limiting iron uptake, 
increasing macrophage iron sequestration and lowering plasma iron levels.
Assays
In the past, research on hepcidin was hampered by the lack of a reliable assay, but the 
development of new assays allowed study of the role of hepdicin in iron metabolism in 
humans. The first assay to detect hepcidin-25 was a semi quantative Surface-Enhanced 
Laser Desorption/ Ionization Time-of-Flight Mass Spectrometry assay (SELDI-TOF MS)32,42. 
Mass spectrometry assays are labour-intensive and require expensive equipment, yet 
they distinguish hepcidin-25, -22 and -20. Enzyme-linked immune sorbent assays (ELISA) 
are easier to use, but measure total hepcidin concentration with different contributions of 
the isoforms, depending on the specificity of the antibody. Notably, it is not clear whether 
these current assays measure free, bound or total hepcidin.
Hepcidin in renal disease, as an iron biomarker, and in acute kidney injury
Anemia and disturbances in iron homeostasis are common in patients with CKD. Most 
patients can be effectively treated with erythropoietin stimulating agents (ESA), yet 
approximately 10% is hypo- or non-responsive to ESA. Iron deficiency contributes to ESA 
resistance and the majority of hemodialysis patients receive intravenous iron, aiming 
to maintain adequate ferritin levels. Of note, high doses of iron or ESA are potentially 
dangerous. Hepcidin may contribute to ESA resistance through trapping of iron in the 
reticuloendothelial system. As such, hepcidin gained a lot of interest as a tool to guide 
treatment with ESA and iron in anemic CKD patients, instigating explorative clinical 
studies. Serum hepcidin levels were found to be elevated in a small series of patients with 
renal impairment42,43.
 In 2005 Kulaksiz et al. suggested a role for the kidney in the production of hepcidin by 
showing that hepcidin is predominantly present in the distal rat tubule35. Interestingly, in 
humans, lower urine hepcidin 24 hours after ischemic injury was found to be associated 
with an increased risk of renal failure after several days31. Thus, locally available hepcidin, 
due to local synthesis, activation, degradation or delivery via glomerular filtration and 
tubular reabsorption, may promote renal recovery.
connective tissue growth factor 
Tubulointerstitial fibrosis is a common final pathway for many kidney diseases, including 
glomerulopathies, and ultimately results in loss of renal function. Transforming growth 
factor-β (TGF-β) is generally regarded as the key fibrogenic cytokine, and connective 
tissue growth factor (CTGF), a 36 to 38-kDa peptide, is an important downstream mediator 
of TGF-β. CTGF seems a candidate biomarker for monitoring ongoing fibrosis; it is readily 
quantifiable in body fluids by using an ELISA.
 In renal biopsies of patients with diabetes mellitus type 2, tubular expression of CTGF 
correlated with serum creatinine, proteinuria, and interstitial fibrosis44. Elevated urinary 
levels of CTGF are reported in patients with diabetic nephropathy, chronic allograft 
nephropathy, IgA nephropathy, focal segmental glomerulosclerosis, and idiopathic 
membranous nephropathy45,46 and correlate with proteinuria and glomerular filtration 
rate in several studies46,47. Although urinary CTGF may reflect local production, it cannot 
be excluded that increased urinary CTGF levels are the consequence of altered glomerular 
or tubular handling.
aim and outline of the thesis
Aim of this thesis is to investigate the role of known biomarkers as predictors in IgA 
nephropathy (part 1). Furthermore we evaluate the renal handling of new, potential 
biomarkers (part 2), since this information is critical to its appropriate use in animals and/
or humans. 
Part 1. Biomarkers in IgAN
Serum creatinine and proteinuria remain the most important clinically used parameters for 
predicting risk of progression to end-stage renal disease in patients with IgA nephropathy. 
Unfortunately, these established biomarkers have insufficient sensitivity and specificity. 
Tubulointerstitial injury plays a key role in the progression of IgA nephropathy and low 
molecular weight proteins are thought to reflect the degree of interstitial damage. In 
patients with idiopathic membranous nephropathy, measurement of low molecular 
weight proteins, established markers of tubular injury, allows identification of patients 
who are at high risk for progression of renal disease with a reasonable sensitivity and 
specificity. In chapter 2 we evaluate the prognostic value of urinary excretion of low 
molecular weight proteins, for predicting progression of kidney disease in patients with IgA 
nephropathy. In chapter 3 we evaluate the prognostic value of two recently discovered 
alternative markers of active tubular damage, KIM-1 and neutrophil gelatinase-associated 
lipocalin (NGAL), for predicting end-stage renal disease in patients with IgA nephropathy. 
In chapter 4 we describe a pilot study that evaluated the relations of intratubular GMP-17 
positive T-lymphocytes with urinary markers of tubular damage and its prognostic value 
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for predicting ESRD. In chapter 5 we evaluate the effect of immunosuppressive therapy 
in patients with IgAN on renal function and we sought to identify predictors of response 
to therapy.
Part 2. Renal handling of the novel biomarkers hepcidin and CTGF
An ideal renal biomarker allows simple, accurate and reproducible quantification, is a 
sensitive indicator of renal injury, is inexpensive, and provides relevant clinical information 
above and beyond other already available tests. Biomarkers can be measured in fluids, 
such as serum, urine, saliva, sweat, but also in kidney biopsy material. Serum or urine 
biomarkers are preferred because they are readily obtainable. Urine is more likely than 
serum to contain biomarkers reflecting processes in the kidney, yet urine markers may 
degrade in the bladder or in a test tube, and degradation may depend on urinary pH.
 In the context of renal disease, detailed understanding of the renal handling of a 
biomarker is critical to its appropriate use in animals and/or humans. In chapter 6, we 
assess the intra-individual variability of serum hepcidin in haemodialysis patients and 
aim to identify significant determinants of the variability of hepcidin. In chapter 7, we 
evaluate the influence of eGFR on serum levels of hepcidin-25 and its isoforms in patients 
with CKD. In chapter 8, we evaluate whether tubular reabsorption processes influence 
urinary excretion of hepcidin. In chapter 9, we examine whether urinary CTGF is filtered 
by the glomeruli and reabsorbed by the tubules and whether tubular dysfuntion results 
in increased urinary CTGF levels. In chapter 10, we summarize and discuss our principle 
findings.
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Background
Immunoglobulin A nephropathy (IgAN) is characterised by high variability in clinical 
course and outcome. Accurate prediction of prognosis is needed to optimise treatment. 
Urinary α1-microglobulin and β2-microglobulin are markers of tubulointerstitial injury and 
predict the risk of end-stage renal disease (ESRD ) in idiopathic membranous nephropathy. 
We questioned the relevance of these markers in IgAN. 
methods
We included patients with biopsy proven IgAN, who were evaluated for proteinuria in our 
centre between 1995 and 2007. Data were analysed using univariate and multivariate Cox 
regression for the outcome variables ESRD and progression (rise in serum creatinine of 
>50% or start of immunosuppressive therapy).
results
Seventy patients (71% men) were selected. Median age was 39 years, median serum 
creatinine 140 μmol/l, and median proteinuria 2.4 g/day. Median urinary α1-microglobulin 
excretion was 23.5 μg/min (range 3.5-275.3) and median urinary β2-microglobulin 
excretion was 0.4 μg/min (range 0.1-62.1). Both α1m and β2m correlated significantly 
with serum creatinine (r = 0.65, p<0.01 and r = 0.62, p<0.01) and total proteinuria (r = 
0.35, p<0.01 and r = 0.28, p<0.05). During follow-up (median 75 months) 25 patients 
(36%) developed ESRD , and 46 patients (66%) showed progression. 19 patients (27%) 
were treated with immunosuppressive agents. In univariate analysis urinary α1- and β2-
microglobulin predicted ESRD and progression. In multivariate analysis only serum 
creatinine and urinary protein were independent predictors of both outcomes.
conclusion
Urinary excretion of low molecular weight proteins did not offer an advantage over total 
proteinuria and serum creatinine in predicting prognosis in patients with IgAN.
introduction
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. The natural 
history is quite variable and published data must be interpreted with caution since many 
patients with mild disease may never come to clinical attention or undergo a renal biopsy. 
End-stage renal disease (ESRD) develops in 20-30% of patients with IgAN within 20 years 
after diagnosis1-4. 
 Although there is a lack of randomized controlled trials, data suggest that a minority 
of patients may benefit from immunosuppressive treatment5-8. Ideally, such treatment 
should be restricted to patients who will progress to ESRD. Several variables have been 
identified as predictors of prognosis i.e. elevated serum creatinine concentration3, 9-13 
, severe proteinuria9, 14-17, arterial hypertension9, 15, 16 and histological characteristics3, 10, 14, 
15. Few studies have showed that clinical features evaluated after one year of follow-up 
predicted prognosis more accurately than at the time of presentation 17, 18. Recently Reich 
et al. reported that persistent proteinuria is the strongest predictor of poor renal outcome 
in IgAN and that sustained reduction of proteinuria to <1 g/24 h is associated with a good 
prognosis 19. Unfortunately, most markers are not very accurate, with low sensitivity and 
specificity.
 In idiopathic membranous nephropathy, high-risk patients can be identified in an 
early stage by measuring low molecular weight proteins such as α1-microglobulin (α1m) 
and β2-microglobulin (β2m) with a sensitivity of 83% and a specificity of 97%
20-22. We 
aimed to determine whether the excretion of low molecular weight (LMW) proteins adds 
to predicting prognosis in patients with IgAN. 
subjects and methods
Population
Since 1995, we have performed standardized protein measurements in patients with 
proteinuria due to glomerular diseases20,21. Patients are referred to our medical center from 
hospitals located mainly in the south-eastern part of the Netherlands. For the present 
study we analyzed the data of adult patients with biopsy proven IgA nephropathy who 
were evaluated for proteinuria in our center between 1995 and 2007, and followed 
thereafter. Patients with other causes of IgA-positive glomerular staining (systemic lupus 
erythematosus, Henoch-Schönlein purpura or liver disease) or a follow-up of less than 12 
months, were excluded from analysis. 
Baseline measurement
Gender, ethnicity, age, body weight and height were recorded at the time of measurement. 
Details of the measurements have been described21. Two 24-h urine samples were 
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obtained for measurement of creatinine and total protein. The excretion of the low and 
high molecular weight proteins was measured under standardized conditions. A urinary 
pH >6.0 is necessary to allow reliable measurements of urinary β2m. Therefore, patients 
used 4000 mg of oral sodium bicarbonate the evening before the measurement. On 
arrival at the ward an additional 2000-4000 mg sodium bicarbonate was used and up to 
500 ml of tap water was given to enforce diuresis. The patients remained supine during 
2 h except for voiding. Blood pressure measurements were taken using an automated 
device (DINAMAP, Criticon, Tampa FL) with six consecutive readings registered every 5 min 
after 10 min rest; these readings were used to calculate the mean arterial pressure (MAP). 
Measurement of urinary pH, β2m, α1m, immunoglobulin G (IgG), transferrin, albumin, total 
protein and creatinine was performed. Beta2-microglobulin excretion was measured only 
in urine with a urinary pH >6.0. Laboratory parameters were measured in blood samples 
collected in the middle of the urine collection period.
 The use of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin 
II type 1 receptor antagonists (ARBs), calcium channel blockers, other antihypertensive 
agents, diuretics, and non-steroidal anti-inflammatory drugs (NSAIDs), as well as HMG-
CoA-reductase inhibitors, was recorded. Current or previous use of corticosteroids, other 
immunosuppressive agents or fish oil was registered.
 Serum creatinine, cholesterol, urinary total protein, and creatinine were measured with 
standard automated techniques. Urinary proteins were measured as described before 23. 
Follow-up
After baseline measurements, patients were commended to the care of their local 
physicians. Immunosuppressive therapy was advised to patients with progressive renal 
disease. We collected data on serum creatinine, albumin, cholesterol and urea, total urinary 
protein and creatinine levels, blood pressure, body weight and exposure to medication 
during follow-up from medical records. 
Calculations and definitions 
Body mass index (BMI) was calculated from body weight and height at baseline. MAP during 
follow-up was calculated as the diastolic pressure plus one third of the pulse pressure. The 
glomerular filtration rate (GFR) at baseline and follow-up was estimated (eGFR) using the 
abbreviated MDRD equation24, 25. Start of follow-up was defined as the time of standardized 
measurement of proteinuria, regardless of the first assessment suggestive of renal disease. 
We defined the following two renal outcomes: ESRD and progression of renal disease. 
ESRD was defined as initiation of dialysis, renal transplantation or an eGFR <15 ml/min per 
1.73m2. Progression of renal disease was defined as an elevation in serum creatinine of 
50% or more since the baseline measurement, the start of immunosuppressive therapy or 
the development of ESRD. 
Statistical Analysis
Missing values for urinary protein concentration in the 24 hour urine samples were 
imputated by using the urinary protein-creatinine ratio which was obtained from the 
2 hour sample, and by using serum albumin. Missing values for low-molecular weight 
proteins were not imputated. 
All baseline variables were compared for patient groups by χ2-test if dichotomous, one 
way ANOVA if continuous and after log transformation if skewed. Each continuous 
baseline variable was divided into tertiles and plotted in a Kaplan-Meier curve for visual 
inspection.
 Possible collinearity for univariate significant predictors was checked. Predictors that 
had a Spearman’s rho smaller than 0.800 were entered into a multivariate Cox model. 
A backward stepwise selection algorithm, criteria for exclusion being a likelihood 
ratio test with p-value greater than 0.05 and smaller than 0.10 for inclusion, was used. 
Possible interactions, based on plausible mechanism, were entered and tested too. The 
most parsimonious model with the best fit, using generalized R2, was considered most 
appropriate26. Internal validation of the selected model was done with a bootstrapping 
procedure using 1000 samples. The predictive value of this model was investigated by 
the area under the receiver operating characteristics (ROC) curve. 
results
Baseline characteristics and outcome variables
Initial demographic, clinical and laboratory data of 70 patients are listed in Table 1. In 
the majority of patients (57%) proteinuria was >2.0 g/d and the estimated GFR <60 ml/
min/1.73m2. Eighty percent of the population were taking ACEIs or ARBs at the time of 
evaluation for proteinuria. Median duration of follow-up was 74 months. The time period 
between onset of renal disease or biopsy and subsequent referral to our center varied. In 
60% of patients the time between biopsy and referral was less than 6 months.
 During follow-up all patients were treated with ACEIs and/or ARBs. Immunosuppressive 
therapy was initiated in 19 patients, the majority of them (74%) were treated with 
cyclophosphamide combined with prednisone. Twenty-five patients (36%) developed 
ESRD, with the shortest survival time being two months. Five and eight year renal survival 
rates from baseline were 78% and 66% (figure 1). In 46 (66%) patients progression of renal 
disease occurred based on an increase in serum creatinine of >50% (n=35), or initiation of 
immunosuppressive therapy (n=11). Thus, of 19 patients who received immunosuppressive 
therapy during follow-up, 8 patients were treated because of a rise in serum creatinine 
of more than 50%. In 11 patients treatment was started earlier. These patients were 
characterised by higher serum creatinine values at baseline and more severe proteinuria 
(table 1). 
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Low molecular weight proteins
Alpha-1-microglobulin levels were not available for two patients, while β2m levels could 
not be measured in nine patients due to a urinary pH <6.0. The urinary excretion of both 
α1m and β2m was increased in patients with IgAN, with median levels of 23.5 µg/min 
(reference value <10 µg/min) and 0.4 µg/min (reference value <0.2 µg/min). 
There was a high correlation between α1m and β2m (r =0.86, p <0.01). Both α1m and β2m 
correlated significantly with serum creatinine (r =0.65, p <0.01 and r =0.62, p <0.01), IgG 
excretion (r =0.59, p <0.01 and r =0.58, p <0.01), and total proteinuria (r =0.35, p <0.01 and 
r =0.28, p <0.05). 
Predictors of outcome
End-Stage Renal Disease: Urinary α1-microglobulin, β2-microglobulin and IgG excretion, 
serum creatinine and urea levels, total urinary protein, eGFR and the use of diuretics 
before baseline were all significantly associated with ESRD. When evaluating tertiles of 
α1m, renal survival in the highest tertile was markedly lower compared with that in the 
lowest and middle tertiles (94% versus 63% at 5 years, 85% versus 44% after 8 years, p= 
0.001) (figure 2). Only one patient within the lowest tertile of urinary β2m developed ESRD. 
Therefore, renal survival in the lowest tertile of β2m was higher than in the middle and 
highest tertile (figure 3). After multivariate Cox regression analysis only baseline serum 
creatinine and total proteinuria proved significant predictors of ESRD when correcting 
for therapy (table 2). Thus, neither α1m nor β2m were independent predictors of ESRD. 
Of note, patients whom were treated with immunosuppressive agents during follow-up 
were less likely to develop ESRD. 
Table 1. Clinical and dem
ographic characteristics at baseline
 
Total group
Progression
N
o progression
 
rise in serum
 creatinine >50%
therapy
p
n (%
 m
ale)
70 (71.4%
)
35 (74.3%
)
11 (81.8%
)
24 (62.5%
)
0.436
age (yrs)
39 [17-70]
36.0 [17-70]
37 [25-59]
45.5 [20-66]
0.164
BM
I (kg/m
²)
26.2 [19.4 - 41.0]
26.1 [20.4 - 31.1]
27.5 [21.2 - 33.2]
26.3 [19.4 - 41.0]
0.605
M
AP (m
m
 H
g)
101.3 [73 - 133.7]
104 [83 - 133.7]
99.8 [73 - 112]
94.3 [80.0 - 133.2]
0.113
urinary protein (g/d)
2.4 [0.4 - 24.4]
2.9 [0.5 - 12.6]
3.6 [0.4 - 24.3]
1.7 [0.4 - 9.6]
0.090
protein-creatinine ratio (g/10m
m
ol)
2.9 [0.5 - 18.2]
3.5 [1.0 - 16.1]
4.5 [0.6 - 18.2]
1.2 [0.5 - 13.3]
0.093
serum
 creatinine (µm
ol/l)
139.5 [70 - 366]
149 [76 - 366]
186 [100 - 274]
112 [70 - 172]
<0.001
serum
 urea (µm
ol/l)
8.3 [4 - 36]
9.1 [4 - 36]
11.1 [6 - 22]
6.3 [4 - 14]
0.007
serum
 album
in (g/l)
38.0 [21 - 46]
38.0 [21 - 46]
37.0 [29 - 45]
39.0 [30 - 44]
0.847
serum
 cholesterol (m
m
ol/l)
5.7 [3.5 - 8.9]
5.9 [3.6 - 8.7]
5.1 [3.6 - 8.9]
5.7 [3.5 - 7.2]
0.468
M
D
RD
4 (m
l/m
in/1.73 m
2)
48.2 [16.5 - 95.5]
44.9 [16.5 - 86.7]
37.1 [22.3 - 82.0]
54.7 [36.3 - 95.5]
0.003
α
₁ -m
icroglobulin excretion (µg/m
in)
23.5 [3.5 - 275.3]
30.6 [3.5 - 275.3]
48.0 [7.8 - 192.0]
14.9 [4.1 - 48.4]
0.010
β
₂ -m
icroglobulin excretion (µg/m
in)
0.4 [0.1 - 62.1]
1.1 [0.1 - 62.1]
1.15 [0.1 - 36.0]
0.30 [0.1 - 27.0]
0.077
IgG
 excretion (m
g/d)
111.4 [11.3 - 1327.2]
144.8 [16.2 - 1327.2]
111.4 [11.3 - 900.1]
68.2 [13.5 - 786.9]
0.038
ESRD
35.70%
65.70%
18.20%
0%
<0.001
tim
e until ESRD
 of last follow
-up (m
onths)
74.6 [2.2 - 145.6]
72.7 [2.2 - 145.6]
97.5 [6.1 - 135.5]
76.9 [12.9 - 125.9]
0.676
tim
e until progression or last follow
-up (m
onths)
39.4 [0.2 - 125.9]
28.1 [0.5 - 114.5]
2.1 [0.2 - 75.6]
76.9 [12.9 - 125.9]
<0.001
interval betw
een biopsy and referral* (m
onths)
2.0 [0 - 209.7-]
5.0 [0 - 187.5
0.7 [0 - 98.9]
1.8 [0 - 209.7
0.965
interval betw
een onset and referral (m
onths)
29.3 [219.7 - 2.0]
38.6 [195.9 - 4.1]
36.0 [179.7 - 2.3]
8.8 [219.7 - 2.0]
0.592
use of ACEi/ARBs before baseline
80.00%
80.00%
81.80%
79.20%
0.984
use of diuretics before baseline
30.00%
34.30%
27.30%
25.00%
0.729
use of other anti-hypertensive m
edication
34.30%
37.10%
45.50%
25.00%
0.437
use of im
m
unosuppressive treatm
ent before baseline
4.30%
5.70%
9.10%
0.00%
0.393
use of ACEi/ARBs during follow
-up
100.00%
100.00%
100.00%
100.00%
use of diuretics during follow
-up
68.60%
71.40%
90.90%
54.20%
0.082
use of other anti-hypertensive m
edication during follow
-up
54.30%
62.90%
63.60%
37.50%
0.126
use of im
m
unosuppressive drugs during follow
-up
27.14%
22.86%
100.00%
0.00%
<0.001
D
ata are expressed as m
edian [range]. *In a few
 patients biopsy w
as perform
ed after evaluation for proteinuria. 
P-values are from
 χ
2-test or AN
O
VA com
paring the three groups: rise in serum
 creatinine, therapy and non-progressors. BM
I; body m
ass index, M
AP; m
ean arterial pressure, 
M
D
RD
; m
odification of diet in renal disease quation, ESRD
; end-stage renal disease, ACEI; angiotensin-converting enzym
e inhibitors, ARB; angiotensin II type I receptor 
antagonist
Renal survival was defined as onset of ESRD.
Figure 1. Renal survival curve in patients with IgAN.
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Progression of renal disease: Urinary α1-microglobulin, β2-microglobulin and IgG excretion, 
serum creatinine and urea levels, total urinary protein, eGFR and age, were significant 
predictors of progression in univariate analysis. Multivariate Cox regression showed that 
only serum creatinine and total urinary protein were independent significant predictors 
of progression (table 2).
Renal survival was defined as onset of ESRD.
Renal survival was defined as onset of ESRD.
Figure 2. Renal survival curve for tertiles of α1-microglobulin in patients with IgAN.
Figure 3. Renal survival curve for tertiles of β2-microglobulin in patients with IgAN.
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Discussion
Our data clearly indicate that the urinary excretion of low molecular weight proteins does 
not predict prognosis in IgAN more accurately than total proteinuria. To our knowledge 
we are the first to report on the prognostic value of urinary excretion of α1- microglobulin 
and β2- microglobulin in IgAN. Others have found a highly significant relation between 
tubulointerstitial damage and the presence of unspecified, urinary LMW proteins, in a 
small cohort of patients with IgAN27. Woo et al. reported a higher incidence of chronic renal 
failure in 60 patients with IgAN who presented with LMW proteinuria and were followed 
for 6 years28. However, patients with LMW proteinuria had more severe proteinuria and 
higher serum creatinine levels.
 In our patients with IgAN urinary excretion of α1m and β2m exceeded normal values. 
Renal survival was significantly lower in patients with values of urinary α1m and β2m in 
higher tertiles. We observed a difference when comparing renal survival curves for tertiles 
of urinary α1m and β2m excretion. This seemingly discrepancy can be explained by the fact 
that β2m could not be measured in 9 patients due to a low urinary pH. These patients were 
characterised by higher serum creatinine levels and more severe proteinuria. Thus, missing 
values are not at random but reflect a impairment of renal function and bicarbonate 
excretion. This illustrates the limitations of β2m as a prognostic marker. Both urinary α1m 
and β2m predicted ESRD and progression of renal disease in univariate analysis. However, 
in multivariate analysis they did not prove to be independent predictors of either outcome. 
These findings are in contrast with previous reports on the good performance of LMW 
proteins as prognostic markers in patients with idiopathic membranous nephropathy. 
Urinary α1m and β2m are considered to reflect tubulointerstitial injury. In general, the 
presence and extent of tubulointerstitial injury determines renal outcome. From this 
perspective, the difference in the predictive value of LMW proteins between IgAN and 
idiopathic membranous nephropathy is remarkable. Of note, the predictive value of LMW 
proteins (such as α1m) in idiopathic membranous nephropathy was validated in patients 
with no or moderate renal impairment, defined as a serum creatinine <135 μmol/l. 
However, even within the subgroup of patients with IgAN and a serum creatinine level 
of <135 μmol/l, α1m does not allow identification of high-risk patients. This difference 
is illustrated in the panels of figure 4. From the figure it is evident that levels of α1m are 
higher in patients with idiopathic membranous nephropathy. These patients presented 
more frequently with nephrotic range proteinuria. Thus, the prognostic value of these 
LMW proteins may be confined to glomerulopathies characterized by nephrotic range 
proteinuria. 
We found baseline serum creatinine and proteinuria to predict ESRD and progression 
of renal disease. The relation between serum creatinine and ESRD is to be expected, 
since a patient with a higher serum creatinine concentration will develop ESRD at an 
earlier time-point, even if the rate of renal function deterioration is similar. To overcome 
this problem we defined a 50% or more increase of serum creatinine concentration as 
progression. We chose a 50% rise to be sure that patients who had a minor increase 
were not marked as progressors. Since multivariate analysis regarding the outcome 
ESRD implied that the natural progression of IgAN is influenced by immunosuppressive 
therapy, this was considered an end-point. The use of initiation of immunosuppressive 
therapy as an end-point can be debated. In our study, 19 out of 70 patients received 
immunosuppressive therapy during follow-up. In 8 patients, treatment was started after 
serum creatinine had increased by 50% or more. The remaining 11 patients received 
immunosuppressive treatment before reaching this 50% rise in serum creatinine. These 
patients were characterized by high serum creatinine and more severe proteinuria at 
baseline. Further delay of treatment was considered inappropriate by their physicians. 
As such, these patients reflect current treatment practice in our region. At the time of 
start of therapy, mean serum creatinine was 221µmol/l, clearly pointing to the severity of 
IgAN. Even with progression as outcome, serum creatinine level and total urinary protein 
excretion remained significant, independent predictors. 
The observation that serum creatinine concentration is a significant, independent 
predictor of progression of renal disease implies that an accelerated rather than a linear 
decline in renal function occurs in the course of the disease. In order to correct for the 
Figure 4A. Correlation between α1-microglobulin and 
proteinuria in patients with iMN.
Figure 4B. Correlation between α1-microglobulin and 
proteinuria in patients with IgAN.
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conclusion
Urinary excretion of the low molecular weight proteins α1- microglobulin and β2- 
microglobulin does not add to predicting prognosis of IgAN. Serum creatinine 
concentration and urinary protein excretion are the most potent predictors of progression 
of IgA nephropathy. 
possible confounding effect of using initiation of immunosuppressive therapy as an 
end-point, we reanalyzed the data using an increase of serum creatinine of >50% as 
only end-point. Serum creatinine concentration remained a significant predictor, which 
possibly reflects that patients with an increased serum creatinine are more likely to 
progress or progress at a faster rate than those with no renal impairment. Our findings 
support observations reported by others and is in line with the hypothesis that loss of 
nephrons gives rise to hyperfiltration of a reduced number of nephrons leading to further 
destruction of nephrons and an accelerated deterioration of renal function29, 30. 
Although data are scarce, immunosuppressive medication may be of benefit for patients 
failing a supportive approach and at high risk for progressive loss of renal function. In 
order to avoid unnecessary immunosuppressive therapy, a model with a high specificity 
is required to guide clinical decisions regarding treatment. When constructing an receiver 
operating characteristics curve (ROC), our model predicting ESRD using serum creatinine 
concentration and urinary protein concentration has an area under the curve (AUC) of 
0.88 (95% CI 0.78-0.95). When predicting progression of renal disease using the same 
variables, the AUC was 0.80 (95% CI 0.69-0.91). Although these values indicate a reasonably 
good performance of our models, closer examination of data learns that a specificity of 
90% is accompanied by a low sensitivity (50-60%). Our models are therefore unsuitable to 
guide clinical decisions. The identification of more accurate prognostic markers remains 
essential.
Admittedly, this study has several limitations. First, it describes a relatively small number 
of patients. Second, when compared to other reported populations, eGFR is lower and 
proteinuria is more severe in our cohort despite a comparable blood pressure. A large 
percentage of patients shows fast progression and many patients developed ESRD. This 
may be due to a selection bias since patients with stable serum creatinine and moderate 
proteinuria are less likely to be biopsied and/or referred to our medical center. Since 
many patients were biopsied in another hospital and material was unavailable, we were 
unable to correlate urinary α1m and β2m with histopathological characteristics. On the 
other hand, in contrary to earlier populations examined, this cohort is comprised of 
patients who were all treated with ACEIs and/ or ARBs, an important element of therapy 
nowadays. Furthermore, we ruled out an effect of therapy while analysing data. Finally, 
the lack of a validation group, as in every other study evaluating the prognostic predictors 
for progression of IgAN, was corrected for by bootstrapping. 
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Background
The variable course of immunoglobulin A nephropathy (IgAN) warrants accurate tools 
for the prediction of progression. Urinary kidney injury molecule-1 (KIM-1) and neutrophil 
gelatinase-associated lipocalin (NGAL) are markers for the detection of early tubular 
damage caused by various renal conditions. We evaluated the prognostic value of these 
markers in patients with IgAN.
methods
We included patients (n=65, 72% male, age 43±13 yrs) with biopsy proven IgAN who were 
evaluated for proteinuria. Urinary KIM-1 and NGAL were measured by enzyme-linked 
immunosorbent assay. We analysed data using Cox regression for the outcome end-stage 
renal disease (ESRD).
results
Median serum creatinine was 142 µmol/L and proteinuria 2.2 g/day. During follow-up 
(median 75 months), 23 patients (35%) developed ESRD. In patients with IgAN median 
urinary KIM-1 excretion was 1.7 ng/min and NGAL excretion was 47 ng/min, both 
significantly higher than in healthy controls. KIM-1 and NGAL were correlated with 
proteinuria (r=0.40 and 0.34 respectively, p<0.01) and each other (r=0.53, p<0.01) but not 
with estimated glomerular filtration rate (eGFR). Interestingly, KIM-1 was not significantly 
correlated with the excretion of α1-microglobulin and β2-microglobulin, known markers 
of tubular injury. Univariate analysis showed that baseline serum creatinine, urinary 
excretion of total protein, α1-microglobulin, β2-microglobulin, IgG, KIM-1 and NGAL were 
significantly associated with ESRD. By multivariate analysis, serum creatinine and KIM-1 
excretion, proved significant independent predictors of ESRD. 
conclusion
KIM-1 and NGAL excretion are increased in patients with IgAN and correlate with 
proteinuria but not with estimated glomerular filtration rate (eGFR). Baseline serum 
creatinine and urinary KIM-1, but not proteinuria, are independent predictors of ESRD. 
introduction
The presentation and course of IgA nephropathy (IgAN) is extremely variable. Long-
term studies report that up to 30% of patients with IgAN progress to end-stage renal 
disease (ESRD) by 20 years1-3. Obviously, published data must be interpreted with caution 
since many patients with mild disease may never come to clinical attention or undergo 
a renal biopsy. The optimal treatment of IgAN remains debatable due to a lack of 
randomized controlled trials. Recent studies suggest that a subset of patients benefits 
from immunosuppressive agents4-6. Ideally, such therapy should be confined to patients 
who will eventually progress to ESRD. However, accurate prediction of ESRD remains a 
challenge. 
 Elevated serum creatinine concentration7-10, severe proteinuria7;11-14, arterial hyper-
tension7;12;14 and histological characteristics2;8;11;14;15 have been identified as baseline 
predictors of prognosis. A few trials have indicated that clinical features evaluated after 
one year of follow-up predicted prognosis more accurately than characteristics at the 
time of presentation13;16. Recently Reich et al. reported that persistent proteinuria is the 
most potent predictor of poor renal outcome in IgAN and that a sustained reduction of 
proteinuria < 1g/day is associated with a good prognosis17. Unfortunately, these prognostic 
markers all have low sensitivity and specificity. More accurate prognostic tools are thus 
needed to predict the course of IgAN and guide decisions regarding treatment.
 Tubulointerstitial injury plays an important role in the progression of IgAN15, as in many 
other renal diseases18. Low molecular weight proteins are thought to reflect the amount of 
interstitial damage. In idiopathic membranous nephropathy, high-risk patients can in fact 
be identified in an early stage by measuring low molecular weight proteins such as α1-
microglobulin (α1m) and β2-microglobulin (β2m) with a sensitivity of 83% and a specificity 
of 97%19-21. Remarkably, the excretion of these low molecular weight proteins does not 
predict renal outcome in patients suffering from IgAN22. Therefore, other biomarkers 
for tubular damage are needed to predict outcome in IgAN. Kidney injury molecule-1 
(KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) are recently discovered 
biomarkers of renal injury, foremost studied in the setting of acute kidney injury23;24. KIM-1 
is selectively expressed by injured proximal tubular cells, providing a strong impetus for 
using KIM-1 as a biomarker of early tubular damage25. Moreover, elevated urinary KIM-
1 levels are strongly related to tubular KIM-1 expression in experimental and in human 
renal disease25-28. KIM-1 has prognostic value not only in acute kidney injury, but also in 
renal transplant recipients, predicting graft loss independent of proteinuria29. Also, urinary 
NGAL has recently emerged as a marker for the detection of early tubular damage, 
predicting progressive renal function decline in human proteinuric disease30-32. We 
therefore investigated whether urinary excretion of KIM-1 and NGAL predict prognosis in 
patients with IgAN.
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materials and methods
Population
In our center, patients with proteinuria due to glomerular diseases are evaluated using a 
standard protocol since 199519. For the present study we analysed the data of adult patients 
with biopsy-proven IgAN who were evaluated for proteinuria in our center between 1995 
and 2007, and followed thereafter. Patients with other causes of IgA-positive glomerular 
staining (systemic lupus erythematosus, Henoch-Schönlein purpura or liver disease) or a 
follow-up of less than 12 months, were excluded from the analysis. Patients were recruited 
from hospitals located mainly in the south-eastern part of the Netherlands.
 Controls were matched for age and gender and were considered healthy if they had 
no history of cardiovascular and/or renal disease, used no medication, had a normal 
blood pressure (systolic blood pressure <140 and diastolic blood pressure <90mmHg) 
and an estimated glomerular filtration rate (eGFR) >60 ml/min/1.73m2. This study was 
performed in adherence to the declaration of Helsinki and approved by the Hospital 
Ethical Committee. All subjects gave written informed consent.
Baseline measurement
All measurements were carried out in the morning, after an overnight fast. Details of the 
measurements have been described elsewhere20. Gender, ethnicity, age, body weight 
and height were recorded at the time of measurement. Two 24-h urine samples were 
obtained for measurement of creatinine and total protein. A urinary pH >6.0 is needed 
to prevent degradation of urinary β2m. Therefore, patients used 4000 mg of oral sodium 
bicarbonate the evening before the measurement. Upon arrival an additional 2000-4000 
mg sodium bicarbonate was given and patients drank 375-500 ml of tap water to enforce 
diuresis. The patients remained supine during 2 h except for voiding. Blood pressure 
measurements were taken using an automated device (Dinamap, Criticon, Tampa FL) with 
six consecutive readings registered every 5 min after 10 min rest; these readings were 
used to calculate the mean arterial pressure (MAP). In controls, measurement of urinary 
protein, KIM-1, NGAL, immunoglobulin G (IgG), albumin and β2m was performed in a 24 
h urine sample.
 Measurement of urinary pH, β2m, α1m, IgG, transferrin, albumin, total protein and 
creatinine was performed. Urine was immediately stored at -80°C until measurement 
of KIM-1 and NGAL. Urinary KIM-1 and NGAL were measured by enzyme-linked 
immunosorbent assy (ELISA) (intra-assay coefficient of variation 7.4%, 6.8%). Antibodies 
were obtained from R&D systems, Minneapolis, USA. Urine samples were diluted two 
times for KIM-1 and 10 or 100 times for NGAL. Detection limit for KIM-1 was 0.042 ng/ml, 
for NGAL 0.63 ng/ml. Laboratory parameters were measured in blood samples collected 
in the middle of the urine collection period. Serum creatinine, cholesterol, urinary total 
protein, and creatinine were measured with standard automated techniques. Urinary 
proteins were measured as described before33. Only in urine with a urinary pH >6.0 β2m 
excretion was measured. 
 The use of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin 
II type 1 receptor antagonists (ARBs), calcium channel blockers, other antihypertensive 
agents, diuretics, and non-steroidal anti-inflammatory drugs (NSAIDs), as well as HMG-
CoA-reductase inhibitors, was recorded. Current or previous use of corticosteroids, other 
immunosuppressive agents or fish oil was registered.
Follow-up
After standardized protein measurements, patients were entrusted to the care of their 
local physicians. Immunosuppressive therapy was advised to patients with progression 
of renal disease. During follow-up we collected data from medical records on serum 
creatinine, albumin, cholesterol, urea, total urinary protein and creatinine levels, blood 
pressure, body weight and use of medication.
Histological classification
Patients were included for evaluation of renal biopsy material if the interval between 
the time of renal biopsy and baseline measurement was ≤ 6 months. Light microscopic 
assessment of renal biopsies was performed in accordance with the Oxford Classification 
of IgA nephropathy15 by a single experienced renal pathologist.
Calculations and definitions 
Body mass index (BMI) was calculated as the ratio between baseline weight and height 
squared. MAP was calculated as the diastolic pressure plus one-third of the pulse pressure. 
The glomerular filtration rate (GFR) at baseline and follow-up was estimated using the 
abbreviated modification of diet in renal disease (MDRD) equation35. Start of follow-up 
was defined as the time of standardized measurement of proteinuria, regardless of the 
first assessment suggestive of renal disease. We defined the outcome ESRD as initiation of 
dialysis, renal transplantation or an eGFR <15 ml/min per 1.73m2. 
Statistical Analysis
Missing values for total urinary protein concentration in the 24-h urine samples were 
imputated by using the urinary protein-creatinine ratio, which was derived from the 
2-h sample, and by using serum albumin. Parameters between groups were compared 
using the Mann–Whitney or Kruskal–Wallis test for non-parametric continuous data, 
independent t-test for parametric data and the chi-square test for categorical data. 
Spearman’s bivariate correlation test was used to examine correlation between 
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nonparametric data. Possible collinearity for univariate significant predictors was checked. 
Predictors that had a Spearman’s rho < 0.80 were entered into a multivariate Cox model. 
A backward stepwise selection algorithm, criteria for exclusion being a likelihood ratio 
test with p-value greater than 0.05 and smaller than 0.10 for inclusion, was used. The 
predictive value of this model was investigated by the area under the receiver operating 
characteristics (ROC) curve. Statistical analysis was performed using SPSS for Windows 
software, version 16.0 (SPSS Inc., Chicago, IL).
results
We studied 65 patients with IgAN and 65 matched healthy controls. Baseline characteristics 
are presented in Table 1. IgAN patients had a higher BMI, higher blood pressure (despite 
frequent use of antihypertensive medication), and serum creatinine. In more than 70% of 
the patients, the baseline measurement was performed within 1 yr after renal biopsy. In 
the majority of patients (57%) proteinuria was >2.0 g/d and the eGFR <60 ml/min/1.73m2. 
Eighty-two percent of the population was using ACEIs or ARBs at the time of evaluation 
for proteinuria. Two patients had previously been treated with steroids. Median duration 
of follow-up was 75 (range 3-146) months. During follow-up all patients were treated 
with ACEIs and/or ARBs. Immunosuppressive therapy was initiated in 19 patients who 
had either progressive deterioration of renal function or persistent proteinuria. The 
majority of them (74%) received cyclophosphamide combined with prednisone. Twenty-
three patients (35%) reached the predefined end point of ESRD. Six of these patients had 
received immunosuppressive therapy. Overall renal survival was 78% at 5 years, and 70% 
at 8 years. The renal survival curve is depicted in Figure 1. 
KIM-1 and NGAL excretion
In patients with IgAN median urinary KIM-1 excretion was 1.7 (interquartile range (IQR) 0.8-
3.1) ng/min and urinary NGAL excretion was 47 (IQR 21.7-104.0) ng/min, both significantly 
higher than values in healthy controls (KIM-1 0.6 (IQR 0.3-0.9) ng/min, NGAL 16.2 (IQR11.3-
21.5) ng/min) (Figure 2). KIM-1 and NGAL were significantly correlated with proteinuria 
(r=0.40 and 0.35 respectively, p<0.01, Fgure 3A) and each other (r=0.53, p<0.01) but not 
with serum creatinine or eGFR (Table 2). Interestingly, KIM-1 was not significantly correlated 
with urinary β2m (Figure 3B) and α1m. There was only a weak correlation between NGAL 
and urinary β2m and α1m. 
Table 1. Clinical and demographic characteristics at baseline
Variable IgAN patients 
n=65
Healthy controls
n=65
p-value
gender (% male) 72 69 0.70
age (yrs) 42±13 39±12 0.97
BMI (kg/m²) 27±4 25±3 <0.05
MAP (mmHg) 101±13 91±8 <0.05
serum albumin (g/l) 38 (21-46) n.a. -
serum cholesterol (mmol/l) 5.8±1.3 4.8±0.8 <0.05
serum creatinine (µmol/l) 142 (70-362) 78 (52-96) <0.05
eGFR (ml/min/1.73 m2) 50±21 92±12 <0.05
proteinuria (g/d) 2.2 (0.4-24.4) n.a. -
KIM-1 excretion (ng/min) 1.7 [0.8-3.1] 0.6 [0.4-0.9] <0.01
NGAL excretion (ng/min) 47 [21.7-104.0] 15.6 [10.4-19.9] <0.01
α₁-microglobulin excretion (µg/min) 24.3 [12.1-48.3]# n.a. -
β₂-microglobulin excretion (µg/min) 0.4 [0.1-2.4]## 0.06 [0.03-0.08] <0.05
IgG excretion (mg/d) 105 [50-201] 0 [0-5.21] <0.05
albumin excretion (mg/d) 2389 [1044-3369] 7.7 [6.0-11.3] <0.05
interval between biopsy and referral* (months) 2.0 (-53-209) - -
use of ACEI/ARBs at baseline (%) 82 0 <0.05
use of diuretics at baseline (%) 31 0 <0.05
use of other anti-hypertensive medication (%) 35 0 <0.05
use of immunosuppressive treatment before 
baseline (%)
3 0 <0.05
Data are expressed as mean±SD, median (range) or median [interquartile range]. Abbreviations are: BMI, body 
mass index; MAP, mean arterial pressure; eGFR, estimated glomerular filtration rate; IgG, immunoglobulin G; KIM-
1, Kidney Injury Molecule 1; NGAL, Neutrophil Gelatinase-Associated Lipocalin, n.a. : not available.
*In few patients biopsy was performed after evaluation for proteinuria. 
# In two patients data on α₁m excretion were not available.
## In nine patients β ₂m excretion could not reliably be measured due to a urinary pH<6.0.
Figure 1. Renal survival curve in patients with IgAN.Renal survival was defined as onset of ESRD.
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Predictors of ESRD
In univariate Cox regression analysis, urinary KIM-1, NGAL, α1-microglobulin, β2-
microglobulin and IgG excretion, total urinary protein, serum creatinine, and eGFR were 
all significantly associated with ESRD (Table 3). By multivariate Cox regression analysis 
baseline serum creatinine, KIM-1 excretion, and immunosuppressive therapy, but not 
proteinuria, proved significant predictors of ESRD. Thus, KIM-1 excretion is an independent 
predictor of ESRD. When constructing a ROC curve, our model predicting ESRD using 
serum creatinine concentration and KIM-1 excretion had an area under the curve (AUC) of 
0.86 (95% confidence interval 0.77-0.95). 
Correlations with histology
Renal biopsy material, obtained within 6 months before or after baseline measurement, 
was available for 36 of 65 patients. In this subgroup of patients (69% male), mean age was 
42±14 years, mean MAP 101±13 mmHg, median serum creatinine 145 µmol/L (range 70-
276), median eGFR 45 (range 22-95) ml/min/1.73m2 and median proteinuria 3.2 (range 0.5-
24.2) g/d at baseline. During a median follow-up of 76 months, 9 patients (25%) received 
immunosuppressive therapy and 13 patients (36%) developed ESRD. The median number 
of glomeruli per biopsy was 12. Data are given in Table 4. The tubulointerstitial score 
correlated with eGFR and with the urinary excretion of the low molecular weight proteins 
α1m and β2m. A higher tubulointerstitial score was also associated with a higher risk of 
ESRD (67% in patients with T2 versus 21% in patients with T0+1, p=0.01). In contrast, the 
tubulointerstitial score did not correlate with KIM-1 or NGAL excretion.
Discussion
Our data indicate that serum creatinine and urinary excretion of KIM-1, but not proteinuria, 
are independent predictors of renal outcome in patients with IgAN. To our knowledge, 
we are the first to report long-term follow-up data on the prognostic value of urinary KIM-
1 and NGAL excretion in primary renal disease. 
 KIM-1 is a recently discovered type I transmembrane protein that is not detected in 
normal kidneys but is up regulated in renal proximal tubules after both acute and chronic 
injury due to various renal diseases23;25;30. Cleavage of KIM-1 by metalloproteinases leads to 
shedding of its soluble 90-kDa ectodomain in the urine. Urinary KIM-1 levels are strongly 
correlated with tubular KIM-1 expression in experimental and human renal disease25-28. 
KIM-1 is thought to be involved in the development of tubular cell injury and interstitial 
fibrosis. It remains unclear if KIM-1 is actively regulating inflammation or a response to 
tubular damage, reflecting tubular repair mechanisms. Experimental data suggest that 
KIM-1, located on epithelial cells, mediates phagocytosis of apoptotic and necrotic cells 
by binding to phosphatidylserine and oxidized lipid epitopes on the apoptotic cell 
Figure 2. Urinary excretion of NGAL and KIM-1 in healthy controls and in patients with IgAN.
Figure 3A. Correlation between urinary KIM-1 excretion and proteinuria in patients with IgAN.
Figure 3B. Correlation between urinary KIM-1 excretion and β2-microglobulin excretion in patients with IgAN.
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surface36. Overall, experimental and human data strongly suggest that KIM-1 reflects 
tubulointerstitial injury and repair37;38. Since urinary KIM-1 is strongly correlated with renal 
tubular expression, it seems a promising biomarker. 
 NGAL is a soluble 25-kDa acute phase protein and was originally purified from 
neutrophils. It is expressed at low levels in several human tissues including the kidney and 
its expression is induced by epithelial injury. Urine and plasma NGAL levels are reported 
to be independent early predictors of acute kidney injury in several studies, mostly 
performed in patients undergoing cardiac surgery39-41. Ding et al. measured urinary 
NGAL in 70 non-hypertensive IgAN patients with normal renal function and proteinuria 
>1.0 g/day while not on ACEIs/ARBs31. They found significantly increased urinary NGAL 
levels in patients with Lee grade III IgAN. Recently, urinary NGAL excretion was shown to 
be a strong predictor of progressive renal function decline during follow-up in human 
proteinuric renal disease42. 
 In the present study urinary KIM-1 and NGAL levels were elevated in patients with IgAN 
compared to healthy controls. Furthermore, KIM-1 and NGAL excretion were significantly 
associated with the development of ESRD, as were known prognostic markers such as 
serum creatinine and proteinuria. Yet, by multivariate analysis KIM-1 along with serum 
creatinine, and not proteinuria nor NGAL, proved to be independent predictors of ESRD. 
Others have reported that proteinuria at diagnosis is not a predictor of renal outcome13;16. 
Moreover, a recent retrospective study performed in over 500 patients with IgAN, 
showed that proteinuria during follow-up was a strong predictor of renal outcome17. 
Patients who reached proteinuria <1 g/day had an excellent prognosis, regardless of 
Table 2. Correlation of urinary KIM-1 with other demographic and biochemical variables. 
Variable rho P-value 
Gender 0.10 0.41
Age -0.11 0.39
BMI -0.11 0.39
MAP -0.11 0.41
Serum albumin -0.52 <0.01
Serum cholesterol 0.23 0.07
Serum creatinine -0.24 0.06
eGFR 0.24 0.06 
Urinary protein 0.40 <0.01
Urinary NGAL 0.53 <0.01 
Urinary α₁-microglobulin 0.15 0.25 
Urinary β₂-microglobulin 0.12 0.36 
Urinary IgG 0.41 <0.01 
Urinary albumin 0.48 <0.01 
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the level of baseline proteinuria. We have previously analysed the data of this patient 
cohort and reported urinary protein as an independent predictor of ESRD, along with 
serum creatinine22. The current analysis clearly indicates that KIM-1 excretion is a better 
predictor than proteinuria, suggesting that KIM-1 provides additional information on 
tubular processes involved in progressive renal failure. Urinary excretion of α1m and β2m - 
established markers of tubulointerstitial injury - is increased in IgAN, but does not predict 
outcome in these patients. KIM-1 was not correlated with α1m and β2m and did prove 
to be an independent predictor of ESRD. This finding underscores the potential of KIM-
1. One could hypothesize that KIM-1 may reflect the process of active tubular damage 
that precedes the development of fibrosis, whereas low molecular weight proteins reflect 
chronic tubulointerstitial injury in patients with IgAN. Analysis of the correlation between 
pathological lesions and baseline characteristics confirms this hypothesis. As expected, 
the tubulointerstitial score correlated with eGFR and with the urinary excretion of the 
low molecular weight proteins. In contrast, the tubulointerstitial score did not correlate 
with KIM-1 excretion, although KIM-1 levels were numerically higher in patients with T2 
score. When constructing an ROC curve, our model predicting ESRD that uses urinary 
KIM-1 excretion and serum creatinine has an area under the curve of 0.86. This indicates 
a reasonable accuracy. However, a specificity of 90% is accompanied by a sensitivity of 
only 60%. Thus, the predictive value of the model is still limited and should not be used to 
guide decisions regarding immunosuppressive therapy in individual patients. Moreover, 
in this cohort of patients with moderate to severe renal impairment at baseline indicating 
the presence of chronic tubulointerstitial injury, serum creatinine was, not unexpectedly, 
the most powerful predictor of ESRD. Our data suggest that urinary KIM-1 excretion may 
be of particular value in patients with normal or mildly impaired renal function, since high 
KIM-1 excretion (i.e. above the median value) predicted progression of ESRD in a subgroup 
of patients with a serum creatinine ≤135 μmol/l (Figure 4). In 15 of these patients, a renal 
biopsy was performed within 6 months of baseline. The vast majority (n=12) was scored 
as having no or absent tubulointerstitial fibrosis (T0), indicating that the patients depicted 
in Figure 4 are indeed expected to have no or minimal tubulointerstitial damage. This 
needs further study. 
 Admittedly, this study has several limitations. First, it describes a small number of 
patients and no follow-up data on the course of KIM-1 and NGAL were obtained. Second, 
when compared to other reported populations, renal impairment and proteinuria are 
more severe in our cohort despite a similar blood pressure. Fast progression of renal 
disease was observed in a large percentage of subjects and eventually many patients 
developed ESRD. Since patients with stable serum creatinine and moderate proteinuria 
are less likely to be biopsied and/or referred to our hospital, this may be due to a selection 
bias. On the other hand, contrary to previously reported populations, this cohort is 
comprised of patients who were all treated with ACEIs and/ or ARBs, an important element 
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of current therapy. Lastly, we cannot exclude a confounding effect of immunosuppressive 
therapy, since 19 patients received immunosuppressive agents and multivariate analysis 
implied that these patients were less likely to develop ESRD. Yet, KIM-1 excretion was 
significantly higher in patients who received immunosuppressive therapy compared to 
those who received supportive treatment (median 3.1 (IQR 1.3-5.5) versus 1.5 (IQR 0.7-2.2) 
ng/ml, p=0.02). Thus, KIM-1 excretion remained a predictor of ESRD, despite a possible 
beneficial effect of immunosuppressive therapy in a subgroup of patients exhibiting 
increased urinary KIM-1 excretion. Therefore, if any confounding effect has occurred, 
the use of immunosuppressive therapy may have attenuated the predictive value of 
KIM-1 excretion in this cohort. The results of our study should be confirmed in a larger 
population, preferably consisting of patients with varying degrees of renal impairment.
conclusion
Urinary KIM-1 and NGAL excretion are increased in patients with IgAN and correlate with 
proteinuria but not with eGFR, urinary β2m and α1m. Baseline serum creatinine and urinary 
KIM-1 are independent predictors of ESRD. Future studies should be undertaken to verify 
the predictive value of KIM-1 excretion in patients with IgAN. 
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Figure 4. Renal survival curve in patients with IgAN and serum creatinine ≤135μmol/L (n=29) categorized according 
to KIM-1 excretion below (straight line) or above (dotted line) the median value. Renal survival was defined as onset 
of ESRD
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introduction
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. In the 
majority of patients the disease manifests as glomerular hematuria and runs a non-
progressive course (so-called benign hematuria). However, 25-50% of patients will 
progress to ESRD after 10-30 years of follow up(1). Thus, the clinical course is highly variable, 
with some patients attaining a spontaneous remission, and others developing end-stage 
kidney disease (ESRD) within a few years after diagnosis. This variable course hinders the 
development of clinical trials and the use of standardised treatment protocols. Accurate 
prediction of prognosis is instrumental in developing individualized treatment protocols. 
Thus far, clinical variables are insufficient to predict prognosis. 
A kidney biopsy is required for the detection of glomerular IgA immune deposits, the 
diagnostic hallmark of IgAN. A variety of grading systems has been developed for 
classifying histopathological changes in IgAN patients2-5. An international consortium 
identified a set of distinct pathological variables as independent prognostic markers in 
patients with IgAN, known as the Oxford classification6, 7. The four predictive pathological 
features were; mesangial hypercellularity, the presence of endocapillary proliferation, 
segmental glomerulosclerosis/adhesion, and severity of tubular atrophy/interstitial 
fibrosis. Validation of these prognostic histopathological variables has been conducted 
in different patient populations8-10. Results vary, but tubulointerstitial fibrosis appears the 
most reproducible prognostic marker. This is hardly surprising since tubulointerstitial injury 
has long been known to predict progression more accurately than glomerular damage 
in glomerulonephritis1, 11, 12. Interstitial fibrosis is preceded by interstitial inflammation, a 
process involving lymphocytes and macrophages and the production of pro- and anti-
inflammatory cytokines. In 2008, Van Es et al. showed that the presence of cytotoxic 
GMP-17-positive T-lymphocytes in the interstitium and within kidney tubules predicted 
progression towards kidney failure in patients with IgAN and normal or near-normal 
glomerular filtration rate13.
 Urinary excretion of low molecular weight (LMW) proteins - such as α1-microglobulin 
(α1m) and β2-microglobulin (β2m) - kidney injury molecule-1 (KIM-1), and neutrophil 
gelatinase-associated lipocalin (NGAL) are thought to reflect the severity of interstitial 
damage. In previous studies we found that low molecular weight proteins, urinary KIM-1 
and NGAL levels were elevated in patients with IgAN compared to healthy controls14, 15. In 
multivariate analysis, urinary KIM-1 along with serum creatinine proved to be independent 
predictors of ESRD. Yet, our model had a limited predictive value, and lacked sufficient 
accuracy to predict prognosis in individual patients. Therefore, we explored whether 
identification and scoring of GMP-17 positive T-lymphocytes, would be of use to improve 
our model for predicting ESRD.
aBstr act
Background
The clinical course in patients with IgA nephropathy (IgAN) is highly variable and accurate 
predictors of prognosis are lacking. Recent studies suggest that urinary excretion of 
low-molecular weight (LMW) proteins, kidney injury molecule-1 (KIM-1) and neutrophil 
gelatinase associated lipocalin (NGAL) is increased in patients with progressive IgAN. We 
previously showed that the presence of GMP-17 positive T-lymphocytes in intact kidney 
tubules predicted outcome in patients with IgAN and a normal or near normal estimated 
glomerular filtration rate (eGFR). 
 The objective of this study was to validate the prognostic value of GMP-17 positive 
T-lymphocytes for predicting progression of kidney disease in IgAN and to correlate 
their presence with urinary markers of early tubular damage. We also evaluated whether 
GMP-17 positive lymphocytes were present in kidney tubules of patients with idiopathic 
membranous nephropathy (iMN).
methods
Adults with IgAN or iMN who had undergone standardised measurements of proteinuria 
in our center within 6 months of kidney biopsy were included in this study. Kidney biopsy 
specimens were evaluated for the presence of GMP-17 positive T-lymphocytes in intact 
kidney tubules. Intra-epithelial GMP-17 positive cells were scored in a semi-quantitative 
manner and categorized as 0-1, 2-3 or ≥4 positive cells within the kidney tubules in the 
whole section.
results
Kidney biopsy material of 24 patients with IgAN allowed reliable scoring of GMP-17 positive 
T-lymphocytes. Intratubular GMP-17 positive T-lymphocytes were present in nine patients. 
GMP-17 positive patients had more severely impaired kidney function (median eGFR 37 vs 
57 ml/min/1.73m2), and a higher urinary excretion of LMW proteins and KIM-1 than GMP-
17 negative patients. However, there was no statistically significant difference regarding 
progression of kidney disease between GMP-17 positive and GMP-17 negative patients 
– 4/9 (44%) versus 9/15 (60%). In three out of six patients with idiopathic membranous 
nephropathy GMP-17 positive T-lymphocytes were observed in the tubules.
conclusion
We failed to confirm the prognostic value of intratubular GMP-17 positive T-lymphocytes 
in predicting progression of IgAN. GMP-17 positive T-lymphocytes can also be detected 
in kidney tubules of patients with idiopathic membranous nephropathy.
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 The purpose of this study was to validate the prognostic value of GMP-17 positive 
T-lymphocytes in an independent cohort of patients with IgAN and to correlate their 
presence with urinary markers of tubular dysfunction. Furthermore, we evaluated the 
presence of GMP-17 positive T-lymphocytes in kidney biopsies of patients with idiopathic 
membranous nephropathy.
materials and methods
Population
Patients with proteinuria due to glomerular diseases are evaluated in our center using a 
standard protocol for almost two decades. For the present study, we analysed the data 
of adult patients with biopsy-proven IgAN who were evaluated for proteinuria in our 
centre between 1995 and 2007 and followed thereafter. Patients with other causes of IgA-
positive glomerular staining (systemic lupus erythematosus, Henoch-Schonlein purpura 
or liver disease) or a follow-up of <12 months were excluded from the analysis. We 
excluded patients in whom the interval between the kidney biopsy and the evaluation of 
proteinuria was >6 months. The study was carried out in accordance with applicable rules 
in the Netherlands concerning the review of research ethics committees and informed 
consent.
Baseline measurement
All measurements were carried out in the morning, after an overnight fast.
Details of the measurements have been described elsewhere(16). Gender, ethnicity, age, 
body weight and height were recorded at the time of measurement. Two 24-h urine 
samples were obtained for measurement of creatinine and total protein. A urinary pH 
>6.0 is needed to prevent degradation of urinary β2m. Therefore, patients used 4 g of oral 
sodium bicarbonate the evening before the measurement. Upon arrival, an additional 2–4 
g sodium bicarbonate was given and patients drank 375–500 ml of tap water to enforce 
diuresis. The patients remained supine during 2 h except for voiding. Blood pressure 
measurements were taken using an automated device (Dinamap; Criticon, Tampa, FL) 
with six consecutive readings registered every 5 min after 10-min rest; these readings 
were used to calculate the mean arterial pressure (MAP). 
In the freshly collected urine samples measurement of urinary pH, β2m, α1m, 
immunoglobulin G (IgG), transferrin, albumin, total protein and creatinine was performed17. 
Only in urine with a urinary pH >6.0, β2m excretion was measured. Urine was immediately 
stored at -80°C until the measurement of KIM-1 and NGAL. Urinary KIM-1 and NGAL were 
measured by enzyme-linked immunosorbent assay as described previously15. Laboratory 
parameters were measured in blood samples collected in the middle of the urine 
collection period. Serum creatinine, cholesterol, urinary total protein and creatinine were 
measured with standard automated techniques. 
Follow-up
After standardised protein measurements, patients were entrusted to the care of their 
local physicians. Immunosuppressive therapy was advised to patients with progression 
of kidney disease. During follow-up, we collected data from medical records on serum 
creatinine, albumin, cholesterol, urea, total urinary protein and creatinine levels, blood 
pressure, body weight and the use of medication.
Histological studies
Biopsy specimens were stained with hematoxylin-eosin, periodic acid Schiff and silver 
methenamine. A single kidney pathologist (IB), who was blinded to information on 
outcome, scored GMP-17-positive T-lymphocytes. 
 Sections measuring 4 mm were deparaffinized in 96% ethanol, blocked for 
endogenous peroxidases in a mixture of 1ml of 30% H2O2 in 250 ml of methanol for 20 min, 
and subsequently hydrated in decreasing ethanol concentrations. Sections were boiled 
in 1mM ethylene diamine tetraacetic acid pH 9 for 12 min. Sections were then incubated 
with antibodies directed against GMP-17 (2550 IM IgG clone 2G9; Immunotech, Marseille, 
France). Binding of these primary antibodies was visualized using horseradish peroxidase-
labeled anti-mouse antibodies (Envision; Dako), and a mixture of 3,3 aminobenzidine 
(0.05%) and NiCl2 (0.07%). Sections were rinsed between each step with phosphate-
buffered saline. Sirius red was used as counterstain to accentuate the tubular basement 
membrane. Ileal biopsies from a patient with Crohn’s disease were used as a positive 
control for GMP-17 staining. 
 Intra-epithelial GMP-17-positive cells were scored as follows: 0, no cells or one cell 
within the kidney tubules in the whole section; 1, two to three positive cells within 
tubules; and 2, four or more positive cells within the tubules. In case of different scores in 
different tissue sections, the highest score was noted as the final score.
Calculations and definitions
Body mass index (BMI) was calculated as the ratio between baseline weight and height 
squared. MAP was calculated as diastolic pressure plus one-third of the pulse pressure. The 
glomerular filtration rate at baseline and follow-up was estimated using the abbreviated 
Modification of Diet in Renal Disease equation . Start of follow-up was defined as the 
time of standardised measurement of proteinuria, regardless of the first assessment 
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suggestive of kidney disease. We defined the outcome ESRD as initiation of dialysis, 
kidney transplantation or an eGFR <15 ml/min/1.73m2. Progression of kidney disease was 
defined as an increase in serum creatinine > 50%.
Statistical analysis
Parameters between groups were compared using the Mann–Whitney or Kruskal–Wallis 
test for nonparametric continuous data, independent t-test for parametric data and 
the chi-square test for categorical data. Spearman’s bivariate correlation test was used 
to examine correlation between nonparametric data. Statistical analysis was performed 
using SPSS for Windows software, version 16.0 (SPSS Inc., Chicago, IL).
results
IgA nephropathy
In the period 1995-2007 70 patients with IgAN were evaluated in our center(14, 15). In 
36 patients the interval between kidney biopsy and protein measurements was < 6 
months. Of 24 patients kidney biopsy material was still available to prepare fresh histology 
slides, which were suitable for GMP-17 staining and allowed reliable scoring. Baseline 
characteristics are depicted in Table 1. Of these 24 patients 13 patients had a rise in serum 
creatinine of >50%, and eight developed ESRD. Median follow-up was 102 (7-146) months. 
During follow-up seven patients were treated with immunosuppressive drugs because of 
progression of IgAN.
 In nine out of 24 (38%) patients GMP-17 positive T-lymphocytes were present in the 
kidney tubules (Figure 1). All of these nine patients were scored as 1, meaning two to 
three GMP-17 positive cells within the kidney tubules. We therefore categorised patients 
as either GMP-17 positive or GMP-17 negative. Baseline characteristics of both groups are 
depicted in Table 2. When comparing both groups, GMP-17 positive patients had more 
severely impaired kidney function, and although severity of proteinuria did not differ, 
GMP-17 positive patients did show a significantly higher urinary excretion of α1m (Figure 
2) and KIM-1. 
Table 1. Baseline characteristics of IgAN patients
N (% male) 24 (71%)
Age (yrs) 38±13.5
BMI (kg/m2) 27±4
MAP (mmHg) 99±13
Creatinine (μmol/l) 141 (70-276)
MDRD (ml/min/1.73m2) 50 (22-95)
Urea (mmol/l) 7.6 (4-36)
Albumin (g/l) 38.5 (21-46)
Proteinuria (g/day) 2.1 (0.47-24.4)
α1-microglobulin excretion (μg/min) 16.6 [8.4-48.4]
β2- microglobulin excretion (ng/min) 260 [111-1238]
KIM-1 excretion (ng/min) 1.6 [0.7-3.2]
NGAL excretion (ng/min) 57 [22-110]
Data are expressed as mean±SD, median (range), median [interquartile range].
Figure 1. Phenotype and localization of GMP-17 positive T-lymphocytes
Figure 2. Boxplot of α1m excretion in GMP-17 positive and negative patients with IgAN
GMP-17 (in black)-positive cytotoxic T-lymphocytes within tubules (open arrows) and in the interstitium (closed 
arrows). The exact localization of double positive cells was sometimes unclear (arrow with asterisk).
Chapter 4 GMP-17 positive T-lymphocytes in IgAN
6968
Chapter
 4
Kidney outcome between GMP-17 positive and GMP-17 negative patients did not differ: 
three out of nine (30%) GMP-17 positive patients developed ESRD, whereas 5 out of 15 
(30%) GMP-17 negative patients did (Table 3). Progression of disease was seen in four 
out of nine (44%) GMP-17 positive patients and nine out of 15 (60%) GMP-17 negative 
patients, which was not a statistically significant difference. Survival analysis with Kaplan 
Meier curves showed no difference between the two groups. As mentioned previously, 
seven patients out of 24 received immunosuppressive treatment during follow-up. Four 
of these seven patients were GMP-17 positive, three patients received treatment before 
progression of kidney disease occurred, three patients were treated and did not show 
progression, whereas one patient was treated after attaining an eGFR compatible with 
ESRD. To correct for possible bias, we also analysed data for the combined outcome of 
ESRD or therapy, and progression of renal disease or therapy, whichever occurred first. 
Again, outcome did not differ between GMP-17 positive and negative patients (Table 3). 
 We separately analysed patients with maintained kidney function. Only nine out of 24 
patients had an eGFR>60ml/min/1.73m2. None of them developed ESRD, three patients 
showed progression of kidney disease. Two out of nine patients were GMP-17 positive, 
one of these two patients showed progression. 
Idiopathic membranous nephropathy
Kidney biopsies of six patients with idiopathic membranous nephropathy were 
evaluated for the presence of GMP-17 positive T-lymphocytes in the tubules. Median 
serum creatinine was 105 (range 61-128) µmol/L, median eGFR was 61 (range 28-75) ml/
min/1.73m2, median proteinuria was 4.75 (range 3.0-11.4) g/d, median urinary excretion 
of β2m was 436 (range 250-22200) ng/min and median urinary excretion of α1m was 53 
(range 23-108) µg/min. In three out of six patients GMP-17 positive T-cells were detected 
in intact kidney tubules. When comparing GMP-17 positive and GMP-17 negative patients, 
GMP-17 positive patients had a slightly better kidney function (median eGFR 71 vs 54 ml/
min/1.73m2, and less proteinuria (median proteinuria 4.1 vs 5.4 g/d), yet excretion of LMW 
proteins was higher (β2m 578 vs 293 ng/min and α1m 61 vs 44 µg/min, Figure 3). 
Table 2. Baseline characteristics of GMP-17 positive and GMP-17 negative IgAN patients.
GMP-17 
positive 
GMP-17 
negative 
p-value
N (% male) 9 (89) 15 (60)
Age (yrs) 40±13 37±14 0.60
BMI (kg/m2) 27±4 28±4 0.64
MAP (mmHg) 94±10 103±14 0.12
Creatinine (μmol/l) 149 (100-276) 128 (70-265) 0.04
MDRD (ml/min/1.73m2) 37 (22-79) 57 (22-95) 0.06
Urea (mmol/l) 9 (5-36) 5.5 (4-19) 0.03
Albumin (g/l) 38 (30-44) 39 (21-46) 0.87
Proteinuria (g/day) 1.7 [1.0-8.9] 2.1 [1.5-3.9] 0.95
IgG excretion (mg/min) 106 [42-203] 65 [36-122] 0.48
α1-microglobulin excretion (μg/min) 39 [28-91] 12 [6-20] 0.01
β2- microglobulin excretion (ng/min) 893 [148-8800]
# 191 [111-840]## 0.17
KIM-1 excretion (ng/min) 3.2 [1.2-5.5] 1.4 [0.6-1.8] 0.05
NGAL excretion (ng/min) 72 [27-212] 40 [22-84] 0.22
Interval between biopsy and measurement 
(months)
0.7 [0.5-4] 1.7 [0.5-2] 0.32
Data are expressed as mean±SD, median (range), median [interquartile range]. # β2m was measured in 13 patients, 
## β2m was measured in 8 patients.
Table 3. Renal outcome of GMP-17 positive and GMP-17 negative IgAN patients.
GMP-17 
positive 
GMP-17 
negative 
p-value
Total group 9 15
ESRD 3 (30%) 5 (30%) NS
Progression of renal disease 4 (44%) 9 (60%) NS
Patients with eGFR <60ml/min/1,73m2 2 7 -
ESRD 0 0 -
Progression of renal disease 1 (50%) 2 (29%) -
Total group
Patients receiving therapy or reaching ESRD 
9
6 (67%)
15
7 (47%) NS
Total group 9 15
Patients receiving therapy or reaching 
progression of renal disease 
6 (78%) 10 (60%) NS
Figure 2. Boxplot of α1m excretion in GMP-17 positive and negative patients with IgAN
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Discussion
Our data failed to confirm the prognostic significance of the presence of GMP-17 positive 
T-lymphocytes in intact kidney tubules for predicting progression of IgAN. The predictive 
role of GMP17 positive cells was previously evaluated in a study of 50 IgAN patients. 
This study showed that GMP-17 positive intra-epithelial T-cells predicted progression 
in a subgroup of patients with an eGFR ≥60ml/min (n=31) with higher positive and 
negative predictive values than conventional markers of progression such as proteinuria 
or interstitial fibrosis. The current study was conducted to validate these findings and to 
correlate the presence of GMP-17 positive T-cells with other urinary markers of disease 
progression such as LMW proteins and KIM-1 and NGAL. Unfortunately, the interval 
between kidney biopsy and proteinuria measurements was >6 months in a large number 
of patients. There also was a lack of suitable biopsy material due to varying methods of 
fixation of material in different centres. Ultimately, only 24 out of our cohort of 70 IgAN 
patients could be included. Kidney outcome between nine GMP-17 positive patients and 
15 GMP-17 negative patients did not differ. Notably, 30% of GMP-17 negative patients 
developed ESRD, and even 60% showed progression of kidney disease. Admittedly, the 
majority of these patients had an eGFR<60 ml/min/1.73m2 at presentation. Of the nine 
patients with an eGFR ≥60ml/min/1.73m2, 2 were GMP-17 positive, and one of these two 
patients showed progression of kidney disease. Again, also two out of the seven GMP-17 
negative patients showed progression. Despite the small number of patients and time 
lapse between kidney biopsy and measurement of urine markers, the results of this pilot 
study certainly raise doubts concerning the previously reported predictive value of GMP-
17 positive intra-epithelial T-lymphocytes.
 Admittedly, there are important differences between this study and the previous one. 
First, the current study included a smaller number of patients (24 vs 50), had a different 
primary outcome (ESRD or a rise in serum creatinine of >50% vs progression defined as 
a decline of the slope of regression of 1000/serum creatinine of >0.2 units per year), with 
less patients reaching the actual outcome (8/24, 33% vs 27/50, 54%). Moreover, seven 
patients in our study were treated with immunosuppression, whereas none were treated 
in the previous study, and only 9/24 (38%) of our patients had an eGFR≥60 ml/min/1.73m2 
(vs 31/51 62%). Lastly, only two out of our nine patients (22%) with an eGFR≥60 were 
GMP-17 positive versus 14 out of 31 patients (45%) in the previous study. This could be 
due to a difference in the number of tissue slices available for evaluation. Since our study 
was retrospective and tissue samples had to be obtained from different centres, it is 
possible that there was simply less renal tissue available for detecting GMP-17 positive 
cells. Although the above mentioned disparities could account for the lack of a predictive 
value of GMP-17 positive cells in this study, we feel that the role of GMP-17 positive cells 
for predicting progression and guiding therapy in individual patients, is limited if there is 
one. One would expect an accurate predictor to prove true, even in a small population. 
Also, a considerable number of GMP-17 negative patients did show progression of kidney 
disease, even in the group with normal or near normal eGFR.
 We hypothesized that the presence of GMP-17 positive T-lymphocytes giving rise to 
tubulitis in the early stages of IgAN, could result in increased levels of urinary markers of 
tubular injury such as KIM-1. In this small number of patients, there was indeed a tendency 
towards increased levels of KIM-1 and other urinary markers of tubular injury or dysfunction, 
especially α1m, in patients with GMP-17 positive intra-epithelial T-lymphocytes. The fact 
that this did not reach statistical significance is likely due to the small number of patients. 
As mentioned previously, the majority of these patients had an eGFR <60ml/min and 
GMP-17 positive patients had a lower eGFR than GMP-17 negative patients. We can 
therefore not exclude that the increased levels of KIM-1 and LMW proteins simply reflect 
more severe tubular dysfunction, which occurs in later stages of IgAN. In previous studies 
we found that LMW proteins did not contribute to predicting prognosis in IgAN, while the 
predictive value of KIM-1 is limited.
 In patients with idiopathic membranous nephropathy, deterioration of kidney 
function is related to tubulointerstitial fibrosis, as with other classes of glomerulonephritis 
such as IgAN. Yet, in idiopathic membranous nephropathy sub-nephrotic proteinuria 
is not associated with loss of eGFR, whereas much lower levels of proteinuria are of 
prognostic importance in patients with IgAN. The mechanisms involved in mediating 
tubular injury are likely to differ between these two glomerular diseases. Since there are 
no data on the presence of GMP-17 positive intra-epithelial T-cells in patients with other 
types of glomerulonephritis, we evaluated the presence of these cells in six patients with 
idiopathic membranous nephropathy with normal or near normal kidney function. We 
found GMP-17 positive T-cells in the kidney tubules in three of these patients, so their 
occurrence in not specific for tubular injury in IgAN. Naturally, it would be of interest to 
study their prognostic value in idiopathic membranous nephropathy, or other glomerular 
diseases.
 Altogether, the results of this small retrospective study put the prognostic value of 
GMP-17 positive intra-epithelial T-lymphocytes in IgAN into question. We can state that 
the occurrence of these cells is not limited to patients with IgAN, since we also observed 
them in patients with membranous nephropathy. 
Ideally, a larger study should be conducted in patients with IgAN with only mild 
impairment of kidney function.
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aBstr act
Background
There is limited evidence to support cytotoxic therapy in patients with IgA nephropathy 
(IgAN) and renal insufficiency. We studied the effect of cytotoxic therapy in patients with 
IgAN and renal insufficiency, and evaluated possible predictors of response.
methods
Retrospective analysis of patients with IgAN who received immunosuppressive therapy. 
Primary outcome measure was progression of renal disease, defined as an increase in 
serum creatinine levels of ≥50% or development of end-stage renal disease (ESRD).
results
From 1996 to 2008, nineteen patients with biopsy-proven IgAN were treated with 
cytotoxic agents and prednisone because of renal insufficiency and/ or severe proteinuria. 
Characteristics of patients at start of therapy: age 42±11 years, serum creatinine 208 (96-
490) μmol/l, estimated glomerular filtration rate (eGFR) 33 (12-65) ml/min/1.73m2, and 
protein-creatinine ratio 3.8 (0.6-18.2) g/10 mmol. Follow-up after initiation of therapy 
was 35 (7-133) months. Ten patients had progressive renal disease, whereas eGFR was 
stable in nine. Serum creatinine levels and proteinuria at the start of treatment were not 
significantly different between responders and non-responders. Proteinuria response at 
six months after start of therapy proved a good predictor: proteinuria decreased by ≥50% 
and/or reached levels below 1 g/day in 8/9 responders. In contrast, proteinuria decreased 
by more than 50% and reached levels <1 g/day in only 3/10 non–responders (p<0.01).
conclusion
Prolonged immunosuppressive therapy with cytotoxic agents and prednisone may 
benefit a subgroup of patients with progressive IgAN. A reduction of proteinuria ≥50% to 
levels below 1 g/day within 6 months predicts a favorable long-term response.
introduction
IgA nephropathy is the most common glomerular disease worldwide. Its natural course 
is highly variable and far from benign in many patients1. Overall, approximately 25% of 
patients experience a lasting remission2, whereas 30% of patients develop end-stage renal 
disease (ESRD) within 20 years3. Risk factors associated with disease progression include 
heavy proteinuria4-7, impaired baseline renal function(8-10), and renal morphological 
lesions such as  the presence of segmental sclerosis and the degree of tubular atrophy/
interstitial fibrosis11, 12. 
 Many patients with IgAN can be effectively treated with Angiotensin Converting 
Enzyme inhibitors (ACEI) or Angiotensin II Receptor Blockers (ARB) (KDIGO guideline 
2012). There is evidence to support the use of corticosteroids in patients with persistent 
proteinuria and minimal renal impairment3-16. It is debated if patients with IgAN and 
renal insufficiency benefit from more aggressive treatment consisting of corticosteroids 
combined with alkylating agents. The evidence is derived from small studies, mostly 
conducted in a period with less defined blood pressure targets and variable use of ACEI/
ARBs as opposed to current guidelines17-20. More specifically, evidence favoring the use of 
cyclophosphamide in patients with non-crescentic IgAN and severe renal insufficiency 
is derived from a single small controlled trial18. During the last decade, we have used 
cytotoxic therapy including cyclophosphamide in patients with advanced or severe IgAN. 
In the present study, we aimed to determine the response to immunosuppressive therapy 
in patients with progressive IgA nephropathy. Specifically, we sought to identify possible 
predictors of response.
methods
Patients
We retrospectively analyzed data of adults with biopsy proven IgAN who were referred 
for therapeutic advice to the Radboud University Medical Centre and the Leiden 
University Medical Centre and were subsequently treated with cytotoxic agents because 
of progressive IgAN. Patients with evidence of systemic disease, such as systemic lupus 
erythematodes, chronic liver disease and Henoch-Schönlein purpura or a follow-up of 
less than 12 months were excluded. Relevant clinical and biochemical data were retrieved 
from the patients' records. Baseline was defined as date of first presentation. During 
follow-up, quantitative analysis of proteinuria was assessed by the ratio of urinary protein 
to urinary creatinine in the majority of patients. This parameter is closely correlated with 
24-hour urinary protein excretion. 
 This study has been carried out in the Netherlands in accordance with the applicable 
rules concerning the review of research ethics committees and informed consent.
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Treatment protocol
Standard immunosuppressive therapy for IgAN consisted of prednisone 40 mg per day 
with monthly tapering for a maximum period of 24 months plus cyclophosphamide 
(1.5 mg/kg) during the first 3 months orally followed by azathioprine (1.5 mg/kg) for 18 
months (derived from study treatment protocol by Ballardie et al.18). During prednisone 
therapy, concomitant treatment with H2-blockers or proton pump inhibitors was used. 
Co-trimoxazole was prescribed to prevent Pneumocystic jiroveci infections during the 
administration of cyclophosphamide. Young women were treated with azathioprine 
and not with cyclophosphamide because the latter is associated with infertility. Severe 
leukopenia, infections or active malignancy were regarded as stringent reasons to 
discontinue immunosuppressive treatment. 
Assessment of response
Primary outcome measure was progression of renal disease defined as an increase 
in serum creatinine levels of ≥ 50% or development of ESRD (serum creatinine ≥ 500 
µmol/l, dialysis or renal transplantation). Proteinuria responses were evaluated in terms of 
a reduction in proteinuria of ≥ 50% or a persistent urine protein-creatinine ratio < 1g/10 
mmol.
Calculations
The glomerular filtration rate was estimated (eGFR) by the simplified Modification of Diet 
in Renal Disease (MDRD) formula(21). Mean arterial pressure (MAP) was calculated as the 
diastolic pressure plus one third of the pulse pressure.
Statistical Analysis
Data values are expressed as mean± standard deviation or median (range) as appropriate. 
Parameters between groups were compared using the Mann-Whitney test for non-
parametric continuous data, the independent t-test for parametric data, and the chi-
square test for categorical data. A p-value of less than 0.05 was considered to be statistically 
significant. Statistical analysis was performed using SPSS for windows software, version 20 
(IBM SPSS).
results
Baseline characteristics
Between 1996 and 2008 19 patients received immunosuppressive therapy because of
progressive IgA nephropathy. 
 Standard immunosuppressive treatment consisting of prednisone plus 
cyclophosphamide during the first 3 months orally followed by a cytotoxic agent was 
prescribed in 11 out of 19 patients. Five patients received cyclophosphamide without 
subsequent alternative cytotoxic therapy. This was due to side-effects (leucopenia, 
infection) or failure of improvement of already severely impaired renal function (n=1). Three 
patients were started on azathioprine plus prednisone instead of cyclophosphamide plus 
prednisone. Clinical characteristics at presentation are depicted in Table 1. 
 At presentation mean age was 39±11 years, median serum creatinine was 128 μmol/l, 
a median eGFR was 55 ml/min/1.73m2, and median proteinuria was 4.5 g/10 mmol 
creatinine. All patients but one were treated with ACEI or ARBs prior to the initiation of 
immunosuppressive therapy. Three patients had previously been treated with prednisone 
monotherapy. In the majority of patients therapy was started because of an increase in 
serum creatinine of 15% or more in the previous 12 months (n=12), or because of a serum 
creatinine > 135 μmol/l and proteinuria > 1gram per day (n=6). In one patient therapy was 
initiated because of severe impairment of renal function at time of presentation. 
The median time between baseline and start of therapy was 19 months. At start of 
therapy, patients were 42±11 years and had a median serum creatinine of 208 μmol/l, a 
median eGFR of 33 ml/min/1.73m2, and a median urine protein-creatinine ratio of 3.8 g/10 
mmol (Table 1).
Table 1. Clinical characteristics of patients receiving cytotoxic therapy
Presentation Start of therapy
No. of patients 19 19
Male /female 14/5 14/5
Age (years) 39±11 42±11
MAP (mmHg) 100±10 106±10
UP/UCr (g/10 mmol creatinine) 4.5 (0.9-18.2) 3.8 (0.6-18.2)
Serum creatinine (μmol/L) 128 (69-285) 208 (96-490)
eGFR (ml/min/1.73m2) 55 (22-87) 33 (12-65)
Use of ACEis or ARBs (%) 89 95
Change in serum creatinine (%) - 39(-19-209)
Change in UP/UCr (%) - -21 (-70-163)
Time from baseline to start of therapy (months) - 19 (0.2-119)
Follow-up after start of therapy (months) 35 (7-133)
Data expressed as median (range) or mean±SD., MAP; mean arterial pressure, UP; urinary protein, 
UCr; urinary creatinine, eGFR; estimated glomerular filtration rate, ACEis; angiotensin converting enzyme 
inhibitors, ARBs; angiotensin II receptor blockers
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Clinical outcome
Follow-up after initiation of therapy was 35 (7-133) months. In 10 patients renal disease 
was progressive despite the initiation of immunosuppressive therapy : 6 developed end-
stage renal disease at a median follow up of 24 months (range 7-46) and 4 experienced 
doubling of serum creatinine after 17 (range 12-81) months. Renal function remained 
stable or improved in 9 patients. 
 Serum creatinine levels and proteinuria at the start of treatment were lower in 
responders (183 (120-381) versus 224 (96-490) μmol/l, p=0.23 and 2.2 (0.6-9.7) versus 
4.1 (0.7-18.2) g/10 mmol creatinine, p=0.31 respectively), but these differences were not 
statistically significant (Table 2). There were no differences in other characteristics at 
baseline between responders and non-responders (Table 2). In 8 out of 9 responders 
proteinuria decreased by ≥ 50% within 6 months and attained levels below 1 g/day in 8 
patients (figure 1A). In contrast, in non-responders proteinuria decreased by more than 
50% and reached values < 1g/day in only 3 out of 10 patients (p<0.01, Figure 1B). 
 Treatment duration was 19 (range 3-81) months. Treatment duration was less than 12 
months in two of the responders, and in 4 of the non-responders (table 3). Following the 
discontinuation of therapy, we observed no relapses of proteinuria.
 Six patients had a serum creatinine level ≥250 µmol/l (the so-called point of no 
return) prior to start of therapy. In this small subgroup renal function remained stable 
after treatment in two patients during a follow-up of more than 8 years. The remaining 
four patients developed ESRD within 21-46 months after initiation of treatment.
Table 3. Overview of treatment schedule and progressors/ non-progressors
Treatment schedule Progressors
(n=10)
Non-progressors 
(n=9)
Standard course, i.e. prednisone plus 
cyclophosphamide for 3 months, followed by 
azathioprine, n=11
n=6 (54%) n=5 (46%)
Shortened course, i.e. cyclophosphamide and 
prednisone ≤3 months without subsequent 
conversion to azathioprine, n=5§
n=2 (40%) n=3 (60%)
Alternative, i.e. prednisone and azathioprine 
instead of cyclophosphamide, n=3#
n=2 (67%) n=1 (33%)
§4 patients were treated for a total of 2.5-3 months with cyclophosphamide and prednisone, 1 patient was 
treated for a longer period thereafter with prednisone monotherapy, # duration of treatment at least 9 months
Table 2. Clinical characteristics of progressors versus non-progressors at start of treatment with cytotoxic agents
Variable Progression of 
renal disease
Stable renal 
function
P-value
N (male/female) 7/3 7/2 0.70
Age (years) 44±14 40±7 0.42
MAP (mmHg) 104±11 104±10 0.96
UP/UCr (g/10 mmol creatinine) 4.1 (0.7-18.2) 2.2 (0.6-9.7) 0.31
Serum creatinine (μmol/L) 224 (96-490) 183 (120-381) 0.23
eGFR (ml/min/1.73m2) 26 (12-65) 36 (17-46) 0.21
Duration of treatment (months) 16 (3-81) 22 (3-63) 0.50
Duration of follow-up after treatment 26 (6-81) 82 (28-133) <0.01
50% reduction in proteinuria ≤ 6 months after 
start of therapy (n)
3* 8 <0.01
Persisting proteinuria < 1g/10mmol creatinine (n) 3* 8 <0.01
Data expressed as median (range) or mean ± SD. MAP; mean arterial pressure, UP; urinary protein, UCr; urinary 
creatinine, eGFR; estimated glomerular filtration rate. *the same patientsFigure 1A. Change in proteinuria after start of immunosuppressive therapy in patients with IgA nephropathy 
who attained a stable eGFR (so called responders).
Figure 1B. Change in proteinuria after start of immunosuppressive therapy in patients with IgA nephropathy 
who showed progression of renal disease.
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Adverse effects
Adverse events were reported in 11 patients (58%) and included anemia (n=3), leucopenia 
(n=4), thrombocytopenia (n=1), infection (n=4) or liver toxicity (n=1). In 2 patients this led 
to discontinuation of immunosuppressive therapy. No patients developed a malignancy 
during follw-up. 
Discussion
This study suggests that immunosuppressive therapy may result in stabilization of 
renal function in approximately 50% of patients with IgA nephropathy at high risk for 
progression of renal disease. More importantly, a decrease in proteinuria of 50% or more 
within six months predicted a sustained response to therapy.
 Over two decades, beneficial effects of corticosteroids have been reported by 
various studies in patients with no or mild renal impairment13, 22-25. However, in patients 
with advanced IgA nephropathy, administration of corticosteroids did not improve 
renal function26. Few randomized controlled trials, enrolling a small number of patients, 
have been conducted investigating the efficacy of cytotoxic agents combined with 
prednisone17-20, 27. Only the study performed by Ballardie et al. showed that prednisone plus 
cytotoxic agents were effective in preserving renal function in patients with moderate, 
progressive disease18. Thus, the optimal management of patients with advanced IgA 
nephropathy remains controversial. 
 Clearly, this small, retrospective and uncontrolled study cannot provide compelling 
evidence for benefit of corticosteroids and cyclophosphamide or azathioprine in high-
risk IgAN patients. Yet, our data support the results reported by Ballardie; based on 
observational data on known major risk factors, at least 70-90% of this study population 
characterized by heavy, persistent proteinuria (median 3.1 g/d) and severe impairment 
of renal function (median serum creatinine 208 µmol/l) at the start of treatment with 
immunosuppressive drugs, would be expected to progress to ESRD28, 29. However, after 
immunosuppressive therapy progression of disease was halted and renal function 
remained stable in approximately 50% of patients.
 Thus, immunosuppressive combination therapy may benefit IgAN patients with poor 
prognosis. Unfortunately, side effects are frequently observed, duration of treatment is 
long and 50% of patients are exposed to cytotoxic agents and prednisone to no avail. 
Therefore, immunosuppressive therapy seems to benefit only a subset of high-risk 
patients with IgAN. Currently it is impossible to identify this subgroup by means of clinical 
or pathological characteristics. Considering this, our finding that a 50% decrease in 
proteinuria within six months after start of therapy is indicative of a sustained response to 
immunosuppressive therapy is highly relevant. In patients lacking a substantial decrease 
in proteinuria after 6 months of therapy, discontinuation of treatment should strongly 
be considered in our opinion. Recently, it has been recognized that patients with IgA 
nephropathy have increased serum levels of galactose deficient IgA1 and that circulating 
auto-antibodies recognizing those galactose deficient IgA1 as an autoantigen or the 
levels of the autoantigen itself allow prediction of disease progression28, 30, 34;36. Perhaps 
these and other promising biomarkers will allow identification of patients responsive to 
immunosuppressive therapy in the near future. 
 The results of this retrospective study differ to some extent from the data reported by 
Ballardie et al. A substantially larger number of patients suffered from therapy-related side 
effects in our study compared with the frequency reported by Ballardie and others (58% 
versus 7-12%)18, 31. Although these side effects were mild and transient in the majority of 
cases, 2 patients withdrew from treatment. Second, several studies including Ballardie’s, 
reported that patients with a serum creatinine level ≥250 µmol/l inescapably develop 
ESRD despite therapy18, 32, 33. After therapy, we observed a stabilization of renal function in 
2 out of 6 patients beyond this so-called point of no return. Thus, even in patients with 
severe renal impairment, immunosuppressive therapy may be of benefit. 
 In conclusion, the optimal management of IgAN remains controversial and 
randomized controlled trials are much needed. Currently, a large randomized prospective 
controlled trial (STOP IgAN trial) is being conducted in order to determine whether 
immunosuppressive therapy is able to prevent progression of renal disease(34). The 
KDIGO Clinical Practice Guideline for Glomerulonephritis suggests corticosteroid therapy 
in patients with persistent proteinuria >1g/d despite 3-6 months of optimized supportive 
care (including ACEi/ARB) and eGFR >50ml/min. Combined immunosuppressive therapy 
is not advised unless there is crescentic IgAN with rapidly deteriorating renal function. In 
our opinion, immunosuppressive therapy can certainly be considered in IgAN patients 
with a decline in renal function and persistent proteinuria >1 g/d. Immunosuppressive 
therapy should only be continued beyond 6 months in those patients demonstrating a 
significant (>50%) decrease in proteinuria. 
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Background
Measurement of serum hepcidin levels may provide a useful alternative to the current 
methods of determining iron status in chronic haemodialysis patients. However, the 
biological variability of this pivotal regulator of iron homeostasis is unclear, and the 
impact of inflammation, dialysis clearance, and iron therapy on hepcidin variability has 
not been established.
methods 
Two independent studies in chronic haemodialysis patients were conducted; serum 
hepcidin levels were measured at the start of dialysis sessions in 20 UK patients and in 43 
Dutch patients by mass spectrometry (MS). Samples from UK patients were also analysed 
by a competitive enzyme-linked immunosorbent assay (cELISA). Coefficient of variance 
(CV1) was calculated and potential factors affecting CV1 were also examined.
results
The median CV1 (interquartile range) was 23% (17-28) for the UK MS, 26% (17-48) for 
the Dutch MS, and 23% (17-39) for the UK cELISA. The CV1 was similar in those patients 
receiving and those not receiving regular intravenous iron. The CV1 was not associated 
with the degree of inflammation. Hepcidin levels were higher following an inter-dialytic 
period of 3 versus 2 days (p=0.02).
conclusions
These findings suggest considerable variability of serum hepcidin levels in haemodialysis 
patients. Inflammation and the use of iron did not impact on the degree of variability, and 
hepcidin levels were higher after an inter-dialytic period of 3 versus 2 days. These findings 
need to be taken into account in future studies assessing the utility of serum hepcidin as 
a guide to the use of iron or erythropoeiesis stimulating agents.
introduction
Hepcidin is a recently discovered small defensin-like peptide that regulates iron 
metabolism. Hepcidin degrades the cellular iron exporter ferroportin, which is expressed 
by enterocytes and macrophages, thereby decreasing intestinal iron uptake and causing 
iron sequestration in the reticulo-endothelial system1-3. Hepcidin synthesis is upregulated 
in the presence of inflammation or iron overload4-6 and is reduced in the presence of 
anaemia7;8, hypoxia4 and iron deficiency9. Thus, inflammation decreases the availability of 
circulating iron, whereas hypoxia or anaemia increases iron release and absorption.
 Chronic haemodialysis (HD) patients have been shown to have elevated hepcidin 
levels10-17. This may partly explain why such patients have reduced erythropoiesis despite 
treatment with erythropoiesis stimulating agents (ESA) and a seemingly adequate iron 
status. Traditional markers of iron status are inaccurate for the detection of iron insufficiency 
in this population, since patients with normal or high ferritin levels and transferrin 
saturation (TSAT) still respond to intravenous (IV) iron18;19. Moreover, these conventional 
parameters do not correlate well with bone marrow iron stores. Iron therapy might be a 
double-edged sword; although iron is necessary for erythropoiesis, excess iron promotes 
oxidative stress and affects immune effector function20;21. Hepcidin has several potential 
advantages over conventional iron parameters such as ferritin in optimizing anaemia 
treatment in patients with renal insufficiency; (1) it directly reflects iron availability and 
demands for erythropoiesis, (2) it integrates the input form both inflammatory and 
erythropoietic pathways and (3) it reflects the status of iron homeostasis more accurately 
than single parameters such as TSAT and soluble transferrin. Hepcidin could thusbecome 
an important tool to predict ESA responsiveness and guide treatment with ESA and iron. 
 The potential role of serum hepcidin was questioned by the recent observations of 
Ford  et al., who reported considerable intra-individual variability of serum hepcidin levels 
obtained at weekly intervals in a small number of HD patients22. The authors noted a 
relationship with the inflammatory status. Importantly, hepcidin was measured using an 
ELISA assay, which is known to detect not only hepcidin-25 but also its isoforms hepcidin-20 
and 22. These biologically inactive isoforms have been reported to accumulate in patients 
with end-stage renal disease (ESRD)11;23. Thus, the intra-individual variability reported by 
Ford  et al. may partly be attributable to variability of these smaller isoforms. 
 In order to meaningfully interpret (changes in) serum hepcidin-25 levels, it is essential 
to obtain additional data on the variability of serum hepcidin-25, and not total hepcidin 
levels in HD patients. We have therefore extended these observations using a validated 
LC MS/MS assay24, and also compared the results with a commercially available ELISA 
(Bachem, UK). Mass spectrometric techniques have been utilized for the quantitation of 
hepcidin24;25. Such mass spectrometry assays are generally regarded as the “gold standard”, 
but are more technically demanding. The use of MS circumvents inherent problems in the 
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analysis since it allows the absolute levels of hepcidin-25 to be assessed. 
 Our aim was to determine the intra-individual variability of serum hepcidin in a cohort 
of haemodialysis patients by measuring the coefficient of variance (CV1) for hepcidin 
using different assays. Furthermore, we aimed to identify significant determinants of 
intra-individual variability. Independent studies were designed and conducted in the UK 
and the Netherlands. Due to substantial differences in data collection, fully combining the 
analysis proved impossible. Therefore, the methods and results of the UK and Dutch study 
will be discussed separately.
materials and methods, part i – Uk study
Study design
All patients dialyzing on two successive days were invited to participate. Patients were 
excluded if they demonstrated any signs of acute or occult bleeding, had an acute 
bacterial infection within 4 weeks, a haematological dyscrasia other than anaemia, acute 
or chronic liver disease, or an active malignancy.
 Nine consecutive pre-dialysis blood samples were scheduled over a period of 3 
weeks during October 2010 at the Department of Renal Medicine, King’s College Hospital, 
London, UK. Two major factors known to affect serum hepcidin levels were prospectively 
assessed; the administration of IV iron and the degree of inflammation. High-sensitivity 
C-reactive protein levels (hsCRP) were measured at each of the 9 time-points. A single 
mid-study sample was taken from each patient for measurement of serum ferritin 
from each patient, at least one week after any administration of IV iron. The data were 
also examined according to the day of the week on which the samples were taken, to 
detect the influence of the inter-dialytic period. 10 patients were dialyzed on Mondays, 
Wednesdays and Fridays, and 10 were dialyzed on Tuesdays, Thursdays and Saturdays. 
The results obtained on a Monday or Tuesday were pooled (Mon/Tue), since these 
samples were taken after an inter-dialytic period of 3 days. Similarly, samples taken on a 
Wednesday or Thursday (Wed/Thurs) were pooled, as were samples taken on a Friday or 
Saturday (Fri/Sat).
 All patients gave informed consent for participation in the study, which was conducted 
in accordance with the Declaration of Helsinki, and was approved by the London Research 
Ethics Committee 1 (LREC 09/H0718/034).
Sample analysis
All samples were drawn from the dialysis catheter or fistula immediately before the start 
of dialysis. The samples were centrifuged, and aliquots of sera were immediately stored 
in cryotubes at -80°C. Samples were then transferred to two separate laboratories (King’s 
College London, UK, and the University of Bialystok, Poland), for measurement of serum 
hepcidin levels (LC MS/MS and a commercially available ELISA, respectively). The samples 
were processed in a single run by two different operators. High-sensitivity C-reactive 
protein (hsCRP) levels were determined using turbidimetry (P.Z. Cormay, Lublin, Poland).
 Hepcidin levels were measured using a high-performance liquid chromatography 
tandem mass spectrometry technique, which has an intra-assay CV1 of 2.3% at hepcidin 
concentrations of 156 ng/ml and 4.0% at concentrations of 312 ng/ml24. 
 The same samples were analysed by ELISA (Bialystok, Poland) using a commercially 
available kit (Bachem, UK). The reported normal range for this assay is 0.02-25 ng/ml, and 
both the calculated intra- and inter-assay variations are below 10%.
Statistical analysis
The CV1 (hepcidin) for every individual was calculated from all 9 hepcidin values acquired 
for each patient. The CV1 was defined as the standard deviation divided by the mean. The 
median and mean CV1 were calculated to determine and compare the variability in serum 
hepcidin for both assays. 
 The CV1 values of those receiving IV iron therapy were compared to those not receiving 
iron. High-sensitivity CRP values were correlated with the corresponding hepcidin values. 
Hepcidin values obtained after an inter-dialytic period of 3 days were compared to the 
values after an inter-dialytic period of 2 days.
 Data were expressed as mean (±SD) or median (IQR – interquartile range) where 
appropriate. The Shapiro-Wilks test was used to test for normality of distribution. 
Comparisons between groups were performed using either a paired Student’s t-test 
or Wilcoxon rank sum for normally and non-normally distributed variables respectively. 
Bivariate correlation coefficients (r) were calculated using the Pearson’s product formula. 
A p-value of <0.05 was considered statistically significant. 
 Analyses were performed using Statistical Package for Social Science version 17.0 for 
Windows XP (SPSS Inc., Chicago Ill., USA). 
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materials and methods, part ii – Dutch study
Study design
The objective of the study was to assess intra-individual variability in serum hepcidin-25 
concentration over 6 weeks in chronic HD patients and to identify significant determinants. 
Blood samples were collected once a week during 6 consecutive weeks, before the start 
of dialysis. Samples were collected from August to October 2010 at the Department of 
Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. 
In order to obtain unbiased data we included all patients who agreed to participate. ESA 
and IV iron administration were continued according to current prescription during the 
study period.
 In accordance with Dutch ethical regulations, all patients consented that blood 
samples would be used for medical research. 
Sample analysis
All samples were drawn from the dialysis catheter or fistula immediately before the start 
of dialysis, and were processed and stored in polypropylene tubes at -80°C. Routine 
laboratory parameters and hepcidin levels were measured within 8 hours and 6 months 
of collection, respectively.
 Serum hepcidin was measured by a combination of weak cation exchange 
chromatography and time-of flight mass spectrometry (TOF MS) as recently described26. 
The intra-run coefficient of variance is 2.2% at 8.6 ng/ml, 3.7% at 22 ng/ml, 2.3% at 37.4 
ng/ml. The inter-run coefficient of variance is 9.1% at 21.8 ng/ml and 3.9% at 36 ng/ml. Of 
note, all samples from an individual patient were measured in a single run. The median 
reference level of serum hepcidin-25 is 11.7 ng/ml, with a range of 1.4-38.8 ng/ml27. All 
other laboratory parameters were measured using standard automated techniques. 
Statistical analysis
Intra-individual variability in serum hepcidin and other variables was expressed as the 
coefficient of variance (CV1, the standard deviation divided by the mean). Week-to-week 
CV1s were calculated for each patient, as well as the mean, median, and range of CV1s for 
serum hepcidin isoforms, haemoglobin, CRP, iron, TSAT and ferritin. Parameters between 
high and low variability (i.e. above and below median CV1) groups were compared using 
the independent t-test for parametric data and the chi-square test for categorical data.
 Correlation coefficients were used to assess associations between laboratory 
parameters. Correlations were calculated using Pearson’s correlation test. If data were 
skewed, log transformation was used. To determine independent baseline predictors of 
the intra-individual variability of serum hepcidin, multiple regression analysis was applied. 
Predictors that showed high collinearity (rho > 0.8) were not simultaneously included in the 
analysis. Potential non-linear dose response relationships were checked using fractional 
polynomials. Robustness of the various models was checked with a jackknife resampling 
technique. The unicity of each regression solution was evaluated by interchanging highly 
correlated baseline predictors. A p-value <0.05 was considered significant for all analyses. 
Statistical analysis was performed using STATA 10 (Statacorp, TX, USA).
results, part i – Uk study
Patient demographics and baseline laboratory data are summarized in Table 1. 20 chronic 
HD patients (14 males) aged between 35 and 85 years were included. Each patient 
underwent dialysis three times weekly. Patients had been receiving haemodialysis for a 
Table 1 – Demographics and baseline characteristics 
UK study Dutch study
n (% male) 20 (70) 43 (56)
age (years) 63 ± 16 62 ± 15
Caucasian (%) 45 98
BMI (kg/m2)  26.1±4.8 24 ± 3.8
antibiotic use previous month (%) 0 26
malignancy in history (%) 5 16
liver disease (%) 0 9
ESA (%) 95 98
ESA dose (x 1000 units)  6 (4-9) 12 (8 – 15)
Iron supplementation (%) 60 95
Iron dose (mg/week)  100 (100–150)** 50 (25 – 50)
Laboratory
Hepcidin 25 (ng/ml) 168.2 (127.9-217.6) 46.7 (28.2 – 73.4)
Hepcidin 20 (ng/ml) n/a 13.1 (8.9 – 19.2)
Ferritin (μg/l) 591.5 (321.9–861.1)** 376 (209 – 503)
Iron (μmol/l) n/a 55.9 (39.1 – 72.6)
Transferrin saturation (%) n/a 19.5 (16.7 – 30.2)
CRP (mg/l) 5.4 (0.8-18.9) 5 (5 – 24)
Hb (g/dl) 10.9 (9.8-11.8) 11.4 (10.5 – 11.9)
CV1
Hepcidin-25 (%) 23 (17 – 28) 26 (17 – 48)
Hepcidin-20 (%) n/a 13 (9 – 21)
Ferritin (%) n/a 12 (11 – 26)
Iron (%) n/a 19 (14 – 30)
Transferrin saturation (%) n/a 20 (13 – 29)
CRP (%) 43.2 (26.9-58.1) 41 (8 – 63)
Hb (%) n/a 4 (3 – 5)
Data are presented as mean ± sd and median (interquartile range).
BMI; body mass index, ESA; erythropoietin stimulating agents, CRP; C reactive protein, Hb; haemoglobin, CV1; 
coefficient of variance. To convert hepcidin-25 from ng/ml to nanomol/l divide by 2.789.
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mean of 4.1 ±4.6 years, and all were stable for at least 3 months. All except one patient were 
dialyzed in the afternoon. All except one patient had been on a stable dose of ESA for >4 
weeks. Eight patients (40%) had received no IV iron for 4 weeks prior to commencement 
of the study, and this was maintained for the 3-week study period. 
Intra-individual variability
Both assays revealed a considerable degree of biological variability in this patient cohort 
(Figure 1). The median CV1 for the mass spectrometry assay was 23% (IQR 17-28), and for 
the ELISA was 23% (IQR 17-39) (p=0.12). A CV1 of less than 20% was seen in only 40% of 
the patients for both assays, a CV1 of 20-25% was found in 15% for both assays, a CV1 of 
25-30% was seen in 25% (MS) and 10% (ELISA), and a CV1 of >30% was seen in 20% (MS) 
and 35% (ELISA).
Figure 1. The coefficient of variance (CV1) of serum hepcidin-25 in 20 UK patients, suing MS and ELISA.
Intermethod difference in hepcidin values
The mass spectrometry assay used in this study previously reported serum hepcidin 
levels of 4.6 ± 2.7 nmol/L (12.8 ± 7.5 ng/ml) in normal healthy individuals24. In the cohort of 
haemodialysis patients recruited to the present study, hepcidin levels were considerably 
greater (mean 172 ± 70 ng/ml; median of 168 ng/ml (IQR128-218)). The data for the Bachem 
ELISA were similar (mean 230±557;median 170 ng/ml (IQR 107-239 ng/ml), p=0.03).
The effect of intravenous iron administration on CV1 and hepcidin levels
The CV1 was not affected by the administration of intravenous iron (Table 2). The median 
CV1 (MS) for hepcidin in the 8 patients who did not receive iron therapy was 26% (IQR 19-
28) compared to 23 % (IQR 2-32) in those who were receiving regular IV iron (p = 0.77). For 
individual hepcidin profiles for these 8 patients see supplementary figure A. Similar results 
were found using the ELISA assay: median CV1 for the group not receiving iron was 23 % 
(IQR 15-34) versus 23 % (IQR 17-57) for the IV iron group (p = 0.29).
 Of the 12 patients receiving IV iron supplementation, 11 were having iron administered 
on a weekly basis across haemodialysis. This provided an opportunity to compare 
hepcidin levels across three time-points: immediately before administration of IV iron, and 
immediately prior to the next two dialysis sessions. There was a small (non-significant) 
increase in serum hepcidin in the sample taken before the next dialysis session, but 
overall there was no clear impact of IV iron on serum hepcidin, possibly due to the fairly 
modest dose administered (100 mg) and the high background levels of serum hepcidin. 
One patient received IV iron during every dialysis session, but his hepcidin CV1 values 
were similar to those of the other patients: 25.6% (MS) and 20.0% (ELISA).
Effect of inflammatory status on CV1 and hepcidin levels
High sensitivity CRP levels were determined in all samples: median 6.1 mg/L (1.1, 18.9) with 
a range of 0.1-140.8 mg/L. The correlation between hepcidin (MS) and hsCRP levels in this 
analysis was weak (r= 0.15; p=0.04) (Figure 2). Mean serum hepcidin levels were significantly 
Table 2 – Effect of intravenous iron on the variability of serum hepcidin levels, UK study.
Patients receiving IV iron Patients not receiving IV iron P-value
n (%) 12 (60) 8 (40)  
CV1 (MS) 23% (20-32) 26% (19-28) 0.77
CV1(ELISA) 23% (17-57) 23% (15-34) 0.29
Data are presented as median (interquartile range)
Figure 2. Correlation between hepcidin (MS assay) and high-sensitivity CRP (log transformed) in UK patients.
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increased in the highest hsCRP tertile when compared to the lowest hsCRP tertile (190.4 
± 91.1 versus 161.1 ± 50.7 ng/mL, respectively (p=0.04). We found no correlation between 
the CV1 for hsCRP and the CV1 for hepcidin (MS: r = 0.38, p = 0.10; ELISA: r = -0.18, p = 0.44).
Effect of inter-dialytic interval on serum hepcidin
Hepcidin levels were higher following a 3-day inter-dialytic interval compared to a 2-day 
inter-dialytic interval (ANOVA; p =0.02) (Figure 3). Both assays demonstrated the highest 
median hepcidin levels on the first day after the weekend (182.8 (138.8-235.0) and 184.1 
(111.9-267.7)) ng/ml with MS and ELISA, respectively.
 No relationship was found between serum hepcidin and dialysis quantity, 
haemoglobin, erythropoietin dosage, or serum ferritin levels (data not shown).
results, part ii – Dutch study
Patient demographics and baseline laboratory data are summarized in Table 1. We 
included 43 consecutive chronic HD patients (24 males), aged between 24 and 83 years. 
36 patients received haemodialysis three times a week for ~4 hours, 22 patients were 
dialyzed in the morning, whereas 14 patients were dialyzed in the afternoon. Seven 
patients were treated with nocturnal dialysis four times a week for ~8h. Median time on 
dialysis was 2.3 years. The majority of patients were treated with IV iron sucrose (n=41) and 
epoetin beta (n=42). Iron sucrose was given once weekly, and blood samples were drawn 
at the start of the session during which IV iron was administered.
Intra-individual variability
One patient died during the study; for this patient only 5 samples were available for 
analysis. For the remaining 42 subjects all 6 samples were collected according to the 
study protocol. The median intra-individual coefficient of variation (CV1) of hepcidin-25 
levels over 6 weeks was 26% (IQR 17-48). CV1 was higher in patients with low levels of 
serum hepcidin (Figure 4) and serum ferritin (Figure 5). Median CV1s of ferritin and CRP 
were 12% (IQR 11-26) and 41% (IQR 8-63), respectively. 
Figure 3. Mean (±SD) serum hepcidin-25 levels (MS assay) measured before nine consecutive dialysis sessions, and 
categorized by the day of the dialysis session in UK patients. Ten patients were dialysed on Mon/Wed/Fri and 10 dialysed 
on Tues/Thurs/Sat (p=0.02; ANOVA).
Figure 4. Correlation of coefficient of variance (CV1) with baseline hepcidin-25 levels in Dutch patients.
Figure 5. Correlation between baseline ferritin and intra-individual coefficient of variance (CV1) of serum hepcidin-25 
in Dutch patients.
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Determinants of intra-individual variability
Comparison of patients with intra-individual variability of hepcidin-25 above (high 
variability) and below (low variability) the median CV1 showed that patients with high 
intra-individual variability had significantly lower baseline hepcidin and ferritin levels and 
lower TSAT (Table 3). CRP levels were not significantly different between these 2 groups. 
By multivariate regression analysis, we found baseline ferritin and CV1 of TSAT, but not CRP, 
to be independent predictors of intra-individual hepcidin-25 variability (R2=0.54). Because 
of collinearity, baseline ferritin can be substituted by baseline hepcidin and CV1 of TSAT 
by CV1 of iron. In the majority of patients there was no correlation between hepcidin-25 
and ferritin, iron, TSAT, CRP, or haemoglobin (Figure 6). In the individual patient, change in 
hepcidin-25 cannot be predicted from change in ferritin or CRP (data not shown). 
 Limiting the analysis to patients with normal CRP levels did not decrease CV1 of 
serum hepcidin-25 levels: median CV1 22% (IQR 16-34). Likewise, repeating the analysis 
after exclusion of patients with hepatitis C (n=2), prostate carcinoma (n=1), blood loss or 
receiving blood transfusion in the month before or during the study (n=9), or patients 
who received an antibiotic in this period (n=8) did not alter the results (median CV1 of 
serum hepcidin-25 levels 27% (IQR 17-48)). 
 Hepcidin-25 variability was also not dependent on the time of dialysis, as illustrated 
by a median CV1 of serum hepcidin-25 levels of 34% (IQR 17-75) in patients on nocturnal 
dialysis compared to a median CV1 of 26% (IQR 17-31) in patients on diurnal dialysis 
(p=0.40). 
Discussion
The results of these studies suggest that there is significant intra-individual variability of 
serum hepcidin in chronic haemodialysis patients, which is consistent with a previous 
report by Ford et al22. The study by Ford et al. had several limitations; the authors studied 
a small number (n=28) of predominantly African-American dialysis patients, and they 
Figure 6. Distributions of intra-individual correlation between hepcidin-25 and ferritin, iron, TSAT, CRP and haemoglobin 
in Dutch patients. Squares represent intra-individual correlations (r-values) between hepcidin and different variables. 
Open squares: P>0.05. Solid squares: p≤0.05.
Table 3 - Baseline characteristics of Dutch HD patients categorized according to low (below median CV1) or high (above 
median CV1) intra-individual variability of hepcidin-25 levels.
High variability Low variability P-value
n (% male) 21 (38%) 21 (48%) 0.35
age [(years) 60 (49 – 70) 64 (55 – 74) 0.39
BMI (kg/m2) 24 (22 – 26) 25 (21 – 28) 0.36
antibiotic use previous month (%) 29% 24% 0.73
malignancy in history (%) 0% 33% 0.004
liver disease (%) 10% 10% 1.0
ESA (%) 100% 95% 0.31
ESA dose (x 1000 units) 12 (8 – 15) 8 (6 – 15) 0.46
ESA Dose changed (%) 33% 38% 0.75
Iron suppletion (%) 100% 90% 0.15
Iron dose (mg/week) 50 (25 – 50) 50 (25 – 50) 0.89
0.52Interval between supplementation and 
hepcidin measurement (weeks)
2 (2-4) 2 (2-4)
Laboratory
Hepcidin 25 (ng/ml) 28.8 (13.9 – 46.9) 64.7 (46.6 – 81.7) 0.0002
Hepcidin 20 (ng/ml) 4.0 (2.7 – 5.1) 11.2 (7.5 – 14.2) 0.03
Ferritin (ng/ml) 237 (170 – 417) 454 (376 – 520) 0.008
Iron (µmol/l) 44.7 (33.5 – 61.5) 61.5 (39.1 – 89.4) 0.07
Transferrin saturation (%) 18.2 (13.8 – 21.7) 24.4 (18.4 – 34.5) 0.01
CRP (mg/l) 5 (5 – 14) 5 (5 – 25) 0.73
Hb (g/dl) 11.4 (10.3 – 11.8) 11.3 (10.8 – 11.9) 0.31
CV1
Hepcidin-25 (%) 37 (32 – 70) 16 (13 – 20) -
Hepcidin-20 (%) 15 (9 –26) 11 (8 – 14) 0.02
Ferritin (%) 21 (12 -29) 11 (8 – 13) 0.03
Iron (%) 26 (15 –42) 16 (14 –22) 0.002
Transferrin saturation (%) 27 (15 –45) 17 (13 – 22) 0.004
CRP (%) 59 (15 –70) 39 (0 – 46) 0.09
Hb (%) 4 (3 –7) 3 (3 – 5) 0.13
Data are presented as mean ± sd and median (interquartile range), percentages are compared with X2 test and 
continuous variables with t-test. BMI; body mass index, ESA; erythropoietin stimulating agents, CRP; C reactive 
protein, Hb; haemoglobin, CV1; coefficient of variance. 
To convert hepcidin-25 from ng/ml to nanomol/l divide by 2.789.
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did not report timing of the blood sample and the duration of the inter-dialytic interval. 
However, the most important limitation of this study by Ford et al. was the use of an 
ELISA assay to measure hepcidin. This is known to cross-react with hepcidin isoforms, 
and the contribution of this lack of specificity to their findings of hepcidin variability was 
impossible to ascertain. In the current studies however, we utilized specific MS assays 
for hepcidin-25, and confirmed significant hepcidin variability. We also attempted to 
examine factors that could potentially influence hepcidin levels (IV iron and the degree 
of inflammation). 
 The hepcidin results obtained using MS were generally lower than those obtained 
using the ELISA. This is likely to be due to the fact that the ELISA is detecting the smaller 
isomers of hepcidin as well as hepcidin-25. Nevertheless, as in previous studies, hepcidin 
levels in haemodialysis patients were consistently elevated compared to healthy 
individuals. Both assays showed a similar degree of hepcidin variability, and the median 
CV1 values were almost identical for MS versus ELISA. 
 Higher hepcidin levels (MS) were seen following a 3-day inter-dialytic interval versus 
a 2-day interval, possibly due to greater generation of hepcidin during the longer dialysis 
free period. 
 It has previously been demonstrated that inflammation (acute and chronic), IV iron, 
and erythropoietin administration12 influence hepcidin levels. In our parallel studies, we 
were unable to demonstrate a convincing association between CRP and hepcidin levels, 
in contrast to the findings of Ford et al. and the multivariate analyses by Zaritsky et al16. 
Interestingly, when using a different MS assay and a different study design, very similar CV1 
values (26%) were observed in the Dutch cohort to those seen in the UK study (24%). 
 We previously suggested that measurement of serum hepcidin might have a role in 
predicting CKD patients’ response to IV iron therapy28. This was investigated by Tessitore 
et al. in 56 haemodialysis patients29. Serum hepcidin did not predict the response to IV 
iron loading. In addition, it was demonstrated that mean serum hepcidin levels did not 
change following IV iron loading, confirming our findings and also those of Weiss  et al13. It 
is possible, therefore, that these negative results may be partly due to significant hepcidin 
variability. 
 It is presently unclear if the variability is related to specific, hitherto unexplained 
features that are characteristic of the dialysis procedure. Future studies must evaluate 
CV1 in predialysis patients to answer this question. The large and unexplained variability 
suggests that it may be difficult to use serum hepcidin-25 levels to guide treatment of 
anaemia in the individual patient. However, we caution against premature conclusions. 
Measurements of serum hepcidin-25 in blood samples collected at shorter time intervals, 
and with and without administration of ESA and IV iron are needed to assess the role of 
serum hepcidin-25 in HD patients. 
 In conclusion, we have independently demonstrated that variability in serum levels 
of hepcidin-25 in haemodialysis patients exceeds 20%, even when using an MS assay. No 
major impact of IV iron or inflammatory status was observed, although a minor effect 
of length of intra-dialytic interval was seen. These data have implications for studies 
examining factors affecting hepcidin levels, and suggest that the utility of serum hepcidin 
as a marker of iron status in haemodialysis patients is limited.
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Background
Hepcidin is a key regulator of iron homeostasis and levels are elevated in patients with 
chronic kidney disease (CKD). Hepcidin may explain the often observed imbalance in iron 
metabolism in patients with CKD. We evaluated the influence of estimated glomerular 
filtration rate (eGFR) on serum levels of hepcidin-25 and its isoforms in patients with renal 
dysfunction. 
methods
Serum levels of the biologically active hepcidin-25 and its isoforms were determined in 
CKD and dialysis patients by a mass spectrometry based assay. 
results
In 83 patients with CKD not requiring dialysis, serum hepcidin-25 levels were not 
significantly increased (5.1 nM versus 4.2 nM in controls, p= 0.30) and were positively 
correlated with ferritin (r= 0.74, p< 0.01). Multiple regression analysis showed ferritin to 
be the only significant predictor of hepcidin-25 levels. Serum hepcidin-25 levels were 
not dependent on eGFR. In contrast, hepcidin-20 and total hepcidin levels showed an 
independent significant inverse correlation with eGFR. In 48 haemodialysis patients, 
median hepcidin-25 levels were significantly higher than in CKD patients (9.4 nM versus 
5.1 nM, p< 0.001) and again strongly correlated with ferritin (r= 0.79, p< 0.001). 
conclusions
eGFR is not a major determinant of serum hepcidin-25 levels. In contrast, the hepcidin 
isoforms hepcidin-20 and hepcidin-22 accumulate in patients with renal impairment. 
introduction
Hepcidin is a recently discovered low molecular weight (LMW) protein that plays an 
important role in iron homeostasis1. Hepcidin may explain the often observed imbalance 
in iron metabolism and the resistance to erythropoiesis-stimulating agents (ESA) in 
patients with impaired renal function. As such, hepcidin could become an important tool 
to predict ESA responsiveness, and to guide treatment with ESA and intravenous iron. In 
addition, hepcidin has the potential to become a target of treatment2, 3. 
 Hepcidin is primarily produced by hepatocytes as an 84-amino-acid (84 aa) pre-
prohepcidin. Subsequent posttranslational processing results in the biological active 25 
aa form (hepcidin-25) that is secreted in plasma and excreted in urine. Additional amino-
terminal degradation results in two smaller isoforms (hepcidin-20 and 22)4, 5. The biological 
significance of hepcidin-20 and 22 is unknown, although in vitro at supraphysiologic 
concentrations, hepcidin-20 shows broad spectrum antimicrobial activity4. Hepcidin 
inhibits the release of iron from macrophages and the absorption of dietary iron from 
the intestine. It does so by causing the internalization and degradation of the cellular 
iron exporter ferroportin, which is highly expressed in macrophages and duodenal 
enterocytes6. The net effect of hepcidin is to increase intracellular iron stores, decrease 
dietary iron absorption, and decrease circulating iron concentrations. 
 Various physiologic and pathologic processes regulate the synthesis of hepcidin. 
An augmented demand for circulating iron due to iron deficiency, hypoxia7, anemia7, 
conditions characterized by ineffective erythropoiesis, or the use of ESA8, leads to a 
decrease in hepcidin synthesis. On the other hand, hepcidin synthesis is increased by 
infection or inflammation7. This is believed to lead to the anemia of chronic disease that 
is characterized by a decrease in circulating iron available for erythropoiesis, despite 
apparently normal iron stores. These latter features are similar to those observed in 
patients with impaired renal function. 
 Hepcidin measurements in serum and urine have long proven to be difficult. Recently, 
both reliable mass spectrometry (MS) based assays and competitive immunoassays have 
become available9, 10. MS assays have the advantage of distinguishing between the three 
hepcidin isoforms, hepcidin-25, 22 and 20. Immunoassays, however, will measure total 
hepcidin levels, with (depending on the specificity of the antibody) different contributions 
from each of the isoforms. 
 Our recent findings suggest that hepcidin-25, like other small peptides such as β2-
microglobulin, is freely filtered and subsequently reabsorbed in the proximal tubules11. 
Accordingly, both serum hepcidin-25 and total hepcidin levels have been found to be 
elevated in small series of patients with renal dysfunction12, 13. Furthermore, Ashby et al., 
exploiting a radio-immunoassay found total hepcidin levels to be elevated and positively 
correlated with ferritin and inversely correlated with estimated GFR (eGFR)10. Yet, it is 
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unclear whether these results obtained for total hepcidin also hold for the bioactive 
hepcidin-25 isoform. 
 Here, we perform studies in patients with impaired renal function by exploiting 
our MS hepcidin assay and report measurements of all 3 hepcidin isoforms in patients 
with chronic kidney disease (CKD) and receiving haemodialysis (HD). To improve our 
understanding of the renal handling of hepcidin, we performed additional studies in 
patients treated by haemodialysis and peritoneal dialysis. 
subjects and methods
Blood samples of 24 healthy controls were collected randomly throughout the day. We 
obtained blood samples of 83 consecutive patients with CKD who visited the outpatient 
clinic of the Radboud University Nijmegen Medical Centre to ensure coverage of the 
full GFR range. Relevant clinical and biochemical data were retrieved from the patients’ 
records. 
Additional blood samples were collected in 48 consecutive patients on haemodialysis, 
using a biocompatible Fresenius polysulfone® dialysis membrane. In all patients, blood 
samples were collected at the start of haemodialysis. To determine whether the artificial 
kidney removed hepcidin, blood samples were drawn from both the arterial (blood 
flowing to the dialyzer) and the venous (blood flowing to the patient) segment of the 
dialysis circuit 5-15 minutes after start and 5-10 minutes before termination of the dialysis 
session in a subgroup of 15 patients. These patients did not receive intravenous iron or 
erythropoietin (EPO) during dialysis. In order to assess the presence of hepcidin in the 
dialysate, dialysate samples were collected within 30 minutes after the start of dialysis. 
After the haemodialysis session, several filters were flushed with a physiologic salt solution 
and acetonitrile in order to determine the presence of hepcidin on the membrane. 
 We measured hepcidin-25 levels in blood and dialysate samples of three patients who 
were treated with peritoneal dialysis, using a pH neutral, lactate-buffered, low glucose 
degradation products solution (Stay-Safe® Balance system, Fresenius Medical Care, 
Germany). The dialysate samples were taken after a 6-8 hour dwell time.
  In accordance with the Dutch ethical regulation, all patients consented that blood 
and dialysate samples would be used for medical research. We measured the following 
parameters in the blood samples: serum creatinine, hemoglobin, serum iron, iron binding 
capacity, ferritin, C-reactive protein (CRP), and hepcidin isoforms. 
Serum hepcidin measurements by use of Matrix-Assisted Laser Desorption/Ionization 
Time-Of-Flight mass spectrometry (MALDI-TOF-MS) were performed between July 
2008 and July 2009 by an update from our previously described method11, 14. For the 
quantification of hepcidin in serum an internal standard (synthetic hepcidin-24, Peptide 
International Inc., Louisville, KY, USA) was added to 50 µL serum before total hepcidin 
was isolated from the sample with Macro-Prep® CM Support beads (Bio-Rad laboratories, 
Hercules, CA, USA) as described11. Next, hepcidin was applied to a MSP 96 polished steel 
MALDI target plate followed by the addition of energy absorbing matrix, 5 mg α-Cyano-
4-hydroxy-cinnamic acid in 1 mL 50% acetonitrile and 0.1% Trifluoro acetic acid, all in 
nitrogen atmosphere. Mass–to-charge (m/z) spectra were generated using MALDI-TOF-
MS (Microflex LT, Bruker Daltonics GmbH, Bremen, Germany) in positive, linear ion mode 
and 500 laser shots. Initial Laser Power; 60%, Laser Attenuator; Offset 25% and Range 
20%. Pulsed ion extraction was set to 150 ns. Concentrations of serum hepcidin were 
expressed as nanomoles per litre. Total hepcidin was calculated as the sum of hepcidin-25, 
hepcidin-22 and hepcidin-20. The Lower Limit Of Detection (LLOD) of this method for 
serum was 0.5 nM with an intra-run coefficient of variation (CV) of 3.7% at 7.9 nM , 2.3% at 
13.4 nM and 2.2 % at 3.1 nM. The inter-run CV is 9.1% at 7.8 nM and 3.9% at 12.9 nM. The 
median reference level of serum hepcidin-25 is 4.2 nM, range 0.5- 13.9 nM. The LLOD of 
this method for dialysate was 0.05 nM. 
calculations
The glomerular filtration rate was estimated (eGFR) by the simplified Modification of Diet 
in Renal Disease (MDRD) formula15, 16. 
statistical analysis
Linear regression analysis was conducted to evaluate the relation between serum 
hepcidin and other relevant parameters. Correlations were calculated using Spearman’s 
or Pearson’s correlation test. If data were skewed log transformation was used. Possible 
collinearity for significant univariate predictors was checked. To determine independent 
predictors of serum hepcidin, multiple regression analysis was applied. Predictors that 
showed high collinearity (Spearman’s rho> 0.8) were not simultaneously included in the 
analysis. Wilcoxon signed rank test was performed to assess differences between hepcidin 
levels in haemodialysis patients. Parameters between groups were compared using the 
Mann-Whitney or Kruskal-Wallis test for non-parametric continuous data, independent 
t-test for parametric data, and the chi-square test for categorical data. Statistical analysis 
was performed using SPSS for windows software, version 16.0 (SPSS Inc, Chicago, IL).
results
We included 83 patients with CKD not requiring dialysis and 48 patients on haemodialysis. 
Clinical and demographic characteristics of both groups and the control group are 
depicted in Table 1. Median eGFR of CKD patients was 36 ml/min/1.73m2 (range 6-93 
ml/min/1.73m2). Causes of CKD were glomerular disease (36%), vascular disease (21%), 
polycystic renal disease (12%), reflux nephropathy (9%), diabetic nephropathy (6%), 
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and other (16%). Patients on haemodialysis were older and showed significantly higher 
values of ferritin and CRP. In HD patients causes of renal disease were vascular disease 
(23%), glomerular disease (19%), diabetic nephropathy (17%), reflux nephropathy (13%), 
polycystic renal disease (4%), and other (24%).
Chronic kidney disease
Serum hepcidin-25 levels were not significantly increased in patients with CKD not 
requiring dialysis compared to 24 healthy controls (median 5.1 versus 4.2 nM, p= 0.30). 
 Overall, in CKD patients serum hepcidin-25 strongly correlated with ferritin (r= 0.74, p< 
0.01, Figure 1A, Table 2), whereas no significant correlation was found between hepcidin-25 
and serum creatinine or eGFR (r= 0.13, p= 0.26 and r= -0.12, p= 0.30 respectively, Figure 
1B, Table 2). Multiple regression analysis, including the putative predictors age, ferritin, 
transferrin, hemoglobin, serum iron, CRP, and eGFR, showed ferritin to be the only 
significant, independent predictor of hepcidin-25 levels (β= 0.736, p< 0.001, R2= 0.54). Of 
note, eGFR had no influence on hepcidin-25 levels. 
Table 1. Clinical and demographic characteristics
Controls
(n=24)
CKD 
(n=83)
Haemodialysis (n=48) P-value
Male (%) 46 60  62 0.234
Age (years) 39±12 55±17$ 61±15 < 0.001
Serum creatinine (µmol/L) 75 [54-102] 151 [62-842]$ - < 0.001
eGFR (ml/min/1.73m2) 84 [67-117] 36 [6-93]$ - < 0.001
Proteinuria (g/10mmol 
creatinine)#
n.a. 0.34 [0.00-16.4] n.a. -
Kt/Vresidual (weekly) - n.a. 0.08 [0.00-0.88] -
Kt/Vdialysis (weekly) - n.a. 4.1 [2.0– 7.5] -
Iron (µmol/L) 19 [9-35] 14 [4-30]$ 8.5 [2-27]* < 0.001
Transferrin (µmol/L) 56 [47-75] 56 [37-81]$ 44 [22-66]* < 0.001
Transferrin saturation (%) 34±7 26±10$ 23±13 < 0.001
Ferritin (µg/L) 102 [12-224] 111 [10-610] 268 [62-2167]* < 0.001
CRP (mg/L) <5 5 [5-75]$ 8 [5-104]* < 0.001
Hb (mmol/L) 8.7±0.5 7.6±1.1$ 6.9±0.9* < 0.001
Hepcidin 25 (nM) 4.2 [0.5-13.9] 5.1 [0.6-29.5] 9.4 [0.5-60.2]* < 0.001
Hepcidin 20 (nM) below LLOD 1.8 [0.6-6.4] 2.7 [1.3-76]* -
Hepcidin 22 (nM) below LLOD 1.1 [0.5-2.2] 1.7 [0.8-2.5]* -
Total Hepcidin (nM) 4.2 [0.5-13.9] 6.8 [0.6-36.2] 11.1 [2.0-65.6]* < 0.001
Median [range], mean±SD, eGFR=estimated glomerular filtration rate, CRP=C-reactive protein, Hb=hemoglobin, 
n.a. = not available, LLOD=lower limit of detection 
#  In 27 patients (32%) proteinuria was > 1 g/10 mmol creatinine, P-value refers to the difference between 
controls, CKD and haemodialysis calculated by Kruskal-Wallis test 
$ significantly different between controls and CKD (p< 0.05) 
* significantly different between CKD and haemodialysis (p< 0.05) 
Figure 1A. Relationship between serum hepcidin-25 and 
serum ferritin in patients with chronic kidney disease not 
requiring dialysis.
Figure 1B. Relationship between serum hepcidin-25 
and estimated glomerular filtration rate in patients 
with chronic kidney disease not requiring dialysis.
There was a significant relationship (r = 0.74, P < 
0.01). Closed symbols represent patients treated with 
erythropoietin.
There was no significant relationship ( r = -0.12, 
P = 0.3).
Table 2. Correlation of hepcidin-25 levels with biochemical and clinical variables in CKD (with and without EPO 
therapy) and haemodialysis patients.
Variable CKD (n=83) Haemodialysis (n=48)
rho p-value rho p-value
Serum creatinine 0.13 0.25 - -
eGFR -0.12 0.30 - -
Proteinuria -0.04 0.73 - -
Transferrin -0.27 0.01 -0.47 0.00
Transferrin saturation 0.14 0.19 -0.24 0.10
Ferritin 0.74 0.00   0.79 0.00
Iron -0.05 0.64 -0.40 0.00
CRP 0.21 0.06   0.52 0.00
Hb -0.04 0.75 -0.38 0.01
EPO-dose 0.08@ 0.45    0.12 0.42
Iron-dose 0.14$ 0.21 -0.04 0.81
Age 0.13 0.11    0.03 0.85
Spearman’s rho was calculated because data were skewed, eGFR= estimated glomerular filtration rate, CRP=C-
reactive protein, Hb=haemoglobin , n.a.= not available @ n=21, $ n=10
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 We specifically questioned if the use of EPO influenced the results. Twenty-one patients 
(25%) were treated with EPO. As expected, EPO-treated patients had a lower eGFR (median 
12 versus 42 ml/min/1.73m2, p< 0.001). There were no differences in serum ferritin levels 
(median 116 versus 106 μg/L, p= 0.42). Serum hepcidin-25 levels were not significantly 
higher in EPO-treated patients (median 8.0 nM versus 4.8 nM, p= 0.31). In multivariate 
regression analysis, EPO therapy was not a predictor of serum hepcidin-25 levels. 
Furthermore, limiting the analysis to EPO-naïve patients did not alter the results observed 
for the whole group; again, serum hepcidin-25 was strongly correlated with ferritin (r= 
0.74, p< 0.01), and no significant correlation was found between hepcidin-25 and serum 
creatinine or eGFR (r= 0.16, p= 0.21 and r= -0.13, p= 0.32 respectively). Multiple regression 
analysis showed ferritin to be the only significant, independent predictor of hepcidin-25 
levels (β= 0.861, p< 0.001, R2= 0.58). Serum levels of hepcidin-20 and hepcidin-22 were 
below the lower limit of detection in 19% and 66% of patients, respectively. In patients 
with hepcidin isoforms above the LLOD, hepcidin-20 and hepcidin-22 correlated with 
ferritin (r= 0.46, p< 0.01, and r=0.41, p= 0.03 respectively, Figure 2) and eGFR (r= -0.49 
p< 0.01 and r= -0.46, p=0.01 respectively, figure 2). Multiple regression analysis of the 
data including patients with concentrations of the hepcidin isoforms above the detection 
limit, showed eGFR to be an independent, significant predictor of hepcidin-20 and total 
hepcidin levels (β= -0.467, p< 0.001, and β= -0.259, p= 0.001 respectively). Furthermore, the 
ratio hepcidin 25/total hepcidin was significantly influenced by eGFR: the ratio was 0.80 
in patients in the highest tertile of eGFR and 0.72 in patients in the lowest tertile of eGFR 
(p=0.044). Thus, a decrease in eGFR was associated with an increase in hepcidin-20 and 
total hepcidin levels. Exclusion of the patients with levels below the detection limit could 
have biased the results. Therefore we re-analysed the data. For this analysis, we attributed 
the lowest measurable value to the patients with levels below the detection limit. Also 
in this analysis, which thus included all patients, eGFR was an independent predictor of 
hepcidin-20 (β = -0.225, p= 0.016). Of note, serum ferritin proved the strongest predictor 
of both hepcidin-20 and total hepcidin, similar to the results described above for serum 
hepcidin-25 levels. 
Haemodialysis
We included 41 patients who received haemodialysis 3 times a week for approximately 
4 hours and seven patients who were treated with nocturnal dialysis four times a week 
for approximately 8 hours. The majority of patients (n=44) were treated with intravenous 
iron and all but one were treated with EPO, median time on dialysis was 26 months (range 
1-64 months). A low-flux membrane was used in 36 patients, whereas 12 patients were 
dialysed using a high-flux membrane. Median blood flow was 300 (range 130-400) ml/
min, median dialysis flow was 500 (range 300-700) ml/min and median ultrafiltration 
volume was 2110 (range 59-3800) ml. Median hepcidin-25 levels were significantly higher 
compared to hepcidin-25 levels in patients with CKD (9.4 versus 5.1 nM, p< 0.001). Again, 
hepcidin-25 was strongly correlated with ferritin (r= 0.79, p< 0.001). Multiple regression 
analysis- including the putative predictors age, ferritin, transferrin, hemoglobin, serum 
iron, and CRP - showed ferritin and serum iron to be significant, independent predictors 
of hepcidin-25 levels (R2 = 0.70 ).
 A significant difference was observed between arterial and venous samples at the 
start of the dialysis procedure compatible with removal of hepcidin-25 by the artificial 
kidney (n=15, 15.9±15.1 versus 8.5±7.5 nM, p= 0.001). The median clearance of hepcidin-25 
was 82 ml/min. Surprisingly, despite a persistent arterial-venous difference at the end 
of dialysis (13.6±11.5 versus 10.3±9.8, p= 0.001), only a very modest reduction in serum 
hepcidin-25 was observed at the end of haemodialysis (arterial values 15.9±15.1 versus 
13.6±11.5 nM, p= 0.03). 
 Hepcidin-25 and its isoforms were present in the ultrafiltrate, but levels were too low 
to allow precise calculation of a sieving coefficient or to account fully for the observed 
arterial-venous difference. Hepcidin was also detected in significant amounts (range 
0.4-2.0 nmol) after eluting the filter with acetonitril, which strongly suggests binding of 
hepcidin to the artificial membrane.
Peritoneal clearance of hepcidin
We measured hepcidin-25 levels in three peritoneal dialysis patients. Hepcidin-25 was 
detected in the dialysate, with an average dialysate/plasma ratio of 0.22. 
Figure 2. Relationship between serum hepcidin-20 and estimated glomerular filtration rate (eGFR) in patients with 
chronic kidney disease not requiring dialysis categorized according to tertiles of ferritin.
There was a significant relationship between hepcidin-20 and eGFR ( r = -0.39, P < 0.001) and between 
hepcidin-20 and serum ferritin levels ( r = 0.60, P < 0.001).
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Discussion
We found that serum hepcidin-25 levels are not significantly increased in patients with 
renal dysfunction not requiring dialysis. Haemodialysis patients however, exhibited 
significantly higher hepcidin-25 levels than patients with CKD. Serum ferritin concentration 
was a significant predictor of hepcidin-25 levels in multiple regression analysis. In contrast, 
eGFR was not an independent predictor of hepcidin-25 levels in patients with CKD. 
Furthermore, serum hepcidin-25 levels decreased only slightly during haemodialysis 
(10-15%), despite an arterio-venous difference in hepcidin levels of > 40%. Admittedly, 
ultrafiltration may have resulted in more concentrated levels of hepcidin-25 and a minor 
underestimation of hepcidin clearance. Since blood samples were not drawn until after 
the initiation of haemodialysis, we cannot exclude an immediate effect of haemodialysis 
on serum hepcidin levels, yet it seems unlikely that hepcidin levels are substantially 
influenced by haemodialysis within such a short period of time.
 Our data corroborate recently published studies reporting higher hepcidin levels in HD 
patients10, 12. There is also agreement that serum ferritin is highly correlated with hepcidin 
levels in patients with CKD and HD10, 12, 13. However, the data seem to differ with respect 
to the role of the eGFR. In two studies the independent effect of eGFR on hepcidin levels 
was not evaluated12, 13. Ashby et al. reported that hepcidin levels in their patients were 
significantly correlated with eGFR, even when corrected for ferritin levels10, whereas in the 
current study hepcidin-25 levels were not related to eGFR. 
 Instead, we found that hepcidin-20 and total hepcidin levels showed an independent 
significant negative relation with eGFR. The apparent discrepancies between our and 
Ashby et al.’s observations might therefore be explained by the use of different assays, and 
in particular the inability of the immunoassay used by Ashby to differentiate between the 
various isoforms. Alternatively, the conflicting results may be attributable to differences in 
the population studied. Also, the findings of Ashby et al. may reflect a type I error or we 
may have failed to detect a slight effect of eGFR on hepcidin levels due to a type II error. 
Yet, based on the data described above we must conclude that serum concentrations of 
hepcidin-25, the bioactive hepcidin isoform, are mainly dependent on ferritin and not on 
eGFR. 
 Our observation that hepcidin-25 is not related to eGFR suggests that hepcidin-25 
differs from other LMW proteins, such as β2-microglobulin or cystatin-C. This might be 
explained by binding of hepcidin to a large carrier protein that precludes it to be freely 
filtered. However, our additional studies are inconsistent with such a hypothesis. First, 
hepcidin was present in the peritoneal dialysate and when the peritoneal clearance 
of hepcidin was plotted on a curve depicting the relationship between the peritoneal 
clearance and the molecular mass of various other freely filtered marker proteins, the 
calculated clearance was compatible with the expected clearance of a freely filterable 
protein of similar molecular mass17. Second, the arterio-venous difference in haemodialysis 
patients suggests that hepcidin-25 is handled similar to other LMW proteins. Admittedly, 
in the latter experiments we were unable to calculate the relative contribution of 
ultrafiltration and of sticking to the membrane of the artificial kidney. 
 Taken together, our findings suggest regulation of serum hepcidin-25 levels, thus 
attenuating any effect of eGFR. Removal of hepcidin-25 by the dialysis membrane, is 
partly compensated for. Studies on the immediate effects of iron administration on the 
increase of serum hepcidin-25 levels are consistent with a fast hepcidin regulation13, 18.
 In conclusion, serum hepcidin-25 levels are not dependent on eGFR. Moreover, serum 
levels of hepcidin-25 decrease only slightly during dialysis, despite considerable removal 
of hepcidin-25 by the artificial kidney. Hepcidin isoforms accumulate in patients with renal 
impairment. The biological relevance of the latter finding is unknown.
Chapter 7 Hepcidin-25 levels are independent of eGFR in CKD
117116
Chapter
 7
references
1.  Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. 
Haematologica 2008; 93(1):90-97.
2.  Swinkels DW, Wetzels JF. Hepcidin: a new tool in the management of anaemia in patients with 
chronic kidney disease? Nephrol Dial Transplant 2008; 23(8):2450-2453.
3.  Deicher R, Horl WH. Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial 
Transplant 2004; 19(3):521-524.
4.  Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the 
liver. J Biol Chem 2001; 276(11):7806-7810.
5.  Kemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D. Novel urine hepcidin assay by 
mass spectrometry. Blood 2005; 106(9):3268-3270.
6.  Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferropor-
tin and inducing its internalization. Science 2004; 306(5704):2090-2093.
7.  Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regu-
lated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110(7):1037-1044.
8.  Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires 
erythropoietic activity. Blood 2006; 108(12):3730-3735.
9.  Piperno A, Mariani R, Trombini P, Girelli D. Hepcidin modulation in human diseases: from research to 
clinic. World J Gastroenterol 2009; 15(5):538-551.
10.  Ashby DR, Gale DP, Busbridge M et al. Plasma hepcidin levels are elevated but responsive to erythro-
poietin therapy in renal disease. Kidney Int 2009.
11.  Swinkels DW, Girelli D, Laarakkers C et al. Advances in quantitative hepcidin measurements by time-
of-flight mass spectrometry. PLoS ONE 2008; 3(7):e2706.
12.  Tomosugi N, Kawabata H, Wakatabe R et al. Detection of serum hepcidin in renal failure and inflam-
mation by using ProteinChip System. Blood 2006; 108(4):1381-1387.
13.  Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 
2008; 112(10):4292-4297.
14.  Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements 
in serum and urine: analytical aspects and clinical implications. Clin Chem 2007; 53(4):620-628.
15.  Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate 
glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in 
Renal Disease Study Group. Ann Intern Med 1999; 130(6):461-470.
16.  Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate 
from serum creatinine. J Am Soc Nephrol 2000; 11:0828.
17.  Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ et al. Peritoneal transport characteristics with 
glucose polymer based dialysate. Kidney Int 1996; 50(3):979-986.
18.  Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the 
synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113(9):1271-1276.
8
chapter
tubular reabsorption and local production of urine 
hepcidine-25 
Hilde P.E. Peters1, Coby M.M. Laarakkers2,Peter Pickkers3, Rosalinde Masereeuw4, Otto C. Boerman5, 
Annemarie Eek5, Elisabeth A.M. Cornelissen6, Dorine W. Swinkels2, Jack F.M. Wetzels1.
1Nephrology, 2Laboratory Medicine, Laboratory of Genetic, Endocrine and Metabolic Diseases, 3Intensive Care Medicine, 
4Pharmacology and Toxicology, 5Nuclear Medicine, and 6Pediatric Nephrology, Radboud University Nijmegen Medical 
Centre, The Netherlands.
BMC Nephrology 2013, Mar;14(70)
Chapter 8 Urinary hepcidin reflects tubular dysfunction and local production
121120
Chapter
 8
aBstr act
Background
Hepcidin is a central regulator of iron metabolism. Serum hepcidin levels are increased 
in patients with renal insufficiency, which may contribute to anemia. Urine hepcidin was 
found to be increased in some patients after cardiac surgery, and these patients were 
less likely to develop acute kidney injury. It has been suggested that urine hepcidin may 
protect by attenuating heme-mediated injury, but processes involved in urine hepcidin 
excretion are unknown. 
methods
To assess the role of tubular reabsorption we compared fractional excretion (FE) of 
hepcidin-25 with FE of β2-microglobulin (β2m) in 30 patients with various degrees of 
tubular impairment due to chronic renal disease. To prove that hepcidin is reabsorbed by 
the tubules in a megalin-dependent manner, we measured urine hepcidin-1 in wild-type 
and kidney specific megalin-deficient mice. 
Lastly, we evaluated FE of hepcidin-25 and β2m in 19 patients who underwent 
cardiopulmonary bypass surgery. Hepcidin was measured by a mass spectrometry assay 
(MS), whereas β2m was measured by ELISA.
results
In patients with chronic renal disease, FE of hepcidin-25 was strongly correlated with FE 
of β2m (r=0.93, P <0.01). In megalin-deficient mice, urine hepcidin-1 was 7-fold increased 
compared to wild-type mice (p<0.01) indicating that proximal tubular reabsorption occurs 
in a megalin-dependent manner. Following cardiac surgery, FE of hepcidin-25 increased 
despite a decline in FE of β2m, potentially indicating local production at 12-24 hours.
conclusions
Hepcidin-25 is reabsorbed by the renal tubules and increased urine hepcidin-25 levels 
may reflect a reduction in tubular uptake. Uncoupling of FE of hepcidin-25 and β2m in 
cardiac surgery patients suggests local production.
introduction
Hepcidin, a peptide predominantly produced by hepatocytes, is a major player in iron 
metabolism1;2. Hepcidin decreases duodenal iron absorption and causes iron sequestration 
in the reticulo-endothelial system3;4. Hepcidin expression is induced by iron storage and 
inflammation5;6 and suppressed by hypoxia and anemia5. Serum hepcidin levels are 
increased in patients with renal insufficiency7;8, and this may contribute to anemia and 
resistance to erythropoietin stimulating agents. 
 Recent studies have pointed to the relevance of urine hepcidin. In patients with lupus 
nephritis, changes in urine hepcidin-20 and -25 predicted renal flares9. Even more striking 
were the findings of Ho et al., who showed that patients with increased urine hepcidin 
levels were at lower risk to develop acute kidney injury (AKI) after cardiac surgery10;11. These 
results have recently been confirmed in a larger study that included 100 patients who 
had undergone cardiopulmonary bypass surgery (CABG)12. It was suggested that urine 
hepcidin may protect against AKI by attenuating heme-mediated injury. 
 In order to meaningfully interpret urine hepcidin as a biomarker, knowledge of renal 
handling is essential. Thus far, it is unclear which processes – filtration, reabsorption, local 
production and/or degradation- govern urine hepcidin excretion. The objective of this 
study was to study the role of tubular reabsorption in kidney hepcidin handling. Our data 
provide evidence for both tubular reabsorption and local production of hepcidin in the 
kidney.
methods
Human studies
Blood and urine samples of healthy controls were collected randomly throughout the 
day as described before13. In order to assess the role of tubular reabsorption we compared 
fractional excretion (FE) of hepcidin-25 with FE of β2-microglobulin (β2m) in patients with 
glomerular or tubular diseases and various degrees of impairment of tubular reabsorption. 
β2m is a low molecular weight protein and an established marker of proximal tubular 
function. Patients were enrolled from February 2009 to October 2010 at the Department 
of Nephrology and Pediatric Nephrology, Radboud University Nijmegen Medical Center. 
Patients with biopsy proven glomerular disease (without an interstitial infiltrate) and 
patients with defined tubular diseases (cystinosis, Dent’s disease) were enrolled. Patients 
with an interstitial infiltrate as concluded from renal biopsy investigations were excluded, 
since monocytes may produce hepcidin14. 
 Hepcidin-25 was also measured in patients after cardiopulmonary bypass surgery. 
Patients were consecutively enrolled from March 2008 to April 2008 at the Department 
of Intensive Care Medicine, Radboud University Nijmegen Medical Centre, and all patients 
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undergoing CABG were included. Serum and urine samples were obtained simultaneously 
either 1-2 hours after surgery (at a time the patient was admitted and stable at the ICU) or 
12-24 hours after the end of surgery (morning urine collected the day after the procedure).
 The study has been carried out in the Netherlands in accordance with the applicable 
rules concerning the review of research ethics committees and informed consent. We 
obtained consent from healthy volunteers. The local ethics committee waived the need 
to get consent from patients, as they were having blood and urine taken as part of 
standard care.
animal experiments
In order to investigate whether hepcidin is reabsorbed in the proximal tubules in a 
megalin-dependent manner, we measured urine hepcidin-1 in wild type and kidney 
specific megalin-deficient C57Bl/6 mice15. Megalin lox/lox; apoECre mice on a C57BL/6 
background were kindly provided by Thomas E. Willnow. The creation of this kidney 
specific megalin-deficient mouse strain was described in detail previously15. Animals 
were bred locally and animals expressing the apoECre gene were identified by means 
of polymerase chain reaction (PCR) analysis. Animals that did not express the apoECre 
gene (megalinlox/lox mice) were used as wild type controls. Approximately 12 weeks old 
female mice were used. Their diet contained 179 mg/kg iron. To collect urine samples, 
mice were individually housed in metabolic cages (Techniplast®). Mice were allowed 
to adapt to these cages during 2 periods of 30 min, after which 24-hour urine samples 
were collected. Prior to 24 h housing in metabolic cages, 2x0.5 ml salt solution was 
administered subcutaneously to prevent dehydration. To prevent hypothermia, room 
temperature was raised to 24 ⁰C with a relative humidity of 53-68%. Food and water were 
available ad libitum. Mice were sacrificed after blood sampling at the end of the 24-hour 
urine collection. Urinary protein profile of wild-type and megalin deficient mice was 
determined by gel electrophoresis.
 Experiments were approved by the Animal Ethical Commission of the Radboud 
University Nijmegen Medical Centre and performed in accordance with national 
guidelines for the care and handling of animals.
Laboratory measurements
Urine and serum samples were processed, aliquoted, and stored in polypropylene tubes 
at −80°C immediately after collection. Routine laboratory parameters and hepcidin levels 
were measured within 8 hours and 6 months of collection, respectively. 
Urinary and serum creatinine were measured with an enzymatic method. Urine β2m was 
measured by ELISA. Urine β2m was only measured in urine with a urinary pH >6.0, since 
degradation of β2m may occur below this pH. Human hepcidin-25 was measured by our 
previously described weak cation exchange time-of-flight mass spectrometry assay16 (TOF 
MS). Hepcidin-1 in urine from mice was measured by surface-enhanced laser desorption 
ionization (SELDI) TOF MS17.
calculations and statistics
Depending on its distribution, data were expressed as median (interquartile range) or 
mean ± SD. Fractional excretion of substance Y was defined as: (Serum Creatinine x Urine 
Y) / (Serum Y x Urine Creatinine) x 100%. In healthy controls, serum and urine hepcidin-25 
were expressed as the mean of four samples collected at different times during the day. 
In mice urinary concentrations were normalized for creatinine to correct for differences 
in urine dilution.
 Glomerular filtration rate (GFR) was estimated by the abbreviated Modification of Diet 
in Renal Disease equation in adults18. In children GFR was estimated using the revised 
Schwartz formula19.
 Statistical analysis was performed using SPSS 16.0 (SPSS Inc, Chicago, IL). Correlations 
were assessed by linear regression, using Spearman’s rho. Mann Whitney test was used 
for comparison of FE of hepcidin-25 in healthy controls and patients with renal disease 
and for comparison of urinary concentrations in wild type and megalin-deficient mice. 
Statistical significance was denoted by two sided P values of <0.05.
results
In 24 healthy controls fractional excretion (FE) of hepcidin-25 was 1.9 (IQR 1.0-3.2)% (table 
1). We evaluated 30 patients with glomerular or tubular diseases and various degrees of 
impairment in tubular reabsorption. Median serum creatinine was 107 (IQR 83-147) µmol/l 
and proteinuria 4.5 (IQR 1.7-9.4) g/d (Table 1). 
Renal disease consisted of idiopathic membranous nephropathy (n=13), focal segmental 
glomerulosclerosis (n=3), infantile nephropathic cystinosis (n=7), or other causes (n=7). 
There was an increased FE of hepcidin-25 in patients with renal disease compared 
to controls (8.0 versus 1.9%, p<0.001). We found a strong correlation between FE of 
hepcidin-25 and FE of β2m (Spearman’s rho=0.93, p<0.01, Figure 1). Since β2m is a marker 
of proximal tubular reabsorption, this data strongly suggest that hepcidin excretion is at 
least partially governed by this process. 
 Megalin is a multiligand endocytic receptor localized in the proximal renal tubules 
and plays an important role in the tubular reabsorption of various filtered proteins, 
amongst which β2m. To prove that the bioactive mouse hepcidin-1 is reabsorbed in the 
proximal tubules in a megalin-dependent manner, we measured urine hepcidin in wild 
type and kidney specific megalin-deficient C57Bl/6 mice. As expected, megalin deficient 
mice did excrete low molecular weight proteins. Urine hepcidin-1 was 7-fold increased in 
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megalin-deficient mice (n=5) compared to wild type mice (n=5, Figure 2; p<0.01). Of note, 
glomerular filtration was not affected in megalin-deficient mice compared to wild type 
mice (creatinine clearance 205±146 versus 249±24 µl/min, NS).
 We next evaluated urine hepcidin-25 in patients who underwent cardiopulmonary 
bypass surgery (Table 1). 24 patients were initially enrolled, but five patients were excluded 
because of a urinary pH <6 at both time intervals, thus precluding reliable measurement 
of β2m. All remaining 19 patients were operated on pump, except for one patient who 
had pre-existing impairment of renal function. Two patients developed acute kidney 
injury after cardiac surgery, with AKI defined as a baseline-to-peak decrease in eGFR by 
50% or more during the first five days post-operatively. pH was >6 in approximately 50% 
of measurements performed in these 19 patients, allowing serum and urine β2m and 
hepcidin quantification in eight patients, 1-2 hours after surgery and in 13 patients 12-
24 hours after surgery. In only 2 patients measurements were performed at both time 
intervals. 
 Immediately after surgery, FE of hepcidin-25 and β2m were 21 and 14%, respectively, 
and correlated strongly (Spearman’s rho=0.79, p=0.02). The ratio between both parameters 
was similar to that in patients with renal disease, and thus compatible with impairment 
of tubular reabsorption. At 12-24 hours after surgery FE β2m decreased (3%), indicating 
recovery from tubular injury. However, FE of hepcidin-25 increased further (33%). As a 
result, FE of hepcidin-25 did no longer correlate with FE of β2m (Spearman’s rho=0.18, 
p=0.55, Figure 1). When plotting serum hepcidin versus urinary excretion of hepcidin (or 
GFR*serum hepcidin vs urinary excretion of hepcidin) there was no evidence of a tubular 
threshold (Figure 3).
Table 1. Clinical and demographic characteristics
Variable Controls 
(n=24)
Renal disease 
(n=30)
CABG 1-2 hours 
(n=8)
CABG 12-24 
hours (n=13)
Male (%) 46 80 88 85
Age (years) 39±12 43±24 65±8 66±10
Serum albumin (g/l) n.a. 34 (24-35) n.a. n.a.
Serum creatinine (μmol/l) 75 (68-83) 107 (23-147) 93 (74-116) 85 (51-102)
eGFR (ml/min/1.73m2) 84 (77-108) 57 (34-65) 73 (58-95) 85 (17-128)
Proteinuria (g/d) n.a. 4.5(1.7-9.4) n.a. n.a.
Serum β2m (mg/l) n.a. 2.9 (2.2-4.6) 2.1 (1.6-2.9) 1.8 (1.3-2.5)
Serum hepcidin-25 (nmol/l) 4.4 (3.2-5.8) 3.1 (1.1-5.7) 4.7 (1.5-7.1) 14.1 (11.1-17.8)
Urine β2m (nmol/mmol 
creatinine)
n.a. 142(13-863)  312(1528-5239) 66(21-86)
Urine hepcidin-25 (nmol/mmol 
creatinine)
0.9 (0.4-1.7) 1.4 (0.3-7.1) 10.4 (0.8-18.7) 52.2 (34.0-112.1)
FE of β2m (%) n.a. 5.1 (0.7-39.1) 14.1 (7.1-20.7) 2.7 (0.8-3.7)
FE of hepcidin-25 (%) 1.9 (1.0-3.2) 8.0 (1.9-20.3) 21.1 (7.2-23.1) 33.1 (22.2-52.9)
Duration of CPB (min) - - 101 (63-147)# 106 (92-125)#
Median (interquartile range), mean ± SD, eGFR = estimated glomerular filtration rate, n.a. = not available, FE 
= fractional excretion, CABG = coronary artery bypass grafting, CPB = cardiopulmonary bypass, # one patient 
underwent off-pump CABG 
Figure 3. Serum hepcidin-25 versus estimated urinary excretion of hepcidin-25 in patients 1-2 and 12-24 hours post 
surgery. There is no correlation indicating a threshold of serum hepcidin-25 above which urinary excretion steeply 
increases. Spearman’s rho is 0.91 for 8 patients at day 1 and 0.16 for patients at day 2.
Figure 1. Correlation between fractional excretion (FE) of hepcidin-25 
and β2-microglobulin (β2m) in patients with renal disease without 
a tubulointerstitial infiltrate (n=30, triangles), and in patients at 1-2 
hours (n=8, white circles) and 12-24 hours (n=13, black circles) after 
cardiopulmonary bypass grafting (CABG). 
Figure 2. Hepcidin-1 in urine of C57Bl/6 
Wild type mice (n=5) and mice with kidney-
specific megalin deficiency (n=5). 
FE of hepcidin correlates with FE of β2m, indicating tubular uptake 
of hepcidin. However, FE of hepcidin increased relatively more in 
patients 12-24 hours after CABG, suggesting local production in 
the kidney.
Urine was normalized for creatinine 
levels. Data are depicted as lower 
quartile, median and upper quartile 
(boxes), and minimum and maximum 
ranges (whiskers). **, P<0.01;megalin 
deficient vs. wild type mice (by Mann 
Whitney test).
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Discussion
Our results indicate that hepcidin-25 is reabsorbed by the renal proximal tubules via 
megalin-mediated endocytosis. In addition, our data suggest that the increase of urine 
hepicidin-25 after cardiac surgery reflects local production of hepcidin in the kidney. 
 Urine hepcidin has recently gained interest as a renal biomarker. However, not much 
is known about the renal handling of hepcidin. Because of its small size (2.8 kDa), free, 
unbound hepcidin is likely to be filtered by the glomeruli. After filtration, hepcidin is almost 
completely reabsorbed by the renal tubules. This conclusion is based on data from a small 
number (n=9) of healthy controls and patients with thalassemia and hemochromatosis, 
where FE of hepcidin was estimated to be less than 3%20;21. 
 In the present study, FE of hepcidin-25 in healthy controls was approximately 2%, thus 
confirming earlier reports and compatible with the suggested extensive tubular uptake20;21. 
In patients with kidney diseases, FE of hepcidin-25 was increased and correlated strongly 
with FE of β2m (r=0.93, p<0.01), a low molecular weight protein that is normally freely 
filtered by the glomerulus and almost completely reabsorbed in the proximal tubule 
through the megalin receptor. By using a mouse model, we confirmed the existence of 
megalin-dependent tubular reabsorption of hepcidin-25. Unlike humans, mice contain 
two related hepcidin genes, hepcidin-1 and 2, of which hepcidin-1 is almost exclusively 
produced in the liver. This peptide is important for iron homeostasis, and is considered the 
mouse equivalent of human hepcidin-253;22;23. Urine hepcidin-1 was significantly higher in 
megalin-deficient mice (p<0.01, Figure 2). 
 We observed that shortly after cardiac surgery, FE of both hepcidin-25 and β2m were 
increased and correlated strongly, reflecting decreased tubular reabsorption. However, 
within 24 hours after surgery we observed a further increase of FE of hepcidin-25, whereas 
at this time point tubular injury became less severe as shown by the reduction in FE of 
β2m. These findings can be explained in two ways; either by the occurrence of saturation 
of tubular reabsorption due to increased tubular delivery of hepcidin-25 thus exceeding 
reabsorption capacity or by production of hepcidin-25 locally in the kidney. Since we did 
not observe a threshold (Figure 3), local production is the most likely explanation. 
 Data on tubular reabsorption or local production are scarce. Kulaksiz  et al. observed 
strong hepcidin expression in the thick ascending limb of the cortex and in the connecting 
tubules, but not in the proximal tubules24. At the cellular level, hepcidin was localized to 
the apical cell pole of the renal epithelial cells, which is suggestive of luminally directed 
release of hepcidin in the urine. Hepcidin-25 may thus be produced by the distal kidney 
tubules24 due to unknown stimuli or by inflammatory cells such as monocytes14.
The origin and regulation of locally produced hepcidin-25 in patients after cardiac surgery 
merits further studies in view of the recent evidence that urine hepcidin may protect 
against the development of AKI. In a nested cohort study Ho  et al. compared urine of 22 
cardiac surgery patients with AKI (defined as ≥50% rise in serum creatinine during the first 
four postoperative days) with urine from 22 randomly selected cardiac surgery patients 
without AKI10. they observed that hepcidin-25 was increased on the first post-operative 
day in patients not developing AKI. The observations of Ho  et al. were corroborated by 
an independent observational study measuring hepcidin through ELISA in 100 cardiac 
surgery patients12: urine hepcidin was 3-7 times higher 6 and 24 hours after surgery in 
AKI-free patients (n=91) compared to nine patients who developed AKI (defined as ≥50% 
rise in serum creatinine or urine output <0.3 ml/kg/hr during the first seven postoperative 
days). Additionally, FE of hepcidin increased from 8 to 40% at 24h post surgery in 93 
patients exposed to cardiac surgery, and was higher in patients who did not develop AKI 
(AKI (n=25) 27% vs AKI-free (n=68) 37%, p=0.049)25.
 As suggested by others26, local production of hepcidin may serve to prevent oxidative 
damage induced by free iron and thereby protect against AKI. Some studies have reported 
that hepcidin binds divalent metals, amongst which Fe2+ 27;28. 
This study is the first to document local production of hepcidin in patients after CABG. 
It has several limitations. First, we included a limited number of patients. Secondly, 
due to a pH <6.0 β2m could not reliably be measured in all samples. Although alfa-1 
microglobulin is a more stable marker of proximal tubular reabsorption and can reliably 
be measured in acidic urine, it is protein-bound and therefore it is impossible to calculate 
the fractional excretion. Third, this study is a pilot study, and our findings were not 
corroborated by histopathological data showing extensive proximal tubular uptake in 
apical endocytic vesicles, nor by data on hepcidin expression or mRNA content in the 
kidney or macrophages. More extensive studies are necessary to evaluate the exact 
timing and location of hepcidin production, and to identify possible factors influencing 
this process. Since increased urinary levels of hepcidin are associated with a decreased 
risk for post-surgical AKI, increasing local production may serve as a strategy to reduce 
the development of AKI.
 In conclusion, our mouse study indicates that proximal tubular reabsorption of urine 
hepcidin-1 occurs in a megalin-dependent manner. In CKD patients FE of hepcidin-25 
correlated strongly with FE of β2m, suggesting that also in human urinary excretion 
of hepcidin-25 is governed by tubular reabsorption of hepcidin. Uncoupling of FE of 
hepcidin-25 and β2m in cardiac surgery patients indicates local production of hepcidin-25. 
This local production of hepcidin-25 may be important in attenuating post-surgical AKI 
and merits further investigation.
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aBstr act
Connective tissue growth factor (CTGF) plays a key role in renal fibrosis. Urinary CTGF 
is elevated in various renal diseases and may have biomarker potential. However, it 
is unknown which processes contribute to elevated urinary CTGF levels. Thus far, 
urinary CTGF was considered to reflect renal expression. We investigated how tubular 
dysfunction affects urinary CTGF levels. To study this we administered recombinant 
CTGF intravenously to rodents. We used both full length CTGF and the amino-terminal 
fragment, since the N-fragment is the predominant form detected in urine. Renal CTGF 
extraction, determined by simultaneous arterial and renal vein sampling, was 18±3% for 
full length CTGF and 21±1% for the N-fragment. Fractional excretion was very low for 
both CTGFs (0.02±0.006% and 0.10±0.02%, respectively), indicating that more than 99% 
of the extracted CTGF was metabolized by the kidney. Immunohistochemistry revealed 
extensive proximal tubular uptake of CTGF in apical endocytic vesicles, and colocalization 
with megalin. Urinary CTGF was elevated in megalin/cubilin deficient mice, but not in 
cubilin deficient mice. Inhibition of tubular reabsorption by Gelofusine reduced renal 
uptake of CTGF and increased urinary CTGF. In healthy volunteers, Gelofusine also induced 
an increase of urinary CTGF excretion, comparable to the increase of β2-microglobulin 
excretion (r = 0.99). Furthermore, urinary CTGF correlated with β2-microglobulin (r = 0.85) 
in renal disease patients (n =108) and only β2-microglobulin emerged as an independent 
determinant of urinary CTGF. Thus, filtered CTGF is normally reabsorbed almost completely 
in proximal tubules via megalin, and elevated urinary CTGF may largely reflect proximal 
tubular dysfunction.
introduction
CONNECTIVE TISSUE GROWTH FACTOR is an important profibrotic growth factor in 
chronic kidney disease (CKD). Elevated urinary connective tissue growth factor levels 
(uCTGF) are reported in diabetic nephropathy (DN), chronic allograft nephropathy (CAN), 
IgA nephropathy, focal segmental glomerular sclerosis and idiopathic membranous 
nephropathy (iMN)1, 6, 17, 24. Urinary CTGF relates to markers of disease severity in CKD. In type 
I DN urinary CTGF excretion correlated with urinary albumin excretion and glomerular 
filtration rate (GFR) and in CAN with biopsy histology and proteinuria6, 24. In iMN uCTGF 
was associated with proteinuria and GFR and uCTGF was an independent predictor of 
deterioration of renal function1. However, despite increasing evidence regarding the 
biomarker potential of uCTGF, interpretation of urinary levels is hampered by lack of 
understanding of the processes contributing to elevated levels.
 Previously, elevated uCTGF was considered to reflect increased intrarenal production 
(26). In many renal diseases, overexpression of CTGF was observed in inflammatory 
glomerular lesions and tubulointerstitial fibrotic areas16, 31. However, we hypothesized 
that reduced tubular reabsorption might contribute importantly to increased urinary 
CTGF excretion. To investigate this we studied whether CTGF is filtered and tubularly 
reabsorbed and whether impairment of tubular reabsorption results in increased 
urinary CTGF excretion. We quantified renal tubular uptake of recombinant CTGF after 
intravenous administration in rodents and evaluated the effect of inhibition of proximal 
tubular reabsorption on uCTGF in healthy rodents and humans. In addition, we examined 
the correlation between urinary levels of CTGF and β2-microglobulin, a sensitive marker of 
tubular dysfunction, in renal disease. Secondary objective was to identify the endocytic 
receptor involved in proximal tubular reabsorption of CTGF.
materials and methods
Recombinant CTGF proteins and anti-CTGF antibodies. Recombinant CTGFs and anti-CTGF 
antibodies were supplied by Fibrogen Inc. (San Francisco, CA). The recombinant human 
CTGFs were produced in a baculovirus expression system in Chinese Hamster Ovary cell 
lines cultured in hollow- fiber fermentors. The proteins were purified by CTGF-affinity 
and cation exchange chromatograpy. Recombinant full length CTGF comprised all four 
domains (Q27-A349) and the N-terminal fragment comprised domain 1 and 2 (Q27-A178). 
 Gelofusine. We purchased Gelofusine (40 g/l) from Braun (Oss, The Netherlands), 
Gelofusine is a modified gelatin consisting of polypeptides with an average molecular 
weight of 30 kDa. In previous studies we have shown that Gelofusine effectively blocks 
tubular reabsorption of LMW proteins30. 
 Animal experiments. Pharmacokinetic studies were performed in mice and rats. All 
experiments were approved by the Animal Ethical Commission of the University of 
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Utrecht and performed in accordance with national guidelines for the care and handling 
of animals. 
C57Bl/6J mice (12 weeks old; Harlan, Horst, The Netherlands) received recombinant 
human CTGF by tail vein injection (single dose), or by intraperitoneal infusion (3 days) 
using micro-osmotic pumps (model 1003D, ALZET, Cupertino, CA). To evaluate the plasma 
disappearance and uptake in the kidneys, mice were killed at various time points after 
bolus injection of full length CTGF or N-CTGF (12.5-50 pmol/g bodyweight). Kidneys 
were harvested and weighed and processed for ELISA or immunohistochemistry as 
described below. To evaluate the effects of inhibition of proximal tubular reabsorption, 
a separate group of mice received Gelofusine (40 g/l; Braun) either by tail vein injection 
(5 μl/g bodyweight) 1-2 min before N-CTGF injection in the other tail vein (n = 3) or by 
tail vein injection (10 μl/g bodyweight) during N-CTGF intraperitoneal infusion (0.6 pmol/
min) by micro-osmotic pump 3 days after intraperitoneal implantation under isoflurane 
anesthesia (n = 3). 
 To identify the endocytic receptors involved in tubular reabsorption of (endogenous) 
CTGF, urine was collected during a 24 hour period from mice deficient for cubilin or 
megalin/cubilin, obtained by crossing mice bearing floxed cubilin alleles or both cubilin 
and megalin floxed alleles with Mox2-Cre (MORE) mice. Surviving offspring exhibited 
a mosaic pattern of cubilin deficiency or megalin and cubilin deficiency11. Deletion of 
cubilin and megalin varied from 70% to over 95%. Age-matched wild-type mice were 
used as controls. Endogenous uCTGF levels were determined by ELISA as described 
below. 
 Studies in rats were performed to quantify the renal extraction and fractional 
excretion. Male Wistar-Kyoto rats (15-17 weeks old; Harlan) were anesthetized with 
intraperitoneal pentobarbital sodium (72 mg/kg). The trachea was intubated with a 16-G 
catheter (Venisystems Abbocath-T, Abbott, Ireland). A PE-90 catheter was placed in the 
left jugular vein for infusion of solutions, a second PE-10 catheter was introduced for 
CTGF infusion and a third PE-10 catheter for supplemental anesthetic. The left femoral 
artery was cannulated with PE-90 tubing for blood withdrawal and pressure monitoring. 
A PE-90 catheter was placed in the bladder for urine collection. The left renal vein was 
exposed through a ventral midline and left subcostal incision, to make it accessible for 
puncture. During surgery, animals received intravenous infusion of 0.9% NaCl and 6% BSA 
followed by 1% BSA after 20 min at a rate of 8 ml/kg/h. Following surgery, infusion rate 
was reduced to 6 ml/kg/h and maintained throughout the experiment. The solution also 
contained 30 mM Inulin (Inutest, Fresenius Pharma, Linz, Austria) and 25 mM PAH (Sigma, 
St Louis, MO) for clearance measurements. After 45 min stabilization period, infusion of full 
length CTGF or N-CTGF was started at 54 pmol/kg/min or 7 pmol/kg/min, respectively, 
based on pilot clearance studies. Urine was collected at 15 min intervals. 90 Min after 
the start of CTGF infusion two arterial blood samples were taken at an interval of 30 min 
to determine fractional CTGF excretion. After a short equilibration period a third arterial 
blood sample was taken simultaneously with puncture of the left renal vein to determine 
renal extraction ratios and tubular uptake. Inulin and PAH were measured as described32.
 Human studies. Effect of impairment of tubular reabsorption on urinary CTGF 
excretion was studied in healthy human volunteers by infusion of Gelofusine 
and in renal disease patients with varying degrees of tubular dysfunction. The 
Gelofusine protocol was approved by the Ethics Review Committee of the University 
Medical Center St.Radboud and informed consent was obtained from healthy 
volunteers. In accordance with Dutch ethical regulations, all patients consented that 
blood and urine samples were used for medical research. The studies were conducted 
according to the principles of the Declaration of Helsinki. 
 Three healthy volunteers received infusion of Gelofusine (40 g/l, Braun), which was 
started at a rate of 10 ml/min for 5 min followed by 3 ml/min during 55 min. CTGF levels 
were measured in urinary samples taken before the infusion and at 30, 60, and 180 min 
after start of the infusion, and in blood samples drawn before and at the end of Gelofusine 
infusion.
 In a cross-sectional study, 108 patients with renal impairment due to glomerular 
diseases were enrolled from March 1995 through March 2004 at the Department of 
Nephrology, Radboud University Nijmegen Medical Center (The Netherlands). Details of 
the cross-sectional study have been described4.
CTGF ELISA. CTGF levels in plasma, urine, and renal homogenates were determined by 
sandwich ELISA, using specific antibodies (FibroGen) directed against distinct epitopes 
in the amino-terminal fragment of CTGF, detecting both full length CTGF and the 
N-fragment. Frozen renal tissue (stored at -80°C) was homogenized in lysis buffer (20 mM 
Tris (Roche, Mannheim, Germany), 150 mM NaCl (Merck, Darmstadt, Germany), 1% Triton 
X-100, 10% glycerol, 1 mM EDTA (Riedel-de Haen, Seelze, Germany), 0.1% SDS (Research 
Organics, Cleveland, OH), 1 mM EGTA, 0.5% sodium deoxycholate, 50 mM NaF, 2 mM 
Na-orthovanadate (Sigma), pH 7.4) containing 5% Protease Inhibitor Cocktail (Sigma). 
Two ELISA assays were used: a human CTGF assay for detection of endogenous CTGF 
in human samples or recombinant human CTGF in rodent samples and a rodent CTGF 
assay for determination of endogenous CTGF in the transgenic mice. For the human CTGF 
assay microtiter plates (Maxisorb; Nunc, Roskilde, Denmark) were coated with capture 
anti-CTGF monoclonal antibody (5 mg/ml; FibroGen). Subsequently, diluted samples and 
standards (recombinant human CTGF; FibroGen) were added and incubated with non-
cross-blocking human anti-CTGF monoclonal antibody conjugated directly to alkaline 
phosphatase (0.5 mg/ml; FibroGen). Para-nitrophenylphosphate (Sigma) was used as 
substrate for the colorimetric reaction. For the rodent CTGF assay a similar protocol was 
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applied: goat anti-N-CTGF polyclonal antibody (7.5 μg/ml; FibroGen) was used for coating 
and a non-cross-blocking human anti-CTGF monoclonal antibody was used for detection, 
followed by incubation with goat anti-human IgG polyclonal antibody conjugated to 
alkaline phosphatase (1:2000; Sigma). Recombinant mouse CTGF (FibroGen) was used for 
standard curves. Assay sensitivities (lower limits of detection) were 0.02 pmol/ml for the 
human CTGF assay and 0.04 pmol/ml for the rodent CTGF assay. The antibody used for 
detection in the human CTGF assay does not cross-react with rodent CTGF. Intra- and 
interassay coefficients of variation were within 10%. Plasma levels of endogenous CTGF 
in healthy rodents, healthy human subjects and renal disease patients are shown in 
Supplementary Table 1.
 In addition to the ELISA assays detecting both full length CTGF and the N-fragment, 
we applied sandwich ELISA technique to specifically detect full length CTGF by using two 
distinct antibodies directed against the carboxy-terminal and amino-terminal fragment. 
We did not measure significant amounts of full length CTGF in human or rodent urine, 
neither in healthy situation nor in case of impaired tubular reabsorption, which is in 
accordance with previous reports6, 12, 19, 27.
 Immunofluorescence. Immunostaining for CTGF was performed on 3 μm formalin-
fixed paraffin-embedded (FFPE) tissue sections. After deparaffinization, antigen retrieval 
was performed by predigestion with Protease XXIV (0.2 M phosphate; Sigma) followed 
by blocking of endogenous peroxidase activity (1% H2O2 in phosphate/citrate buffer). 
Sections were incubated with CTGF-specific human monoclonal antibody (FibroGen) (24 
μg/ml in PBS/1% BSA) for 1 h followed by incubation with rabbit anti-human IgG (Dako, 
Glostrup, Denmark) (1:100, 30 min). Amplification was performed with Powervision poly-
peroxidase goat anti-rabbit IgG (Klinipath, Duiven, The Netherlands) (30 min) and FITC 
Tyramide Amplification Reagent (PerkinElmer, Boston, MA) (1:50, 10 min). TO-PRO 3 Iodide 
(Molecular Probes, Eugene, OR) was used for nuclear counterstaining.
 For double immunofluorescence staining for CTGF and megalin 3 μm deparaffinized 
FFPE sections were pretreated by boiling in Tris-EDTA buffer pH 9.0 and incubated 
with goat anti-rat megalin polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA) (1:50) for 1 h followed by incubation with peroxidase-conjugated rabbit anti-goat 
IgG (Dako) (1:50, 30 min) and amplification with FITC Tyramide Amplification Reagent 
(PerkinElmer) (1:50, 10 min). Subsequently, sections were incubated with CTGF-specific 
human monoclonal antibody (FibroGen) (24 μg/ml) for 1h followed by incubation with 
Alexa Fluor 647-conjugated goat anti-human IgG (Molecular Probes) (1:50, 30 min).
 Slides were mounted in Vectashield (Vector Laboratories, Ontario, Canada), and 
visualized by confocal laser scanning microscopy. For all stainings, incubation with 
secondary antibody alone served as a negative control.
Immunohistochemistry. To identify proximal tubules, staining with Lotus tetragonolobus 
agglutinin (LTA) was applied (5, 28). Deparaffinized FFPE sections (3 μm) were pretreated 
by boiling in citrate buffer pH 6.0 and incubated with HRP-conjugated LTA (Sigma) (1:32) for 
1 h followed by incubation with NovaRed for ten minutes (Vector Laboratories). Sections 
were counterstained with hematoxylin and visualized by Nikon Eclipse E800 microscope 
(Nikon Netherlands, Lijnden, the Netherlands). 
 Consecutive sections were stained with LTA and anti-CTGF (see Immunofluorescence). 
Images of corresponding areas were merged by digital selection and coloring of LTA-
positive areas using Adobe Photoshop software version 11.0 (Adobe Systems, San Jose, 
CA).
 Measurement of creatinine. Urinary and serum creatinine were measured with 
enzymatic assays (J2L Elitech (Labarthe-Inard, France) for murine samples, DiaSys 
(Holzheim, Germany) for rat samples and Roche (Mannheim, Germany) for human 
samples (automated technique)). 
 Measurement of β2M. Urinary β2M was measured by ELISA, as described before (18). 
To avoid degradation of urinary β2M, subjects ingested 4 g sodium bicarbonate on the 
evening before the test. β2m was only measured in urine with a urinary pH >6.0.
 Calculations and statistics. Data, expressed as mean ± SEM, were compared with 
Student’s t test (two-tailed). Paired Student’s t-test was used for comparison of urinary 
concentrations in mice and fractional excretions in humans before and after Gelofusine 
administration. Statistical analysis of subsequent urinary concentrations during Gelofusine 
infusion in humans was performed by ANOVA for repeated measures. Correlations were 
assessed by linear regression. In the patient study, urinary CTGF, urinary β2M, plasma CTGF 
and serum creatinine were logarithmically transformed before analysis because of their 
skewed distribution. Urinary concentrations were expressed in mol/g creatinine to correct 
for differences in urine dilution. GFR was estimated by the abbreviated Modification of Diet 
in Renal Disease equation21. Renal clearances and fractional excretions were calculated by 
standard formulae. Renal extraction was calculated as follows:
Tubular uptake was expressed as percentage of the amount of N-CTGF extracted by the 
kidney and calculated as follows:
where V is the urinary flow rate and ERPF the effective renal plasma flow.
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results
Plasma CTGF is glomerularly filtered, almost completely reabsorbed by proximal tubules and 
only minimally excreted in urine. First, we investigated the fate of recombinant human 
CTGF that was administered intravenously to healthy mice. Using recombinant human 
CTGF and human CTGF specific antibodies we could distinguish between endogenous 
and exogenous CTGF and exclude contribution of locally produced CTGF to measured 
tissue levels. We administered both full length CTGF and the amino-terminal fragment but 
focused our analyses primarily on N-CTGF since this is the predominant form detected in 
urine6, 12, 19, 27. Intravenous bolus injection of N-CTGF led to rapid accumulation in the renal 
cortex (Fig. 1A). Immunofluorescent staining showed abundant N-CTGF in endocytic 
vesicles in renal PTCs (Fig. 1, B-C). Localization in apical vesicles suggested that circulating 
N-CTGF was glomerularly filtered and subsequently reabsorbed from the luminal fluid. 
Recombinant full length CTGF was also filtered and tubularly reabsorbed (Fig. 1D). LTA 
and CTGF staining of consecutive sections identified the CTGF containing segments as 
proximal tubules (Fig. 2). Thus, in healthy mice CTGF is glomerularly filtered and to a large 
extent endocytosed by PTCs. 
 To quantify renal extraction and fractional excretion, we performed additional 
experiments in anesthetized rats which received CTGF by continuous infusion. After 
reaching steady state, kinetic parameters were calculated from steady state plasma 
concentrations and urinary excretion, as summarized in Table 1. For determination of renal 
extraction, blood samples were drawn simultaneously from the renal vein and femoral 
artery. Renal N-CTGF extraction was 21±1%, which was 74% of that of inulin. For full length 
CTGF renal extraction was 18±3%. Tubular uptake was almost complete, resulting in 
fractional excretions of less than 1% (Table 1). Thus, in healthy rats renally extracted CTGF 
is almost completely metabolized by the kidney and minimally excreted in the urine. 
Inhibition of tubular reabsorption reduces renal CTGF uptake and increases urinary CTGF 
excretion. We next studied the effect of tubular reabsorption impairment on uCTGF. 
Gelofusine, a modified gelatin employed clinically applied as a plasma volume expander, 
was used to inhibit proximal tubular reabsorption (13, 30). In mice, intravenous injection of 
Gelofusine 1-2 min prior to i.v. bolus injection of N-CTGF reduced cortical N-CTGF uptake 
by 49±11% (P < 0.05; Fig. 3A). Pretreatment with Gelofusine resulted in a comparable 
decrease in cortical uptake of full length CTGF (Supplementary figure). Moreover, a 
single intravenous bolus dose of Gelofusine during continuous N-CTGF infusion by 
intraperitoneal mini-osmotic pump in mice increased urinary N-CTGF 15±1-fold (P < 0.05; 
Fig. 3B).
 In addition to experiments with recombinant CTGFs in mice, we also studied the 
effect of inhibition of tubular reabsorption on urinary excretion of endogenous CTGF 
in healthy human volunteers. While basal levels were low, Gelofusine infusion induced 
Fig. 1. Renal CTGF accumulation after single dose intravenous administration of recombinant human N-CTGF in mice. 
A: estimated renal N-CTGF levels at different time points after injection, determined by ELISA. Each dot represents 
one animal. Curve fitting, performed with GraphPad Prism, was by one-phase exponential decay model. B-D: 
immunofluorescence of C57Bl/6J kidney by using human anti-CTGF (green) and TO-PRO 3 Iodide for nuclear 
staining (red), visualized by confocal laser scanning microscopy. B: N-CTGF treated animal at 10 min showing 
abundant N-CTGF in proximal tubules, intensely staining the brush border. Magnification × 630. C: N-CTGF 
treated animal at 30 min showing abundant N-CTGF positive apical endocytic vesicles in proximal tubular cells. 
Magnification × 1000. D: CTGF treated animal at 6 min showing CTGF in proximal tubules. Magnification × 630. 
E: saline treated animal. Magnification × 630.
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a 23±1-fold increase in uCTGF (P < 0.01), which was paralleled by an increase in urinary 
β2-microglobulin (uβ2M) (r = 0.99) (Fig. 4, A and B). Fractional excretion of CTGF increased 
from 0.47±0.1% to 13±3% (P < 0.05). These results demonstrate that, in healthy subjects, 
diminished tubular reuptake of CTGF from the luminal fluid is sufficient to induce a 
significant increase of uCTGF.
 In renal disease, elevated urinary CTGF is tightly associated with tubular dysfunction. To 
investigate whether uCTGF in renal disease correlated with urine levels of uβ2M as a 
marker of tubular dysfunction, we analyzed urines of 108 patients with renal impairment 
due to glomerular diseases. The patients had varying degrees of tubular dysfunction, 
as indicated by a wide range of uβ2M levels. General characteristics are summarized in 
the Supplementary Table 2. We observed a tight correlation between uCTGF and uβ2M 
Fig. 2. Colocalization of (N-)CTGF and Lotus tetragonobolus agglutinin (LTA), a proximal tubule marker. 
Consecutive sections of mouse kidney after intravenous administration of recombinant human (N-)CTGF were 
stained with human anti-CTGF (green) and LTA (red). CTGF positive endocytic vesicles are located exclusively in 
LTA positive proximal tubules. Original magnification × 200. 
Table 1. Renal handling parameters of recombinant human CTGF in healthy rats
Parameter n-fragment
(n = 4)
Full length CTGF
(N = 4)
Body weight (g) 323 ± 28 309 ± 11
Mean arterial pressure (mmHg) 92 ± 7 101 ± 2
GFR (ml/kg/min; inulin) 7.8 ± 0.5 9.0 ± 0.1
Renal plasma flow (ml/kg/min; PAH) 30 ± 4 30 ± 1
Renal extraction (%)
           Inulin 
           CTGF
29 ± 2
21 ± 0.7
25 ± 2
18 ± 3
Tubular uptake of CTGF 
           (% of extracted amount)
99.9 ± 0.02 99.96 ± 0.004*
Fractional excretion of CTGF (%) 0.10 ± 0.02 0.025 ± 0.006*
Values are means ± SE. *P < 0.01
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Fig. 4.  Effect of inhibition of proximal tubular reabsorption by Gelofusine in humans. A: Gelofusine infusion for 60 min in 3 healthy 
volunteers (▲, ●, ■) induced a 231-fold increase in urinary CTGF (uCTGF) (P = 0.004; repeated measures ANOVA) which was 
paralleled by an increase in urinary β2-microglobulin (uβ2m). B: uCTGF and  uβ2m were tightly correlated before, during and after 
Gelofusine infusion.
Fig. 3. Effect of inhibition of proximal tubular reabsorption by Gelofusine in mice. 
A: estimated renal levels of recombinant human N-CTGF 10-15 min after intravenous N-CTGF administration 
in mice. Gelofusine administration prior to N-CTGF injection (n = 3) reduced renal N-CTGF accumulation as 
compared to saline pretreatment (n = 3) (P = 0.03, unpaired t test). Gelofusine administration did not affect 
plasma N-CTGF levels.B: urinary N-CTGF levels during continuous infusion of recombinant human N-CTGF by 
intraperitoneal mini-osmotic pump in 3 mice before (16h urine collection) and within 1 hour after intravenous 
administration of Gelofusine bolus injection. Urinary N-CTGF increased from 0.22±0.03 to 3.4±0.7 nmol/g 
creatinine (P = 0.04; paired t test).  
Fig. 4. Effect of inhibition of proximal tubular reabsorption by Gelofusine in humans. 
A: Gelofusine infusion for 60 min in 3 healthy volunteers (▲, ▲, ▲) induced a 23±1-fold incr se in urinary CTGF 
(uCTGF) (P = 0.004; repeated measures ANOVA) which was paralleled by an increase in u in ry β2-microglobulin 
(uβ2M). B: uCTGF and uβ2M were tightly correlated before, during and after Gelofusine infusion. 
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(r = 0.85; P < 0.001, Fig. 5). Urinary β2M emerged as the only independent determinant of 
uCTGF (β 0.81; P < 0.001) in a multiple linear regression model containing age, eGFR (or 
serum creatinine) and plasma CTGF, which were all significantly associated with uCTGF in 
univariate analysis. This is strong evidence that tubular dysfunction is a major determinant 
of uCTGF increase in renal disease.
 Megalin is involved in proximal tubular reabsorption of CTGF. To identify the endocytic 
receptor involved in the proximal tubular reabsorption of CTGF, we studied uCTGF in 
transgenic mice with deficiencies of the endocytic receptors megalin and/or cubilin. 
These multiligand receptors are known to be responsible for tubular reabsorption of most 
of the filtered proteins7. In MOX2-Cre transgenic mice with a mosaic expression pattern 
of megalin and cubilin in the kidney, exhibiting combined deficiency of both receptors, 
uCTGF was very high (14±1.5 nmol/g creatinine), while in cubilin KO and wild type mice 
uCTGF levels were below level of quantification. There were no differences in plasma 
CTGF between these various mouse strains. Immunofluorescent staining after intravenous 
administration of CTGF in healthy C57Bl/6J mice revealed colocalization of megalin and 
CTGF in the cortical (proximal) tubules (Fig. 6). These results show that proximal tubular 
endocytosis of CTGF is mediated by the multiligand receptor megalin.
Discussion
The main finding of our studies is that failure of proximal tubular reabsorption is a major 
determinant of increased urinary CTGF. In healthy animals, intravenously administered 
CTGF was filtered in the glomerulus, but only minimal excretion in the urine was observed. 
This was found to be due to almost complete reabsorption in proximal tubular cells by 
megalin-mediated endocytosis. 
 Our data show that both full length and the N-CTGF fragment are similarly handled 
by the kidney. For both CTGFs we observed extensive proximal tubular uptake in apical 
endocytic vesicles, very low fractional excretions (< 1%) and almost complete tubular 
uptake of extracted CTGF (> 99%). We focused our analyses on the amino-terminal 
fragment of CTGF since this is the predominant CTGF peptide in urine6, 12, 19, 27 and because 
the biomarker potential of CTGF has been studied most extensively for this proteolytic 
fragment1, 2, 6, 10, 12, 19, 24, 25, 27. 
 After intravenous administration in rats, renal extraction of circulating N-CTGF was 
74% of that of inulin. Since we found no immunohistochemical evidence for basolateral 
uptake in proximal tubular epithelial cells, we assume that most of the extracted N-CTGF 
was filtered into the primary urine by glomerular sieving, which would imply a sieving 
coefficient of approximately 0.7. This is consistent with the observation that proteins 
smaller than 20 kDa have sieving coefficients greater than 0.522. The high degree of tubular 
reabsorption of filtered N-CTGF and low fractional excretion (FE) are also in accordance 
with previously observed values for other LMW proteins, e.g. β2M (fractional reabsorption 
99.97%, FE 0.03%) and lysozyme (FE 0.4%)3, 20, 33.
 Impairment of proximal tubular reabsorption, either induced by Gelofusine 
administration or in human renal disease, was consistently associated with an increase 
in urinary CTGF excretion in close correlation with that of β2-microglobulin. Tubular 
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Fig. 5. Correlation between log transformed urinary CTGF (uCTGF) and urinary β2-microglobulin (uβ2M) in 108 chronic 
kidney disease patients. 
Fig. 6. Colocalization of (N-)CTGF and megalin in the mouse kidney. 
Immunofluorescence of mouse kidney 10 min after intravenous administration of recombinant human 
N-CTGF and full length CTGF by using human anti-CTGF (green) and goat anti-megalin (red). The amino-
terminal fragment and full length CTGF are located exclusively in megalin positive proximal tubules. Original 
magnification × 200. 
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dysfunction is an important parameter in the assessment of renal damage. In CKD, 
the degree of tubulointerstitial damage and the amount of LMW proteinuria are better 
predictors of functional outcome than the severity of glomerular damage or the total 
amount of proteinuria8, 9. In diabetic nephropathy, LMW proteinuria was found even 
before the occurrence of microalbuminuria, probably representing a sign of incipient 
DN9, 15. Our results imply that uCTGF, reflecting proximal tubular dysfunction, may be a 
valuable prognostic marker in renal disease. Moreover, in contrast to known proximal 
tubular dysfunction markers such as the biologically inert β2M and a1-microglobulin, 
luminal accumulation of CTGF and its fragments might contribute actively to the 
pathogenic process14, 23. Consistent with such a concept, uCTGF predicted progression 
of microalbuminuria in diabetic patients29 and in another study uCTGF independently 
predicted deterioration of renal function in patients with iMN (1). However, the true 
clinical value of uCTGF in renal disease still needs to be established.
 Although we show that uCTGF is highly dependent on tubular function and tightly 
associated with uβ2M, the correlation between the two proteins is not absolute (R
2 = 0.72). 
This might reflect disease associated regulation of CTGF production, either systemically or 
locally in different segments of the nephron16, 31. As expected for a filtered solute, plasma 
CTGF was correlated with uCTGF in univariate analysis. However, it did not emerge as an 
independent determinant in multivariate analysis. The relative contribution of increased 
local CTGF production could not be determined because the filtered load was unknown. 
Considering the virtually complete proximal reabsorption from the primary urine in the 
healthy kidney, CTGF produced in the glomeruli and released into the luminal fluid will 
have limited impact on uCTGF as long as the proximal endocytic apparatus is intact. On 
the other hand, luminal secretion of CTGF expressed in distal tubules would be expected 
to considerably affect urinary CTGF levels, but the linearity of the relationship between 
uβ2M and uCTGF indicates that tubular dysfunction is the major determinant of uCTGF in 
the renal diseases included in our survey. Yet, the relative contribution of increased local 
synthesis on uCTGF in specific renal diseases remains to be elucidated in future studies 
 In conclusion, CTGF is reabsorbed almost completely from the glomerular filtrate in 
proximal tubules via megalin-mediated endocytosis in the healthy kidney, and elevated 
uCTGF may largely reflect proximal tubular dysfunction. This should be taken into account 
when using uCTGF as a biomarker and in experimental work addressing its pathogenic 
involvement in chronic kidney disease. 
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Supplementary Table 1. Plasma CTGF levels in healthy rodents, healthy human subjects and renal disease patients
Species Plasma CTGF (nmol/l)
Mice 0.23 (0.19-0.29)
Rats 0.27 (0.18-0.37)
Humans
           Healthy subjects
           Renal disease patients
0.097 (0.06-0.16)
0.21 (0.11-0.39)
Values are median (interquartile range)
Supplementary Table 2. Characteristics of 108 patients with renal disease
Characteristic N = 108
Male:female 73:35
Age (yr; median (range)) 46 (16 to 82)
Serum creatinine (mg/dl; median (range)) 1.1 (0.5 to 3.3)
eGFR (ml/min per 1.73 m2; median (range)) 63 (19 to 145)
Proteinuria (g/10 mmol creatinine; median (range)) 4.6 (0.1 to 18.2)
Renal disease (N)
        Idiopathic membranous nephropathy
        IgA nephropathy
        Focal glomerular sclerosis
52
43
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In the first part of this chapter we summarize our findings. In the second part we discuss 
our findings, provide information on the relevance of biomarkers for current practice, and 
provide perspectives for future research.
part 1a. Biomarkers to predict outcome in iga nephropathy
In chapter 2, we evaluated whether the urinary excretion of the low molecular weight 
(LMW) proteins α1microglobulin (α1m) and β2microglobulin (β2m) predicted renal 
outcome in a cohort of 70 patients with histologically proven IgAN. These patients 
were mostly referred for advice regarding treatment. The majority of patients (57%) had 
significant proteinuria (>2 g/d), and impaired kidney function (eGFR < 60 ml/min/1.73m2). 
Twenty-five patients (36%) developed ESRD, and 46 patients (66%) had an increase in 
serum creatinine of > 50% after a median follow-up of 75 months. Nineteen patients 
(27%) received immunosuppressive treatment. Mean urinary excretion of α1m and β2m 
was increased above normal values. However, only baseline serum creatinine and total 
proteinuria proved significant independent predictors of ESRD or progression of renal 
disease. Of note, patients that received immunosuppressive therapy were less likely to 
develop ESRD. We concluded that measuring urinary excretion of α1m and β2m has no 
added value in predicting renal outcome over established clinical predictors such as 
baseline proteinuria and eGFR. 
 In recent years novel urinary biomarkers for acute and chronic kidney injury 
were described. We selected two biomarkers of early tubular damage, kidney injury 
molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) and studied 
their accuracy in predicting renal outcome in patients with IgAN. This study, described in 
chapter 3, included most of the abovementioned patients who had been evaluated in 
our hospital for treatment advice, with available stored urine samples. Sixty-five patients 
were evaluated. During a median follow-up of 76 months, 23 patients (35%) developed 
ESRD, and immunosuppressive therapy was started in 19 patients (29%). Urinary 
excretion of both KIM-1 and NGAL was significantly higher in patients with IgAN than 
in age and sex matched controls. Urinary KIM-1 and NGAL were correlated with each 
other (r = 0.53, p <0.01), and with proteinuria (r = 0.40 and 0.34, respectively, p <0.01), 
but not with eGFR. Of note, urinary KIM-1 was not correlated with urinary α1m or β2m. 
In univariate analysis eGFR, proteinuria, urinary excretion of KIM-1, NGAL, α1m, β2m, IgG 
and albumin, and immunosuppressive therapy all were significantly associated with ESRD. 
In multivariate analysis serum creatinine, urinary KIM-1, and immunosuppressive therapy 
proved independent predictors of ESRD. When constructing a ROC curve, the model that 
used serum creatinine and urinary KIM-1 excretion for predicting ESRD had an AUC of 
0.86, indicating a reasonable accuracy. Additional analysis suggested that urinary KIM-1 
excretion predicted ESRD specifically in the subgroup of patients with normal or mildly 
impaired kidney function. 
 The diagnosis IgAN requires a kidney biopsy to identify mesangial IgA in the 
glomeruli. For many years pathologists have developed grading systems for IgAN with 
the expectation that scoring of histological variables would allow risk-stratification. 
Thus far, the severity of tubulointerstitial fibrosis is the best-validated and most potent 
histologic prognostic marker. Since inflammation, characterized by recruitment of 
T-lymphocytes and macrophages, precedes fibrosis, it was hypothesized that detailed 
analysis of inflammatory cells would allow predicting outcome. Indeed, in 2008 a Dutch 
study that included 50 patients with IgAN showed that the presence of GMP-17 positive 
T-lymphocytes in the kidney tubules predicted progression of kidney disease. In this 
study, immunophenotyping and localization of interstitial infiltrate was determined by 
using a subset of monoclonal antibodies against a variety of leukocytic markers. Statistical 
analysis revealed that of the morphologic changes and immunophenotypic parameters 
the presence of GMP-17+/CD8+ intraepithelial lymphocytes in the tubules was the most 
sensitive marker with the highest likelihood ratio. Risk prediction was limited to the 
subgroup of 31 patients with no or mildly impaired renal function. 
 In chapter 4, we aimed to validate the prognostic value of this parameter. This study 
included 24 patients with IgAN and available stored kidney biopsies. The presence of 
GMP-17 positive T-lymphocytes was scored semi-quantitatively. In 9 patients (38%) GMP-
17 positive T-lymphocytes were found. At the time of the biopsy, GMP-17 positive patients 
had more severely impaired kidney function, and higher urinary levels of LMW proteins 
and KIM-1 than GMP-17 negative patients. During a median follow-up of 102 months, 
eight patients (33%) developed ESRD, whereas 13 patients (54%) had an increase in serum 
creatinine of > 50%. There was no difference regarding ESRD or progression of kidney 
disease between GMP-17 positive and GMP-17 negative patients: three out of nine (33%) 
vs. five out of 15 (30%) and four out of nine (44%) vs. nine out of 15 (60%), respectively. 
Limiting our analysis to patients with an eGFR ≥ 60 ml/min/1.73m2 left only nine patients. 
Two of these were GMP-17 positive, none developed ESRD, and of the three patients who 
showed progression of renal disease one was GMP-17 positive. Despite its limitations, 
our small retrospective study certainly puts the previously reported prognostic value 
into question. Notably, the presence of GMP-17 positive T-lymphocytes was significantly 
correlated with higher levels of α1m, and in our previous study (chapter 2), α1m did 
not predict progression of renal disease. In three out of six patients with idiopathic 
membranous nephropathy GMP-17 positive T-lymphocytes were observed in the tubules, 
so the presence of these lymphocytes is not restricted to patients with IgAN. 
 In chapter 5, we studied the effect of immunosuppressive therapy in 19 patients 
with IgAN at high risk for progression of kidney disease (median eGFR 33 ml/min/1.73m2, 
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median urine protein-creatinine ratio 3.8 g/10mmol). This study specifically aimed at 
identifying a biomarker predicting response to therapy. Most patients were treated with 
cyclophosphamide and prednisone, treatment duration was 19 (range 3-81) months. 
During follow-up (median 35 months after start of treatment), 10 patients showed 
progression of kidney disease, whereas eGFR remained stable in 9 patients. Based on 
the clinical characteristics progression would have been expected in more than 80% of 
patients. Thus, our study supports the efficacy of immunosuppressive therapy in patients 
with IgAN. More important was our observation that a reduction of proteinuria ≥ 50% at 
6 months after start of treatment predicted a favourable long-term response. 
part 1b. renal handling of hepcidin and ctgf
Our studies in patients with IgAN clearly demonstrated the almost negligible role of 
established biomarkers such as low molecular weight proteins, KIM-1, and histological 
markers in predicting outcome in patients with IgAN. Therefore, we searched for other 
potentially useful biomarkers. In this thesis we focused on hepcidin and CTGF. Before 
assessing the role of these novel biomarkers in IgAN, we performed studies to evaluate 
relevant items such as variability of assays and renal handling. 
 The interest in hepcidin as biomarker for kidney disease was stimulated by studies 
that showed that in patients with lupus nephritis, alterations in urinary hepcidin predicted 
renal flares. Furthermore, elevated urinary hepcidin levels predicted a lower risk for acute 
kidney injury (AKI) in patients after cardiac surgery. In chapter 6, we evaluated the intra-
individual variability of serum hepcidin and its determinants in a cohort of 63 hemodialysis 
patients. Serum hepcidin was measured using mass spectrometry (MS) and ELISA assays. 
With both assays there was a considerable intra-individual variability of serum hepcidin 
levels, with 60% of patients having a coefficient of variance (CV1, i.e. standard deviation 
divided by mean) >20%. Surprisingly, administration of iron and degree of inflammation 
had no major impact on variability. The large and unexplained variability suggests that 
serum hepcidin-25 levels are unsuitable to guide treatment of anemia in the individual 
hemodialysis patient in daily clinical practice. Moreover, when evaluating urinary hepcidin 
as a biomarker, urinary levels may vary considerably due to variations in serum levels, 
unless hepcidin is not freely filtered (e.g. due to binding) or unless hepcidin is (almost) 
completely reabsorbed by the renal tubules.
 Being a small peptide, hepcidin-25 is likely to be freely filtered by the glomerulus and 
subsequently reabsorbed by the kidney tubules. In chapter 7, we evaluated the influence 
of eGFR on serum levels of hepcidin-25 and its isoforms in 83 patients with CKD not 
requiring dialysis. Compared to 24 healthy controls serum hepcidin-25 levels were not 
significantly increased in CKD patients (median 4.2 nM vs. 5.1 nM, p = 0.30). eGFR dit not 
influence serum hepcidin-25 levels, and ferritin was the sole independent predictor of 
serum hepcidin-25 levels. In contrast, serum hepcidin-20 and 22 levels rose with a decline 
in eGFR. This finding may explain why previous studies reported an association between 
total hepcidin and eGFR. Our finding that hepcidin-25 is not dependent on eGFR might 
suggest that hepcidin is bound to a larger carrier protein which prevents it from being 
freely filtered. Yet, results from an additional study in three peritoneal dialysis patients 
failed to support this hypothesis: the calculated clearance of hepcidin-25 by peritoneal 
dialysis was compatible with the expected clearance based on its molecular mass. In 48 
hemodialysis patients hepcidin-25 levels were higher than in the CKD patients (median 
9.4 vs. 5.1 nM, p<0.001), and strongly correlated with ferritin. A significant difference was 
observed between arterial and venous samples compatible with removal of hepcidin 
by the artificial kidney (clearance 82 ml/min). This again suggests that hepcidin-25 is 
handled like other unbound small proteins. Interestingly, we found that despite clearance 
of hepcidin-25 by hemodialysis, serum levels of hepcidin decreased only slightly during 
dialysis. This might be due to rapid increased synthesis of hepcidin or due to release of 
hepcidin-25 from available stores. 
 Solid data defining whether the appearance of hepcidin in the urine reflects filtration, 
tubular reabsorption, or local production are not available, but essential. In chapter 8, 
we studied the role of tubular reabsorption in kidney handling of hepcidin by comparing 
fractional excretion (FE) of hepcidin-25 with FE of β2m in 30 patients with various 
degrees of impairment in tubular reabsorption (median eGFR 57 ml/min/1.73m2, median 
proteinuria 4.5 g/d). FE of hepcidin-25 was higher in patients than in 24 controls (8.0 vs 
1.9 %, p < 0.001) and strongly correlated with FE of β2m (r = 0.93, p < 0.01), the latter 
being an established marker of proximal tubular reabsorption. To prove that hepcidin is 
reabsorbed in the proximal tubule by binding to megalin, we measured urine hepcidin-1 
in wild type and kidney specific megalin-deficient mice. Indeed, urine hepcidin-1 was 
increased in megalin-deficient mice compared to wild-type mice (p < 0.01) indicating 
that reabsorption is dependent on megalin-mediated endocytosis. We also measured 
hepcidin in 19 patients after cardiopulmonary surgery, two of these patients developed 
acute kidney injury (AKI). Immediately after surgery FE of hepcidin and β2m were 21 and 
14% (r = 0.79, p = 0.02), indicating impairment of tubular reabsorption. At 12-24 hours 
after surgery FE of β2m decreased to 3% indicating an improvement of tubular damage, 
but FE of hepcidin increased further to 33%. These findings suggest that the kidney 
locally produces hepcidin-25. Local production of hepcidin-25 may protect against AKI 
by attenuating oxidative injury due to free iron. The results of this pilot study should be 
corroborated with histopathological data showing proximal tubular uptake of hepcidin 
and hepcidin expression by the kidney or macrophages. Moreover, the exact timing and 
the possible factors influencing local production should be evaluated in future studies, 
since upregulation of urinary hepcidin might protect against AKI. It is suggested by 
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several investigators that kidney damage in patients with IgAN is partly explained by 
hematuria, and the consequence of haem-induced tubular injury. Since hepcidin may 
protect against iron-mediated injury, local production of hepcidin in the kidney may be 
beneficial in IgAN. Studies of urinary hepcidin in IgAN and other hematuric glomerular 
diseases are needed. 
 Connective tissue growth factor (CTGF) is a profibrotic peptide and may be another 
potential biomarker for early tubulointerstitial fibrosis. Elevated urinary CTGF levels have 
been reported in patients with diabetic glomerulopathy and other glomerular diseases 
such as IgAN. Elevated urinary CTGF was considered to reflect increased intrarenal 
production. In chapter 9, we studied glomerular and tubular handling of CTGF. In healthy 
subjects FE of CTGF was low (<1%), and impairment of tubular reabsorption by gelofusin 
administration, which competitively blocks protein reabsorption, induced a significant 
increase in urinary CTGF. Urinary CTGF was also elevated in megalin-deficient mice. Lastly, 
we observed that CTGF strongly correlated with β2m. Thus, we conclude that CTGF is 
filtered and almost completely reabsorbed via megalin-mediated endocytosis in the 
kidney tubules, and elevated urinary CTGF is mainly explained by tubular dysfunction. 
This should be considered when using urinary CTGF as a biomarker. In the context of 
predicting progression in patients with IgAN, CTGF does not seem to be an accurate 
marker, since it is strongly correlated with β2m, which failed to predict prognosis.
part 2. general discussion
In this thesis we have studied the role of biomarkers in predicting prognosis in patients 
with IgAN. Overall, our studies may seem disappointing: the urinary excretion of low 
molecular weight proteins did not predict renal outcome; although urinary excretion of 
KIM-1 proved a statistically significant, independent predictor of outcome, its value in 
clinical practice is doubtful; we could not confirm the predictive value of the presence 
of GMP-17 positive lymphocytes in the kidney tubuli. The most promising finding was 
that the level of proteinuria after 6 months of immunosuppressive therapy could reliably 
predict long-term response to therapy. Monitoring proteinuria, a rather old-fashioned 
traditional biomarker, thus may help in guiding therapy. 
 In recent years many investigators have evaluated biomarkers in IgAN and promising 
results have been reported. This may seem contradictory to our findings. Yet, it is 
important to carefully evaluate the weaknesses and strengths of these biomarker studies. 
It is too early to draw too optimistic conclusions. 
1 Why do we need biomarkers in IgAN? 
IgAN is a disease with a very heterogeneous course. Although IgAN is defined by the 
presence of IgA deposits in the mesangium, the mere presence of IgA in the mesangium 
does not suffice to define IgAN as a disease. In fact, IgA deposits can be observed in many 
Table 1: Multistep pathogenesis of IgAN and potential biomarkers
Proposed phases in the 
pathogenesis of IgAN
Traditional biomarkers Novel biomarkers
1.  Increased circulating galactose-
deficient IgA1 (gd-IgA1)
Genetic markers 
Galactose-deficient IgA1 levels in 
serum
2.  Generation of galactose-deficient 
IgA1 antibodies (IgG or IgA)
Galactose-deficient IgA1 specific 
antibodies in serum
3.  Mesangial deposition of galactose-
deficient IgA1 containing immune 
complexes
4.  Activation, proliferation and damage 
of mesangial cells
Hematuria MicroRNA profiling in blood and 
urine (e.g. miR-148b)
Complement in urine and blood 
(e.g. mannose binding lectin, resp 
IgA/C3 ratio)
Urine and serum proteomics
Markers of oxidative stress (e.g. 
AOPPs)
Urine cytokines (e.g. MCP-1)
5.  Glomerulosclerosis and 
tubulointerstitial fibrosis
Serum creatinine/ eGFR 
Proteinuria 
Interstitial fibrosis on biopsy
Clinical risk score 
Proteinuria during follow-up 
Isolated macroscopic 
hematuria
Persistent microscopic 
hematuria
Immunohistochemistry for 
fibroblasts (e.g. FSP1)/ mesangial 
matrix markers on biopsy
Low-molecular-weight proteins in 
urine (e.g. hemopexin)
M(E)ST score on biopsy
Complement in urine and blood 
(e.g. mannose binding lectin, resp 
IgA/C3 ratio)
Glomerular density measurement 
on biopsy
Urine and serum proteomics
Markers of oxidative stress (e.g. 
AOPPs)
Urine cytokines (e.g. MCP-1)
FSP1: fibroblast specific protein 1-positive, AOPP: advanced oxidation protein product, MCP: monocyte attractant 
protein
apparently healthy individuals1. The pathogenesis of IgAN involves a multistep process 
starting with the initial phase of producing galactose deficient IgA1, and ending with 
progressive kidney failure2. The various steps are illustrated in Figure 1 and Table 1.
 Clinically, the disease manifests with microscopic or sometimes bouts of macroscopic 
hematuria. This phase cannot clinically be discerned from thin basement membrane 
nephropathy, a disorder that is even more benign. A minority of patients who present with 
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microscopic hematuria will develop proteinuria, a clear signal of disease progression. Many 
of patients with proteinuria will develop progressive disease, characterised by hypertension 
and renal insufficiency. In this stage, immunosuppressive therapy is effective in improving 
renal survival, although overall outcome, even with immunosuppressive therapy, is worse 
in patients with already established renal failure (eGFR < 50 ml/min/1.73m2). 
If we consider biomarkers in IgAN, it is evident that biomarkers may serve different goals:
a. Biomarkers that allow confirming diagnosis in a non-invasive manner
b Biomarkers that allow predicting outcome
b1.  Biomarkers that allow predicting progression in untreated patients, thus selecting 
patients most likely to benefit from treatment, preferably in an early stage of disease 
thereby increasing the effect of therapy
b2.  Biomarkers that allow predicting response to therapy, thus selecting patients most 
likely to benefit from treatment, and selecting the optimal type of therapy for an 
individual patient
b3.  Biomarkers that allow predicting progression in treated patients, thus selecting patients 
with ongoing active disease whom are likely to require additional and perhaps more 
aggressive therapy
 Unfortunately, most studies do not allow specific evaluation of the various outcome 
measures. This is evident from Table 2, which summarizes the characteristics of the patients 
that were included in recent predictor studies3-6. It is evident that these studies all included 
a very heterogeneous patient population, as reflected by the wide range in proteinuria, 
eGFR, and histological damage. Furthermore, 25-55% of patients in these studies received 
immunosuppressive therapy during follow-up. Thus, at best, these studies can evaluate 
associations between a biomarker and overall outcome. Confounding by indication, 
collinearity of parameters etcetera, will bias the analyses.
2 Limitations of (studies of) novel biomarkers
In general, biomarker studies evaluate the association between the presence or level of 
the relevant biomarker and outcome. It is not sufficient to find a significant association in 
univariate analyses, since a relevant biomarker should provide additional value and prove 
an independent predictor in multivariate analysis. Moreover, novel biomarkers should be 
superior to traditional biomarkers such as proteinuria and their incorporation in prediction 
models should improve overall prediction. The role of a biomarker is often suggested by 
studies in an initial (incipient) cohort, but the value of a biomarker must be confirmed in a 
validation study. Finally, a statistical significant effect may not be clinically relevant. 
2a: Novel versus traditional biomarkers 
Traditional biomarkers predict prognosis with reasonable accuracy. Proteinuria, eGFR, and 
hypertension are well known predictors of outcome in IgAN. In a recent study Xie et al. 
improved the performance of these clinical parameters by combining them in a risk score 
based on eGFR, systolic blood pressure, haemoglobin and serum albumin4. The ROC 
curve for predicting ESRD after 10 yr was 0.85, reflecting reasonable accuracy. Although 
sensitivity and specificity are not mentioned, an overall accuracy of 85% may reflect a 
sensitivity of 85% and a corresponding specificity of 85%. 
 The study of Xie et al. also included a heterogeneous patient group (see Table 2) and 
conclusions cannot be generalised to untreated patients with normal renal function. Still, 
it is clear that in patients with established IgAN it will be difficult to find novel biomarkers 
that improve prediction over and beyond risk prediction by traditional risk factors.
 Our study is an example (chapter 3). Both serum creatinine and proteinuria predicted 
outcome. A model based on serum creatinine predicted outcome with reasonable 
accuracy (AUC 0.82). In multivariate analysis urinary excretion of KIM-1 proved a statistically 
significant independent predictor of outcome. However, the ROC AUC increased only 
from 0.82 to 0.86, indicating that the use of KIM-1 only improved accuracy slightly.
For many years investigators have tried to use kidney biopsy findings to predict outcome. 
Glomerulosclerosis, interstitial fibrosis and vascular hyalinosis all have been associated 
with outcome. However, the value of histology over clinical risk variables has been 
Increased circulating galactose-
deficient IgA1 (gd-IgA1)
Removal of glomerular IgA1
Inhibition of complement activation, 
blockade of cytokines/ growth 
factors (e.g. anti-PDGF, RAS blockade, 
tyrosine kinase inhibitors)
Restore mucosal defect and 
hyperreactivity to antigens by topical 
immunosuppression (e.g. budesonide) 
and/ or specific diet
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Figure 1. Model for pathogenesis of IgA nephropathy and current/ potential (printed in italics) therapeutic options.
Adapted from Floege J. Am J Kidney Dis. 2011 Dec;58(6):992-1004
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difficult to prove. In 2009, an international study identified mesangial hypercellularity 
(M), endocapillary proliferation (E), segmental sclerosis (S) and tubular atrophy/interstitial 
fibrosis (T) as independent predictors of renal outcome7. Recently, the predictive value 
of this classification was validated in the large, multicentre European VALIGA study 
that included 1147 patients6. Again, clinical characteristics were quite variable (Table 
2), and the study included patients with minimal proteinuria as well as patients with 
severe renal insufficiency (eGFR < 30 ml/min/1.73m2). Overall 46% of patients received 
immunosuppressive therapy. A close look at the results provides interesting information, 
relevant for the interpretation of all biomarker studies. 
 The authors observed a close association between the E score and proteinuria, 
whereas the M, S, and T scores were associated with proteinuria, eGFR and blood pressure. 
The M, S, and T score predicted outcome, the E score was not associated with outcome. 
Of note, the predictive value of the pathology score was no longer present in the patients 
who received immunosuppressive therapy. Thus, clearly the use of immunosuppressive 
therapy affected the performance of biomarkers.
 The VALIGA study also showed that clinical predictors such as eGFR, and time-averaged 
proteinuria were more accurate than histological predictors (AUC 0.72 vs 0.65). Adding 
histological parameters to clinical parameters improved prediction, but only in untreated 
patients. The authors write that ‘’the added value of pathology was evident’’. Still, the AUC 
improved from 0.72 to only 0.75, a minor increase, with limited clinical relevance. 
 Although the VALIGA study is a cross-sectional study in a heterogeneous patient 
group, there are several other interesting findings. As already mentioned, the use of 
immunosuppressive therapy had a major impact on the relevance of the histological 
biomarkers, indicating that in future studies we must differentiate between biomarkers 
that predict outcome in untreated patients, and biomarkers that are relevant for treated 
patients.
 Even more important is the observation that time-averaged proteinuria during follow-
up is a good predictor of outcome. This may not be surprising, and is a confirmation of 
other studies8,9. Still, the data indicate that it is important to differentiate between time-
averaged proteinuria < 0.5 g/day and proteinuria of 0.5-1.0 g/day with 10 yr risk of kidney 
survival averaging 96% versus 85% respectively. 
 In view of the low risk of ESRD in a 10 yr period, it is more revealing to consider the 
risk of proteinuria progression. After 10 years of follow-up approximately 40% of patients 
with initial proteinuria <0.5 g/day had progressed to proteinuria > 1 g/day. Of note, in this 
subgroup of patients (n=219) the E score proved a significant predictor, with a Hazard 
ratio of developing proteinuria > 1 g/day or > 2 g/day being 2.3 and 3.5 respectively. 
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2b. Novel biomarkers should not be used to predict ESRD
As discussed, IgAN involves a multistep process. In Table 1 we have tried to dissect the 
various steps involved in this process (column 1). Next, we have added traditional and 
novel biomarkers, in relation to the pathogenic pathways (column 2). This table clearly 
illustrates why most biomarker studies fail: most biomarkers only reflect one step in the 
multifactorial process of progressive IgAN. The final outcome is the consequence of the 
combination of these factors. Therefore, one biomarker will never be able to predict final 
outcome with sufficient accuracy. Obviously, biomarkers that reflect the final stage of 
process (i.e. severe kidney injury) are more likely to be better predictors of ESRD. This 
explains the predictive value of biomarkers of severe kidney injury such as proteinuria, 
eGFR, and severe tubular atrophy. 
3 Change in current practice and prospects for future research 
Traditional clinical parameters such as eGFR, proteinuria, and blood pressure are good 
predictors of outcome, certainly when considering outcome after 10 years. It has 
become evident that regular measurement of proteinuria during follow-up adds valuable 
information. Time-averaged proteinuria should be our main guide in the management 
of patient with IgAN. The recent studies show that time-averaged proteinuria should 
be below 0.5 g/day. This founding should influence current practice, and in particular 
should stimulate performing a kidney biopsy in an earlier stage (Figure 2). Thus far, most 
nephrologists would wait until proteinuria exceeds 1-2 g/day. 
 The VALIGA study suggested benefits of immunosuppressive therapy even in patients 
with eGFR < 50 ml/min/1.73m2. Unfortunately late treatment is not the most effective: 
renal survival after 10 yr approximates 90% in patients with initial eGFR > 50 ml/min/
min/1.73m2 and only 60% in patients with initial eGFR 50 ml//min/1.73m2 10. Thus, it is 
important to start treatment in an early stage of the disease, although this obviously will 
increase the number of patients that are treated unnecessarily. Here is the unmet need for 
predictive biomarkers (see below). 
 For now, it would be important to predict responsiveness to immunosuppressive 
therapy. As such, a Japanese study suggested that the number of fibroblasts in the 
interstitium could serve as an excellent predictor of steroid response11. 
 These investigators counted the number of cells that stained positive for fibroblast 
specific protein 1. The number of FSP positive cells correlated with the degree of 
tubulointerstitial fibrosis and negatively with eGFR. 
 A higher number of cells decreased the likelihood of stabilisation of eGFR and 
reduction of proteinuria with steroid therapy. Using the optimal cut-off value of 32.6 cells/
high power field sensitivity was 0.75% and specificity 0.87%. Although the accuracy of this 
method seems reasonable, we argue that introduction of this methodology (which would 
often require a new kidney biopsy) would lead to undertreatment: 25% of patients who 
are considered treatment-resistant based on the test results would respond to steroids 
and thus maintain eGFR for a longer period. 
 Our finding that a reduction of proteinuria at 6 months after start of therapy is a good 
predictor therefore is relevant. In this way patients that do respond will be selected for 
continuous treatment. In non-responders treatment can be stopped, and the period 
of unnecessary therapy is at least reduced. Hopefully, the increased knowledge of the 
multistep pathogenesis of IgA nephropathy and its genetic and environmental modifiers 
will result in novel potent therapies with less adverse effects in the near future (Figure 1).
 Future studies should focus on patients with early stage IgAN. Predictor studies 
should only include patients with normal eGFR and limited proteinuria, and progression 
of proteinuria could be the optimal outcome measure. In these studies combinations of 
the various biomarkers should be tested for their predictive value. Also, it is important to 
evaluate changes in biomarkers during follow-up. IgAN is a dynamic disease and a single 
baseline measurement probably will never suffice. 
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Deel 1a. Biomarkers om de uitkomst van iga nefropathie te voorspellen
In hoofdstuk 2 gaan we in op de voorspellende waarde van urinemarkers voor proximale 
tubulusdysfunctie (α1-microglobuline (α1m) en β2-microglobuline (β2m)) in een cohort 
van 70 patiënten met IgA nefropathie (IgAN) bewezen middels een nierbiopsie. Deze 
patiënten werden verwezen voor een behandeladvies. De meerderheid had een 
forse proteïnurie (>2g/d), en een gestoorde nierfunctie (eGFR <60ml/min/1,73m2). Na 
ruim 6 jaar, was bij 25 van hen sprake van nierfalen en maar liefst twee derde had een 
nierfunctieverslechtering van >50%. Immunosuppressieve behandeling werd gegeven 
aan 19 patiënten. De gemiddelde uitscheiding van α1m en β2m was meer dan normaal. 
Maar alleen het serum creatinine en de mate van proteïnurie bleken onafhankelijke 
voorspellers van eindstadium nierfalen of verslechtering van de nierfunctie. Opmerkelijk 
genoeg hadden patiënten die een immunosuppressieve behandeling ondergingen een 
kleinere kans op nierfalen. Het meten van de uitscheiding middels de urine van α1m en 
β2m helpt dus niet om verslechtering van de nierfunctie te voorspellen.
 De laatste jaren is melding gemaakt van nieuwe urine biomarkers voor acute en 
chronische nierschade. Wij selecteerden twee biomarkers van beginnende schade aan 
de tubuli, te weten kidney injury molecule-1 (KIM-1) en neutrophil gelatinase-associated 
lipocalin (NGAL) en bestudeerden hun waarde om het beloop van de nierfunctie te 
voorspellen bij patiënten met een IgA nefropathie. Deze studie, die wordt beschreven 
in hoofdstuk 2, bevat vrijwel alle hierboven genoemde patiënten van wie opgeslagen 
urine voorradig was. Zesenvijftig patiënten werden ruim 6 jaar gevolgd, 23 van hen 
ontwikkelden nierfalen, wederom was bij 19 patiënten immunosuppressieve behandeling 
gestart. De uitscheiding via de urine van KIM-1 en NGAL was veel hoger bij patiënten met 
IgAN was hoger dan bij gezonde vrijwilligers. KIM-1 en NGAL correleerden met elkaar 
(r=0,53, p<0,01) en met proteïnurie (r=0,40 en 0,34 respectievelijk, p<0,01), maar niet met 
eGFR. Ook was er geen correlatie tussen uitscheiding van KIM-1 en α1m en β2m. Univariate 
analyse liet zien dat eGFR, proteïnurie, urine uitscheiding van KIM-1, NGAL, α1m, β2m, IgG 
en albumine, en immunosuppressieve therapie allen geassocieerd waren met nierfalen. 
Middels multivariate analyse bleken alleen serum creatinine, urine uitscheiding van KIM-
1 en behandeling met immunosuppressieve medicatie onafhankelijke voorspellers van 
nierfalen. Wanneer dit wordt uitgezet in een zogenaamde receiver operator characteristics 
curve (ROC) lijkt dit model een redelijk voorspellende waarde te hebben (area under the 
curve (AUC) 0.86). Aanvullende analyse doet vermoeden dat urine uitscheiding van KIM-
1 nierfalen vooral voorspelt in een subgroep van patiënten met IgAN en een slechts 
minimaal gestoorde nierfunctie.
 Voor het stellen van de diagnose IgAN is een nierbiopt absoluut noodzakelijk. Al jaren 
worden door pathologen scoringssystemen ontwikkeld om zo een risico inschatting te 
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Deel 1b. Verwerking van hepcidine en ctgf door de nieren
De hierboven beschreven onderzoeken in patiënten met IgAN laten zien dat er geen of 
slechts een zeer bescheiden rol is voor nieuwe biomarkers zoals α1m en β2m, KIM-1 en 
histologische variabelen wanneer het gaat om het voorspellen van de kans op progressie 
van nierfalen. Aldus zijn we op zoek gegaan naar andere biomarkers. We hebben ons 
daarbij beperkt tot hepcidine en CTGF. Alvorens de prognostische waarde van deze 
nieuwe biomarkers in IgAN na te gaan, hebben we onderzocht hoe betrouwbaar gebruikte 
assays zijn waarmee deze biomarkers worden gemeten en hoe deze biomarkers door de 
nieren worden verwerkt. 
 Hepcidine kwam in beeld als een biomarker voor nierziekte nadat verschillende 
onderzoeken lieten zien dat opvlamming van lupus nefritis kunnen worden voorspeld 
door verandering in urine hepcidine. Daarnaast werd beschreven dat hoge urine hepcidine 
concentraties gepaard gaan met een lager risico op acute nierschade in patiënten die 
een hartchirurgie hebben ondergaan. In hoofdstuk 6 bespreken we de intra-individuele 
variabiliteit van serum hepcidine en factoren die het serum hepcidine beïnvloeden in 
63 chronische hemodialyse patiënten. Serum hepcidine werd gemeten middels massa 
spectrometrie (MS) en ELISA. Bij beide methodes was varieerden de serum hepcidine 
waarden aanzienlijk binnen een individu; 60% van de patiënten had een coëfficiënt 
van variantie (CV1, te weten standaard deviatie gedeeld door het gemiddelde) > 20%. 
Verrassenderwijs hadden toediening van intraveneus ijzer en het CRP gehalte geen grote 
invloed op deze variabiliteit. Deze forse en grotendeels onverklaarde variabiliteit doet 
vermoeden dat serum hepidin-25 waarden niet geschikt zijn om een anemie behandeling 
voor een individuele patiënt op te baseren. Met het oog op urine hepcidine als biomarker, 
is aannemelijk dat variaties in het serum eveneens zullen leiden tot variaties in de urine, 
tenzij hepcidine eiwitgebonden is en daardoor niet of nauwelijks gefiltreerd wordt door 
de glomerulus of indien hepcidine vrijwel volledig wordt gereabsorbeerd door de renale 
tubuli. 
 Gezien het feit dat hepcidine-25 een zeer klein eiwit is, ligt het voor de hand dat het 
vrij gefiltreerd wordt door de glomerulus en vervolgens tubulair wordt gereabsorbeerd. 
In hoofdstuk 7 beschrijven we de invloed van de eGFR op serum hepcidine-25, maar 
ook hepcidine-20 en -22 waarden gemeten in 83 patiënten met chronisch nierfalen die 
niet dialyse afhankelijk waren. Serum hepcidine-25 waarden waren niet significant hoger 
dan bij controles (4,2 versus 5,1nM, p=0,30). De geschatte glomerulaire filtratie (eGFR) was 
niet van invloed op serum hepcidine-25 spiegels, ferritine was de enige onafhankelijk 
voorspeller van serum hepcidine-25 waarden. De concentraties van de verschillende 
isovormen hepcidine-20 en 22 namen echter toe naarmate de nierfunctie en daarmee 
de eGFR afnam. Dit verklaart waarom eerdere studies wel een relatie beschrijven tussen 
kunnen maken voor wat betreft nierfalen. Tot dusverre is de mate van tubulointerstitiele 
fibrose en dus verlittekening van het nierweefsel, de meest krachtige voorspeller. Aangezien 
een ontsteking met de influx van allerlei ontstekingscellen vooraf gaat aan fibrose, lijkt 
het logisch dat ontstekingscellen een voorspellende waarde hebben. Inderdaad liet 
een Leidse studie in 2008 zien dat in 50 patiënten met IgAN de aanwezigheid van een 
bepaald type ontstekingscellen, zogenaamde GMP-17 positieve T-cellen in de niertubuli 
de kans op verslechtering van de nierfunctie voorspelden. In hoofdstuk 4 trachten we de 
voorspellende waarde van de aanwezigheid van deze cellen te bevestigen in een deel 
van onze eerder beschreven groep patiënten met een IgAN en te kijken naar hun relatie 
met urine markers. Van 24 patiënten is nog nierweefsel beschikbaar, bij 9 van hen zijn 
dergelijke cellen aantoonbaar. Deze patiënten worden gekenmerkt door een slechtere 
nierfunctie en meer eiwitverlies in de urine. Na verloop van zo’n 9 jaar, treedt bij 8 
patiënten nierfalen op, bij 13 van de 24 patiënten is sprake van >50% functieverlies van 
de nieren. Er lijkt geen verschil te zijn tussen het optreden van nierfalen of het beloop 
van de nierfunctie bij patiënte die wel of geen van dergelijke cellen in het nierweefsel 
hebben (3/9 vergeleken met 5/15 voor wat betreft nierfalen). Wanneer we onze analyse 
beperkten tot patiënten met een relatief goede nierfunctie bij aanvang, bleven er slechts 
9 patiënten over, daarvan waren er bij 2 GMP-17 positieve T-cellen aantoonbaar. Geen van 
hen ontwikkelde nierfalen. Hoewel dit een kleine studie betrof met beperkingen, trekken 
deze bevindingen de prognostische waarde van GMP-17 positieve T-lymfocyten in the 
nierbiopt in twijfel. Overigens waren deze GMP-17 T-lymfocyten gecorreleerd met α1m 
uitscheiding. In hoofdstuk 2 zien we dat de uitscheiding van α1m niet voorspellend is voor 
nierfalen. Bij patiënten met een geheel andere nierziekte (idiopathische membraneuze 
nefropathie) bleken deze cellen overigens aan aanwezig.
 In hoofdstuk 5 bestuderen we het effect van immunosuppressieve behandeling bij 19 
patiënten met IgAN die een groot risico hebben op verlies van de nierfunctie (mediane 
eGFR 33ml/min/1,73m2 en mediane eiwit/kreatinine ratio 3,8g/10mmol). Deze studie 
was er met name op gericht om een biomarker te identificeren die de respons op de 
behandeling zou voorspellen. Patiënten werden behandeld met cyclofosfamide en 
prednison, de mediane behandelduur was 19 maanden. Gedurende het verdere beloop 
(mediane follow-up 35 maanden na start van behandeling), was er bij 10 patiënten sprake 
van een achteruitgang van de nierfunctie, terwijl de nierfunctie bij 9 stabiel bleef. Gezien 
de slechte karakteristieken bij aanvang van de studie, zou bij meer dan 80% verslechtering 
van de nierfunctie te verwachten zijn. Er lijkt dus een positief effect te zijn van behadeling. 
Belangrijker nog was de observatie dat een verminderen van de proteïnurie van meer 
dan 50% 6 maanden na start van de behandeling een goede uitkomst op lange termijn 
voorspelde.
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de eGFR en serum hepcidine waarden. Onze bevinding dat hepcidine-25 niet afhankelijk 
is van de eGFR kan erop duiden dat hepcidine eiwit gebonden is. Echter, dit wordt 
tegengesproken door data verkregen van patiënten die peritoneaal dialyse ondergaan; 
de berekende klaring kwam daarbij overeen met de te verwachten klaring op basis van 
het molecuulgewicht. Bij 48 patiënten die behandeld werden met hemodialyse vonden 
we duidelijk hogere hepcidine-25 concentraties dan in patiënten met nierschade die 
niet dialyse afhankelijk waren (mediaan 94 versus 5,2nM, p<0,001), hepcidine-25 was 
sterk gecorreleerd met ferritine. Hepcidine waarden afgenomen tijdens de dialyse waren 
veel hogere uit de arteriële lijn dan in de veneuze lijn, hetgeen wijst op verwijdering van 
hepcidine25 door de kunstnier (klaring 82ml/min). Opmerkelijk genoeg was er desondanks 
slechts een geringe daling van hepcidine-25 tijdens de dialyse sessie. Mogelijk momt dit 
door een snelle synthese van hepcidine danwel het vrijkomen van hepcidine uit een of 
andere opslag.
 Concrete gegevens over hoe de nier met hepcidine omgaat, te weten of hepcidine 
vrij wordt gefiltreerd, of hepcidine tubulair wordt gereabsorbeerd, of lokaal wordt 
geproduceerd, ontbreken, maar zijn essentieel. In hoofdstuk 8 rapporteren we de tubulaire 
reabsorptie van hepcidine door de fractionele excretie (FE) van hepcidine te vergelijken 
met de FE van β2m (wordt normaliter vrijwel volledig gereabsorbeerd door de tubuli) 
gemeten in 30 patiënten met verschillende gradaties van tubulaire dysfunctie. (mediane 
eGFR 57ml/min/1,73m2, mediane proteïnurie 4,5g/d). De FE van hepcidine-25 was hoger 
in patiënten dan in 24 controles (8,0 versus 1,9%, p<0,001) en sterk gecorreleerd met de 
FE van β2m (r=0,093, P<0,001). Om te bewijzen dat hepcidine wordt gereabsorbeerd in de 
proximale tubulus door middel van binding aan megaline, hebben we urine hepcidinee-1 
gemeten in wild-type and megaline deficiënte muizen. Inderdaar bleek urine hepcidine-1 
significant verhoogd bij de muizen zonder megaline in de nier, waarmee waarschijnlijk 
is dat hepcidine reabsorptie afhankelijk is van megaline-gemedieerde endocytose. In 
19 patiënten die cardiopulmonale chirurgie hebben ondergaan en waarvan er 2 acute 
nierschade ontwikkelden, hebben we eveneens hepcidine bepalingen uitgevoerd. Direct 
na de operatie was de FE van hepcidine en β2m 21 en 14% (r=0,79, p=0,02), daarmee 
aangevend dat er verminderde tubulaire reabsorptie was. Na 12-24 uur was de FE van 
β2m gedaald naar 3%, duidend op een verbetering van de tubulaire reabsorptie, maar 
de FE van hepcidine steeg verder door tot 33%. Deze gegevens wijzen erop dat de nier 
hepcidine-25 produceert. Lokale productie van hepcidine-25 zou beschermend kunnen 
zijn tegen acute nierschade door het verminderen van oxidatieve schade ten gevolge 
van vrij ijzer. De resultaten van dit onderzoek zouden moeten worden onderbouwd 
door histopathologische data waarbij inzichtelijk wordt gemaakt dat hepcidine tubulair 
wordt opgenomen en dat hepcidine tot expressie wordt gebracht door de nier en/of 
macrofagen. Bovendien zou verder onderzoek moeten plaatsvinden naar de exacte 
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timing en de factoren die de lokale productie beïnvloeden, aangezien verhoging van 
urine hepcidine mogelijk beschermt tegen acute nierschade. Verschillende onderzoekers 
suggereren dat nierschade bij patiënten met IgAN deels wordt veroorzaakt door 
hematurie, en haem geïnduceerd tubulaire schade. Indien hepcidine beschermt tegen 
ijzer gemedieerde nierschade, zou lokale aanmaak van hepcidine in de nier gunstig 
kunnen zijn in IgAN. Onderzoek in naar urine hepcidine en andere glomerulaire ziekten 
met hematurie zijn noodzakelijk.
Connective tissue growth factor (CTGF) is een profibrotisch eiwit en een andere potentiele 
biomarkers voor vroege tubulointerstitiele schade. Verhoogde urine CTGF waarden zijn 
beschreven bij patiënten met een diabetische nefropathie en overige glomerulaire 
ziekten zoals IgAN. Een verhoogd urine CTGF werd gezien als een uiting van verhoogde 
productie van de nier. In hoofdstuk 9 beschrijven we de glomerulaire en tubulaire 
verwerking van CTGF. In gezonde personen was de FE van CTGF laag (<1%). Blokkade van 
de tubulaire reabsorptie door gelofusine infusie gaf aanleiding tot een significant hogere 
urine CTGF concentratie. Urine CTGF was eveneens verhoogd in megaline deficiënte 
muizen. Tot slot zagen we dat CTGF sterk gecorreleerd was met β2m. We concluderen 
aldus dat CTGF wordt gefiltreerd en vrijwel compleet wordt geresorbeerd via megaline 
gemedieerde endocytose in de tubuli van de nier. Een verhoogd urine CTGF wordt met 
name verklaard door tubulaire dysfunctie. Dit moet in acht worden wanneer CTGF als 
biomarker wordt ingezet. In het kader van het voorspellen van progressie in patiënten 
met IgAN, lijkt CTGF geen goede marker, het is immers sterk gecorreleerd met β2m en dit 
eiwit bleek eerder geen voorspellende waarde te hebben.
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Dit proefschrift was niet mogelijk geweest zonder de hulp en ondersteuning van velen. 
Iedereen die op enigerlei wijze heeft bijgedragen wil ik heel hartelijk bedanken. Een 
aantal mensen wil ik in het bijzonder noemen.
Prof. dr. J. F.M. Wetzels, beste Jack, jij bent de drijvende kracht geweest achter dit 
proefschrift. Ik ben je enorm dankbaar dat je dit promotietraject voor me mogelijk hebt 
gemaakt. Je was er altijd voor me als ik hulp nodig had en tot op het laatst toe was het 
kortdurend van gedachten wisselen tussen de stapels op jouw kamer voldoende om 
met frisse moed en een nieuwe invalshoek weer aan de slag te gaan. Ik heb gedurende 
de jaren veel geleerd van je heldere, consequente manier van redeneren en bewonder 
je integriteit en de wijze waarop je in staat bent onderzoeksresultaten te vertalen naar de 
dagelijkse patiëntzorg. Het mooiste wat dit promotietraject me heeft gebracht is jouw 
vriendschap.
Prof. dr. D.W. Swinkels, beste Dorine, je hebt me vol enthousiasme wegwijs gemaakt 
in de wereld van hepcidine. Jouw oprechte interesse voor hepcidine in het kader van 
nierziekten, maakte het mogelijk om op prettige en soepele wijze samen een aantal 
studies te voltooien, waarbij jouw optimisme, inzichten en contacten onontbeerlijk waren.
Prof. dr. H. Van Goor, beste Harry, dankzij Anne-Roos hebben we tijdens een ASN lunch 
in San Diego de basis gelegd voor een vruchtbare samenwerking op het gebied van 
KIM-1 en NGAL. Jouw gedrevenheid heeft indruk op me gemaakt, evenals het gemak 
waarmee je zeer uiteenlopende onderwerpen ter sprake kon brengen tijdens de lunches 
die volgden. 
Prof. dr. L. Van Es, beste Bob, je hebt me zeer gastvrij ontvangen in Leiden en me in de 
gelegenheid gesteld om onder begeleiding van Annemieke van der Wal nierweefsel te 
bewerken en te kleuren. 
Prof. dr. R. Goldschmeding, beste Roel, in de beginfase van mijn promotie heb ik met je 
mogen samenwerken. Ik ben je erkentelijk voor je hulp en wijze adviezen.
De manuscript commissie bestaande uit prof. dr. J.W.M. Lenders, prof. dr. J.G.J. Hoenderop 
en dr. M.G. Vervloet, wil ik bedanken voor hun kritische beschouwing en goedkeuring van 
het manuscript.
Coby Laarakkers, jij was mijn rots in de branding bij het hepcidine onderzoek. Geduldig, 
deskundig, nauwgezet en altijd bereid mee te denken. Ik ben je zeer dankbaar.
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Dr. Roos Masereeuw, dankzij jouw hulp bij de dierexperimenten kon er een brug worden 
geslagen tussen het klinisch onderzoek en de basale studies naar hepcidine. 
Dr. Jan van den Brand, je hebt me tijdens dit proefschrift enorm geholpen, allereerst 
door samen middels statusonderzoek data te verzamelen, later als steun en toeverlaat als 
het aankwam op statistiek. Waarbij ik de propensity score als een absoluut hoogtepunt 
beschouw.
Dr. Julia Hofstra, lieve Julia, met Barack in de barak. We werkten samen in het Rijnstate, 
begonnen tegelijkertijd (met Judith in de rol van NIO) op de afdeling nierziekten in het 
UMCN en hebben samen heel wat uren in de Zeldenrustbarak aan onderzoek besteed. Ik 
ben blij met zo’n fantastische collega in de academie die ik altijd om raad kan vragen en 
ben er trots op dat je vandaag mijn paranimf wil zijn. 
Dr. Eric Steenbergen, een serie IgA biopten scoren volgens de MEST classificatie, deed je 
gemoedelijk maar efficiënt. Dank voor al je hulp, ik hoop in de toekomst op het gebied 
van de patiëntzorg nog veel met je samen te werken.
Dr. Femke Waanders en dr. Esther Meijer, dank voor het verrichten van de bepalingen van 
KIM-1 en NGAL en jullie waardevolle bijdrage aan dit manuscript. 
Dr. Ingeborg Bajema, hartelijk dank voor het beoordelen van de diverse niercoupes op de 
aanwezigheid van GMP-17 positieve T-lymfocyten.
Dr. Stefan Berger, dank voor de patiënt data uit het LUMC en voor je nuttige kritiek.
Dr. Karin Gerritsen en dr. Tri Nguyen, dank voor alle hulp op het gebied van CTGF, ik heb 
veel bewondering voor het basale onderzoek dat jullie beiden hebben verricht.
Secretariaat, staf en research verpleegkundigen van de afdeling nierziekten in het UMCN, 
bedankt voor jullie betrokkenheid en toewijding bij mijn opleiding tot nefroloog en bij 
dit onderzoek. 
Secretariaat en verpleegkundigen van de afdeling hemodialyse in het UMCN, jullie hulp 
bij het stickeren, afnemen en verzamelen van alle buizen bij hemodialyse en peritoneaal 
dialyse patiënten op de meest uiteenlopende momenten, was onmisbaar.
Alle mede auteurs van de artikelen in dit proefschrift; dank voor jullie bijdrage en voor de 
prettige samenwerking.
Sectiegenoten: Joop, Sabine, Karlijn, Judith, Hans en Joan, jullie hebben op vele manieren 
een waardevolle bijdrage geleverd aan dit manuscript. Op belangrijke momenten 
maakten jullie het mogelijk dat ik me op dit onderzoek kon concentreren, door een 
aantal taken als vanzelfsprekend over te nemen en dat maakte het verschil. Ik voel me 
een bevoorrecht mens om deel uit te mogen maken van dit team en hoop nog vele jaren 
met jullie te mogen samenwerken.
Judith, lieve Judith, het is ons gelukt! En wat geweldig dat we dit vandaag samen kunnen 
afronden en vieren, dat maakt het extra speciaal. Je bent een fantastische collega en hebt 
me zo ontzettend geholpen de afgelopen tijd. 
Vrienden en familie, ik heb jullie niet altijd de aandacht gegeven die jullie verdienen, maar 
ben ontzettend blij met jullie in mijn leven.
Anne-Roos Frenay, al jaren volg je mij op de voet. Heel bijzonder dat onze paden zich 
zo vaak kruisen. Ik heb er alle vertrouwen in dat we elkaar in de toekomst blijven zien 
(uiteraard bij jouw promotie) en ben ontzettend blij met jou als paranimf.   
Lieve mama en papa, door de jaren heen hebben jullie me altijd gesteund tijdens studie 
en werk. De afgelopen tijd is jullie hulp bij de zorg voor Charlotte heel belangrijk geweest, 
ik kan altijd op jullie terugvallen, en dat biedt geborgenheid. 
Lieve Loes-Sophie, lieve zus, als ik weer eens vergeten ben een cadeau te kopen voor een 
verjaardag of andere gelegenheid, help jij me altijd uit de brand, je herinnert me zelfs aan 
mijn eigen trouwdag. Ik ben trots op de manier waarop jij zorgt voor Joep, Daan en Roos. 
Lieve Frances, jij geeft me naast liefde ook alle ruimte om me te ontwikkelen en hebt 
er altijd op vertrouwd dat we samen een plek zouden vinden voor een thuis. Nu het 
eindelijk zover is, hoop ik dat er meer tijd zal zijn om met zijn drieën te genieten.
Lieve Charlotte, jij hebt geen enkele boodschap aan dit manuscript en leest veel liever 
met mama ‘Het Walvisje’, waarbij je nooit nalaat het laatste woord van de laatste zin vol 
vuur aan te vullen: ‘Hier is het heerlijk, het water is blauw. Jij hoort bij mij. En ik hoor bij jou.’ 
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Hilde Petra Everdien Peters werd geboren op 21 maart 1977 in Doornenburg als dochter 
van Ellen Buying en Willem Peters. Na haar eindexamen aan het Stedelijk Gymnasium te 
Nijmegen, begon zij in 1995 met haar studie geneeskunde aan de Radboud Universiteit 
te Nijmegen. In 2000 behaalde zij het doctoraal examen, gevolgd door het arts-examen 
in 2002. Na haar arts-examen startte ze haar klinische loopbaan als basisarts in het 
Rijnstate Ziekenhuis in Arnhem, alwaar ze in september 2003 startte met de opleiding tot 
internist (opleiders dr. R. van Leusen en dr. L. Verschoor). Vanaf juli 2006 werd de opleiding 
voortgezet in het UMC St Radboud te Nijmegen (opleiders prof. dr. J.W.M. van der Meer 
en prof. dr. J. de Graaf). In mei 2007 werd gestart met de opleiding tot nefroloog in het 
UMC St Radboud (opleider prof. dr. J.H.M. Berden). De opleiding werd afgewisseld met 
onderzoek onder leiding van prof. dr. J.F.M. Wetzels, hetgeen wordt beschreven in dit 
proefschrift. In september 2009 volgde registratie als internist, in september 2010 werd de 
opleiding tot nefroloog afgerond. Sinds december 2010 werkt zij als internist-nefroloog 
in de Isala Klinieken te Zwolle, waarbij zij sinds juni 2011 deel uitmaakt van de maatschap 
interne geneeskunde.
Hilde is getrouwd met Frances Dethmers en samen hebben zij een dochter, Charlotte.
